The Economics of Vivax Malaria Treatment by Devine, Angela
Open Research Online
The Open University’s repository of research publications
and other research outputs
The Economics of Vivax Malaria Treatment
Thesis
How to cite:
Devine, Angela (2018). The Economics of Vivax Malaria Treatment. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2017 The Author
Version: Submitted Version
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Mahidol Oxford Tropical Medicine Research Unit,
Affiliated Research Centre of The Open University
The Economics of Vivax Malaria Treatment
Angela Devine BSc, MSc
Thesis offered for the degree of Doctor of Philosophy
The Open University, UK
23 December 2017
Health Economics

Abstract
The control and eventual elimination of malaria will require widescale adoption of strategies
to ensure early diagnosis and highly effective treatment of infected individuals. In Plasmodium
vivax, multiple relapse episodes can only be averted by treating the dormant liver stage of
the parasite life cycle - a strategy known as radical cure. This thesis aims to investigate key
factors determining treatment-seeking behaviour and costs associated with vivax malaria, how
these influence healthcare decisions, the cost-effectiveness of screening tests and treatments
for radical cure, and the cost-benefit implications of their global implementation.
Treatment-seeking behaviour, assessed in Papua, Indonesia, demonstrated that household
costs per person seeking treatment for vivax malaria were similar to those for falciparum
malaria. Switching from ineffective to effective malaria treatment in the public sector improved
the behaviour of patients and both public and private healthcare providers. Diagnostic
strategies were investigated on the Thai-Myanmar border, where screening for glucose-6-
phosphate-dehydrogenase (G6PD) deficiency prior to radical cure reduced the disease burden
while being a cost-effective option for healthcare providers that do not use radical cure and a
potentially cost-saving alternative where primaquine is prescribed without screening. The
costs of implementing G6PD screening were collected in three countries, and highlighted that
RDTs consistently reduced costs as compared to the widely-used fluorescent spot test. Across
four countries, the indirect cost due to lost productivity was the largest cost component for
households of patients with vivax malaria. After combining provider and patient costs with
case estimates, the global economic burden of vivax malaria was estimated to be US$330
million per year. Adopting a policy of screening for G6PD deficiency with delivery of highly
effective radical cure was projected to save US$45 million.
P. vivax malaria causes a large economic burden that can be reduced substantially by
delivering safe and effective radical cure.
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Chapter 1
Introduction
Malaria is a parasitic disease that has aﬄicted mankind for more than 100,000 years.
Nearly every country in the world was once endemic for malaria, but its range has been
reduced significantly since malaria control efforts began in the early 20th century [1]. Of
the five species of malaria that infect humans, the majority of clinical cases are caused
by Plasmodium falciparum and Plasmodium vivax. The predominant burden of disease
is attributable to P. falciparum, particularly in Sub-Saharan Africa. More recently,
however, P. vivax has been recognised as an increasingly important cause of morbidity
and mortality [2, 3, 4, 5]. While P. falciparum is more likely to result in direct mortality,
multiple relapsing episodes of P. vivax can lead to long-term morbidity and indirect
mortality [6, 7]. Despite the increased interest in the clinical and epidemiological
consequences of P. vivax infections, the associated costs and cost-effectiveness of its
diagnosis and treatment has been understudied [8]. Understanding the costs and
effects of the diagnosis and treatment of vivax infections is critical to policymakers
and healthcare providers with limited resources. This thesis focuses on the costs of P.
vivax malaria, cost-effectiveness of different treatment options and the global economic
burden attributable to the parasite.
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Figure 1.1: The spatial distribution of P. vivax endemicity in 2010. Coloured areas represent the average proportion of the population
estimated to be infected with P. vivax at any one time over a one year time period. The dark grey areas display where unstable transmission
takes place. Downloaded from: http://www.map.ox.ac.uk/browse-resources/endemicity/Pv_mean/world/ [9].
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1.1 Epidemiology
While P. vivax rarely occurs in Africa (where the main burden of malaria lies), P. vivax
is the predominant cause of malaria in Asia and Central and South America, accounting
for more than 50% and 71-81% of cases, respectively [2]. The global spatial distribution
of vivax malaria is shown in Figure 1.1. A number of important biological differences
between P. vivax and P. falciparum underpin the variations in their epidemiology and
response to malaria control interventions. Perhaps the most important is P. vivax ’s
ability to form dormant liver stages that can recur weeks to months after the primary
infection. Furthermore, P. vivax can survive in geographical locations unsuitable to
sustaining P. falciparum infection. It is spread by a wide range of mosquito vectors,
some of which live in temperate climates and bite humans outdoors and during the
daytime [4], and transmission occurs early in the parasite’s life cycle before the individual
becomes symptomatic [10]. These factors make P. vivax much harder to control and
eliminate than P. falciparum; hence, in countries reporting fewer than 5,000 cases of
malaria per year over 70% of reported episodes are due to P. vivax [11].
An infectious bite by a mosquito injects sporozoites into the host’s peripheral blood
stream, which then travel to the liver where they invade liver cells (hepatocytes); in
turn the cells release thousands of merozoites that initiate the blood stage infection.
The blood stage infection results in asexual multiplication until the rising parasitaemia
causes a host immune response that causes a cycle of chills and fever that usually
repeats every 24 or 48 hours. Other clinical symptoms include headache, anorexia,
myalgia, abdominal pain, cough, diarrhoea and anaemia [11]. A key difference from P.
falciparum, is that once the sporozoites of P. vivax and P. ovale invade the hepatocytes
a proportion of infected cells differentiate to form dormant stages (hypnozoites), that
can reactivate weeks or months later to initiate another blood stage infection, which
are known as relapses (Figure 1.2) [12, 13].
The frequency and periodicity of P. vivax relapses varies significantly between
geographical regions. In equatorial locations up to 80% of patients will experience
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Figure 1.2: The P. vivax life cycle differs from P. falciparum in that hypnozoites may
be reactivated after the initial infection, causing relapses. Figure from [13].
a relapse and often these occur within six to eight weeks of the primary infection.
Whereas in more temperate regions the risk of relapse is much lower and the relapses
that do occur, do so much later, often many months after the primary attack [12]. The
number of relapses also varies considerably. In military patients returning from high
burden areas, soldiers experienced up to 20 relapses over two years [14]. The periodicity
of P. vivax strains have been categorised in a variety ways [15, 16].
In addition to relapsing infections, recurrent parasitaemia following a primary
episode of malaria can be due to either reinfection or recrudescence. Reinfection
refers to a new episode of malaria originating from another infectious mosquito bite,
whereas a recrudescence refers to a parasite surviving in the blood after treatment, and
subsequently multiplying after the concentrations of the drug drop below therapeutic
levels. While the incidence of any recurrence can be quantified, no reliable method is
currently available for discriminating whether the recurrence was due to reinfection,
relapse or recrudescences. All recurrences can occur with or without symptoms. A
mathematical modelling study in Papua New Guinea estimated that up to 70% of
recurrences were due to relapse, and this figure rose to 96% in Thailand [17]. A study
4
CHAPTER 1. INTRODUCTION
using more recent data from Thailand used a Cox model to estimate that 79% of
recurrences were relapses [18]. This lower percentage is likely due to the longer follow up
time and a lower load of hypnozoites associated with a decrease in malaria transmission
in the study area.
Where vivax is endemic, immunity develops rapidly, with the peak prevalence
occurring in young children and infants [19, 20]. Young children are at particular risk of
anaemia and malnutrition due to repeated episodes caused by relapses [6, 21]. The early
ring forms of P. vivax and P. falciparum are almost identical by microscopy; hence,
where P. vivax and P. falciparum are co-endemic, it can be difficult to distinguish
between the species, particularly as vivax malaria has a lower parasitaemia [5]. These
challenges mean that vivax malaria is less likely to be diagnosed and adequately treated.
1.2 Vivax malaria treatment
Chloroquine has been the traditional treatment for the blood stages of P. vivax and is
the usual treatment for acute infections in most vivax endemic countries. High-grade
chloroquine resistance in P. falciparum has resulted in a switch in antimalarial policy
to artemisinin combination therapy (ACT), which is increasingly used to treat vivax
malaria. The difficulties in distinguishing between true parasite recrudescence and other
recurrences, have resulted in great difficulty in interpreting P. vivax drug efficacy trials,
often causing chloroquine resistance to go unnoticed. Using conservative definitions,
a meta-analysis suggests that chloroquine-resistant P. vivax is widespread and rising
[22, 23]. Several countries have switched to ACT for both species of malaria, including
The Solomon Islands, Vanuatu, Papua New Guinea and Indonesia [22, 24].
While ACTs are highly effective at clearing the blood stages of P. vivax, they have
no efficacy against hypnozoites. An 8-aminoquinoline called primaquine is currently the
only licensed drug that can be prescribed for radical cure. Again, because of difficulties
distinguishing relapses from reinfections, it is difficult to tell whether resistance to
primaquine exists [25]; but a high-dose regimen can prevent over 85% of recurrent
infections when supervised [26, 27]. The standard treatment regimen for primaquine
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requires pills to be taken over 14 days. While this treatment is generally regarded to be
efficacious if all the pills are taken, patient adherence to primaquine is often low due to
the lengthy regimen [28, 29]. While interventions such as directly observed therapy and
patient-centred communication training for healthcare providers, have been successful
in improving adherence to treatment regimens for diseases like tuberculosis and HIV,
fewer interventions have been evaluated for malaria. Two studies in Thailand found
directly observed therapy to improve malaria outcomes [30, 31]; however, in Pakistan
no difference was seen [32]. Accordingly, interventions to improve adherence will need
to be adapted to the setting [33]; designing and evaluating these interventions will be
an important objective for P. vivax research in the coming years.
Shorter treatment regimens over seven days could improve adherence [34, 35], and a
large study is currently underway to assess the safety and non-inferiority of a seven day
regimen [36]. Seven day regimens require a higher daily dose which is associated with
more gastrointestinal side-effects and, importantly, an increased potential to induce
haemolytic anaemia particularly in individuals with glucose-6-phosphate dehydrogenase
(G6PD) deficiency.
1.3 The challenge of G6PD deficiency
G6PD deficiency is the most common human enzyme defect, ranging in prevalence from
less than 1% to over 30% of some populations. The prevalence of G6PD deficiency
is particularly high in malaria endemic areas [37, 38]. Around 140 variants of G6PD
deficiency exist, and the haemolytic risks associated with each variant varies [39]. G6PD
is an enzyme that turns carbohydrates into energy, protecting red blood cells from
oxidative stress. Individuals with G6PD deficiency either do not have enough of the
enzyme or the enzyme does not properly function, and both of these factors result in
more rapid death of red blood cells. Nearly 400 million individuals worldwide have
G6PD deficiency; these individuals are vulnerable to primaquine-induced haemolysis
that gives rise to a range of clinical manifestations from mild to severe and even fatal
[39].
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G6PD deficiency is an x-linked disorder; hence, males have only one copy of the
gene and can be hemizygous normal or deficient, whereas females carry two copies of
the gene and therefore can be either homozygous normal or deficient, or heterozygous.
Due to X-chromosome inactivation, heterozygous females are genetic mosaics with cells
randomly inactivating one chromosome or the other, a process known as lyonisation.
This process results in a broad spectrum of enzyme activity in females, whilst in males
individuals have either normal or very low enzyme activity [39]. The genotype refers
to the genetic mutation that causes deficiency, whereas the phenotype, refers to the
degree of enzymatic activity that determines the clinical outcome. The classification
of enzymatic activity as normal or deficient is determined by population median and
varies by location. The risk of haemolysis worsens as the enzyme activity falls, with
standard 14 day primaquine regimen often contraindicated in patients with an activity
less than 30%. One recent study, however, demonstrated that female heterozygotes
with activity less than 70% may also have significant haemolysis [40].
Several studies have shown that the prevalence of G6PD deficiency in patients
presenting with P. vivax malaria is lower than that in the general population; suggesting
that G6PD deficiency may confer a degree of protection against malaria [41, 42, 43].
This protection is likely to vary by G6PD variant and parasite strain. In individuals
with severe G6PD deficiency, radical cure can be achieved with a weekly dose of
primaquine administered for eight weeks [44], although little clinical evidence has
been provided regarding the safety and efficacy of such a regimen. Primaquine is also
contraindicated in pregnant women due to the unknown G6PD status of the foetus.
It is also contraindicated in breastfeeding women due to concerns of excretion of the
drug in breast milk; however, recent evidence suggests that the amount of primaquine
excreted in the milk is low and thus dangers to the infant may have been exaggerated
[45].
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1.4 Screening for G6PD deficiency and future
options for radical cure
The World Health Organisation (WHO) recommends that primaquine should be used
for the radical cure of P. vivax patients, but where possible all patients should be tested
for G6PD deficiency prior to administration [44], in many malaria endemic communities
routine G6PD screening is not undertaken prior to primaquine administration, either
due to the lack of suitable point-of-care diagnostics or the cost and logistical difficulties
of delivering these. In such areas patients with G6PD deficiency may be put at risk
of severe drug-induced haemolysis. While the degree of risk is not well-defined and
possibly very low [46], healthcare providers are often reluctant to prescribe primaquine
for fear of these immediate adverse effects. In areas where primaquine is not used,
patients are at high risk of relapse and a cumulative risk of severe anaemia due to
parasite-induced haemolysis. For these reasons, it is difficult to weigh up the risks and
benefits of primaquine use.
Other barriers to routine G6PD testing include the additional costs of implemen-
tation, the clinical perception that the risk of drug-induced haemolysis is low or that
radical cure is not a priority due to the perception that vivax malaria is benign [47].
Spectrophotometry is the gold standard test of G6PD activity, but requires specialised
staff and laboratory facilities [48, 49]. Until recently, the only point-of-care test for
G6PD deficiency was the fluorescent spot test (FST). The FST requires basic laboratory
equipment, rendering it difficult to implement in many field settings. Recently developed
qualitative point-of-care G6PD RDTs have a high sensitivity for detecting severe G6PD
deficiency, but do not identify those individuals with moderate G6PD deficiency, such
as heterozygous females [50, 51, 52]. These currently available G6PD RDTs can be
difficult to interpret, potentially lowering their diagnostic accuracy due to misreading
the result [53]. Ultimately, the implementation of G6PD RDTs is undermined by the
lack of licenses that would allow national malaria control programs to purchase them
with global fund subsidy. Until screening tests for G6PD deficiency are widely available
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and affordable, policymakers and health workers in many areas will be reluctant to use
primaquine for the treatment of P. vivax.
Tafenoquine is another 8-aminoquinoline drug, currently in phase III clinical trials
with registration anticipated in 2018. It can achieve radical cure with a single dose,
eliminating the issues associated with poor patient adherence to a 14 day primaquine
regimen [54, 55, 56]. While one study showed its haemolytic potential to be similar to 14
day primaquine in heterozygous females, the drug has an increased risk of a prolonged
haemolysis due to its longer half-life. Accordingly, the prescription of tafenoquine will
demand a quantitative test to screen for G6PD deficiency to rule out patients with an
enzyme activity less than 70% [54].
1.5 Prospects and challenges for inclusion of P.
vivax in malaria elimination campaigns
As discussed above, P. falciparum is more susceptible to traditional control measures,
such as bednets (which target mosquitos that bite at night), screening (which is more
likely to detect falciparum infections with their higher parastaemia) and treatment for
blood stage infections (which ignores the hypnozoite reservoir). These factors result in
a greater decrease in P. falciparum than P. vivax in co-endemic areas. Even in areas
where the burden of disease is largely due to P. vivax, the focus of malaria elimination
efforts is usually on P. falciparum. One example is the malaria elimination efforts in
the Greater Mekong Subregion. These focus on P. falciparum, due to the urgency
engendered by the emergence of artemisinin resistance [57], but had no impact on vivax
malaria since radical cure was not given to patients who presented with it [58].
The elimination of vivax malaria therefore presents daunting challenges and any
prospects of success will require frequent use of radical treatment for infected individuals,
many of whom are asymptomatic. Excluding vivax malaria as a target for elimination
could in fact compromise P. falciparum elimination campaigns and efforts to maintain
malaria free status. If communities continue to experience cases of malaria, even if due
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to another type of parasite, then it could result in reduced willingness to participate
in future elimination activities for the remaining species of malaria and to prevent
re-introduction of P. falciparum. In an effort to accelerate malaria elimination in the
Greater Mekong Subregion, the use of mass drug administration or mass screening and
treatment is now being investigated. Alongside these programs, intense community en-
gagement activities are required to communicate the importance of taking antimalarials
to eliminate P. falciparum from the community. While campaigns can explain that they
are targeting only one type of malaria, it will be challenging to re-engage with these
communities after P. falciparum elimination if they do not understand the distinction
between species. Finally, any delay in the elimination of P. vivax will likely require
financial and human resources to be sustained over a much longer period of time than
if both species was addressed jointly.
1.6 The intersection of P. vivax with health
economics
Health economics has great potential to improve the health of populations by optimising
the amount of health gained for money spent. While the bulk of research in health
economics focuses on the cost of illness and economic evaluation, or the micro-economic
impact of alternative strategies for delivering health care, the field of health economics
encompasses a much broader remit, most of which is beyond the scope of this thesis but
touched upon briefly here. As described by Williams, a number of factors influence health
and are influenced by health, including education, wealth, life style and employment
conditions [59]. An example of this in vivax malaria is that a single episode can impair
educational attainment [60] while a person’s education can influence their knowledge
about when they should seek treatment for febrile illness because it could be malaria.
Poorer individuals are more likely to be at risk of vivax malaria due to occupational
hazards (i.e. more time outside due to farming and hunting) while those who have
malaria are likely to incur financial and productivity losses from their illness.
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Demand is a particularly thorny issue in that health care is typically needed,
rather than wanted, and because of the agency relationship between patients and their
healthcare providers. This is a potential conflict of interest in that those who give the
expert opinion on what care is needed are also responsible for supplying that care. For
P. vivax, this is most obvious in the use of radical cure. In some settings healthcare
providers don’t prescribe primaquine due to fear of haemolysis in individuals with G6PD
deficiency, but in other settings patients are given primaquine without screening for
G6PD deficiency because healthcare providers do not see it as enough of a risk. Vivax
malaria patients are reliant on their healthcare providers to tell them whether radical
cure should be taken and also to provide it for them. Further information assymmetries
include the lack of perfect information about the risk of primaquine-induced haemolysis
and the risk of recurrence due to P. vivax.
The supply of health care involves the cost of delivering care and how different
systems of financing health care impact the behaviour of those who supply it. Most of
the financing for malaria is vertical and focused on P. falciparum instead of P. vivax,
which can influence how malaria is diagnosed and treated in a community. Countries
with P. vivax are less likely to receive international support for malaria control than P.
falciparum [61]. Ideally, supply and demand should balance out through market-clearing
prices where the quantity supplied is equal to the quantity demanded, but again, health
economics is different. Instead, the rationing of care often occurs through mechanisms
such as waiting times and priority-setting criteria. Another potential market failure
for vivax malaria is common amongst the infectious diseases: effective treatment and
control will have a positive externality in terms of the prevention of onward transmission.
Moreover, the planning, budgeting and monitoring mechanisms implemented in a health
system will influence the incentives of the stakeholders to discover and implementation
of improvements to its efficiency. Evaluations at the whole system level can explore the
overall performance, including equity and allocative efficiency (whether the resources
spent on health care are producing the most possible health).
Moving to economic evaluation, cost-effectiveness analysis is an approach that
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enables the comparison of different healthcare options by using a common outcome
unit. Often, a specific type of cost-effectiveness analysis called a cost-utility analysis
is used, enabling comparisons between diseases with a common measure of outcome
encompassing both mortality and morbidity, and its implications for quality of life.
The two most frequently used outcomes are quality-adjusted life-years (QALYs) and
disability-adjust life-years (DALYs). Studies using QALYs seek to maximise them.
These are more frequently used in developed countries and involve a tariff that reflects
the preferences of the community where the decision is taking place. In contrast to
QALYs, the aim is to minimise DALYs. These are applicable across populations and
are more commonly used in developing countries.
Regardless of the metric used, the use of cost-effectiveness analyses to evaluate
alternative courses of actions is essential to making the most efficient use of scarce
resources [62, 63]. When an intervention saves money while improving outcomes, it
“dominates” the alternative; and the decision to adopt should be straightforward. When
comparing interventions where one option improves outcomes but costs more, the
alternatives can be compared using the incremental cost-effectiveness ratio (ICER),
which involves the increase in costs divided by the increase in QALYs or reduction in
DALYs. If the ICER is less than the willingness to pay (WTP) threshold, then the
intervention is considered to be cost-effective.
The WHO initially recommended that the WTP threshold per DALY averted be set
at one to three times the gross domestic product (GDP) per capita [64], but recently
re-emphasised that decisions need to be context-specific and that other factors, such as
feasibility and budget impact, should also be considered [65]. This guidance is in line
with recent studies that have suggested that the WTP threshold should be much lower
[66, 67]. Since the country-level financing for malaria is often a ring-fenced amount
of money, one alternative is to use resource allocation based on cost-effectiveness [68].
Another option is to use a form of economic evaluation called cost-benefit analysis
where the effects are valuated in monetary terms. When the monetised benefits exceed
the costs, then a policy should be implemented. In this way, changes in global health
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expenditures can be compared to options in other sectors.
1.7 The economics of P. vivax treatment
Although great progress has been made in describing disease outcomes due to P. vivax,
many questions remain about the cost-effectiveness of its diagnosis, treatment and
management. As previously discussed, the supply of funding for malaria is often
focused on P. falciparum due to the urgency of the elimination campaigns. A recent
literature review by White et al. found only 16 studies that have addressed the costs
and cost-effectiveness of vivax interventions [8]. To contrast those numbers, a systematic
review by the same author published five years prior found 55 studies on the costs and
cost-effectiveness of malaria control, most of which were focused on P. falciparum [69].
When limiting to the diagnosis and treatment of vivax, only nine previous studies were
included in White et al.’s review. Three of those studies focused only on diagnostic
testing while the remaining included treatment options. The nine studies included a
range of percentages of P. vivax cases from 30% in Papua New Guinea [70] to over 90%
in Afghanistan [71]. The study in Papua New Guinea was the only one to examine
a unified treatment of ACT for both P. vivax and P. falciparum, finding it to be a
cost-effective option using a 42 day follow up period [70]. To update White et al.’s
review, a search using the terms “vivax” and “cost” or “economic”: no further relevant
studies were found.
The economic burden of P. vivax is difficult to determine for a variety of reasons.
Cases often occur in rural areas where there are poor healthcare systems and it is often
difficult to access care, which can influence treatment-seeking behaviour and the demand
for care. Deaths often occur away from facilities, resulting in them not being diagnosed
or reported [5]. While it is still commonly believed that these symptoms are only caused
by P. falciparum, a meta-analysis of P. vivax clinical trials listed an extensive number of
associated severe outcomes including severe anaemia, shock, multiple convulsions, renal
dysfunction, respiratory dysfunction and cerebral malaria [72]. Furthermore, repeated
vivax episodes can increase vulnerability to other diseases, such as malnutrition and
13
CHAPTER 1. INTRODUCTION
anaemia, and it can be difficult to disentangle these factors [6, 21, 73].
In addition to morbidity and mortality, the costs associated with treating the disease
need to be considered. Costs to the healthcare provider comprise of the direct cost
to diagnose and treat a clinical case. When expanding to the societal perspective,
the direct costs of seeking treatment for the patient and any companions, which may
occur multiple times per episode, and the cost of transport should be included. The
indirect costs of disease, including lost productivity, are rarely documented but can be
substantial, particularly as children who bear the highest burden of disease will require
a caretaker. Finally, the impact of malaria episodes on educational and developmental
attainment are increasingly recognized, but again the evidence base for vivax is less
established than that for P. falciparum [60, 74]. For example, a number of studies have
shown the impact of P. falciparum on education [75, 76], but evidence on the impact of
P. vivax on education are scarce.
1.8 Aims and objectives
The aim of this thesis is to describe the costs and cost-effectiveness of treatment options
for P. vivax malaria and the burden of disease associated with it. The specific objectives
are the following:
1. Describe the costs due to vivax malaria episodes from the societal and healthcare
provider perspectives (Chapters 2 & 5).
2. Describe the treatment-seeking behaviour and provider compliance following
implementation of a universal policy of ACT for all species of malaria in Timika,
Indonesia, where a large proportion of cases are due to vivax malaria (Chapter
3).
3. Evaluate the cost-effectiveness of screening for G6PD deficiency before treatment
with supervised primaquine therapy (Chapter 4).
4. Describe what is currently known about the global economic cost burden due
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to P. vivax malaria, the potential costs associated with a worldwide policy of
screening before giving radical cure, and the potential cost-benefit associated with
a reduction in vivax episodes (Chapter 6).
The thesis is divided into five main chapters (Chapters 2-6) and an overall discussion
(Chapter 7) that combines the economic analyses undertaken in the preceding chapters
and discusses the implications for the allocation of resources required for the diagnosis,
treatment, control and ultimately, the elimination of vivax malaria.
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Treatment-seeking behaviour and
associated costs for malaria in
Papua, Indonesia
This chapter has been published as Karyana M*, Devine A*, Kenangalem E, Burdarm
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seeking behaviour and associated costs for malaria in Papua, Indonesia. Malar J.
2016;15(1):536. https://doi.org/10.1186/s12936-016-1588-8. PMID: 27821127.
* Joint first authors.
2.1 Introduction
Great progress has been made in reducing the burden of malaria in the Asia Pacific
region, however the ultimate goal of eliminating malaria has been undermined by the
emergence and spread of drug resistance. The WHO recommends that once antimalarial
efficacy falls below 90%, treatment policy should be changed with a combination therapy
with greater than 95% efficacy [1].
The impact of any antimalarial drug policy will depend on how it is implemented,
and whether it ensures that individuals with malaria can easily access and receive the
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right treatment and diagnostics at an affordable cost. Early diagnosis of individuals with
malaria and administration of effective treatment is critical both to individual patients
in ensuring rapid resolution of symptoms and preventing progression to severe disease,
but also the community, by reducing further transmission and spread of antimalarial
drug resistance.
In many malaria-endemic countries, the private sector is an important source of care
for individuals seeking treatment for malaria and most of the spending is out-of-pocket.
The private sector comprises a diverse range of providers including private hospitals,
registered pharmacies and unlicensed drug shops. Having an understanding of the role of
different types of healthcare providers and engaging with them appropriately is therefore
very important if changes in policy are to result in actual change in how patients with
malaria are treated. Treatment-seeking behaviour of patients with symptomatic malaria
is influenced by socio-economic factors, knowledge and beliefs, and access to healthcare
provision. Malaria disproportionately affects rural poor households for whom one
episode of illness can have catastrophic results, not only in terms of morbidity and
mortality but also in terms of financial burden.
The literature on treatment-seeking behaviour for malaria, has shown that individuals
often begin by taking treatment at home or from traditional healers and then move on
to private drug sellers with few accessing public facilities directly [2, 3]. In Sub-Saharan
Africa, which carries the highest burden of malaria, studies have shown that less than
25% of the private providers have malaria tests available [4, 5]. In Asia, a recent
household survey in Cambodia showed that two-thirds of individuals seek treatment at
private providers [6]. Another survey in Myanmar revealed that nearly half of those
who sought treatment did so at private providers where they were less likely to receive a
diagnostic test for malaria and more likely to receive antimalarials without a diagnosis
[7].
The greatest burden of malaria in Indonesia is in the eastern provinces including
Papua, where P. falciparum and P. vivax are the dominant species [8, 9]. Malaria
outbreaks are frequent, often triggered by the migration of non-immune individuals
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from low to high transmission areas [10]. Prior to 2006, the first-line treatment of
uncomplicated P. falciparum malaria was chloroquine plus sulfadoxine-pyrimethamine
(SP) and that for patients with uncomplicated P. vivax was chloroquine with 14 days
of unsupervised primaquine (total dose 3.5mg/kg over 14 days), for patients over one
year of age [11]. A series of antimalarial efficacy studies conducted in 2004 and 2005,
documented high levels of resistance to both chloroquine and SP [12, 13].
At the time of this household survey, little data were available on treatment-seeking
behaviour, antimalarial drug use and household costs of treatment for malaria in
Indonesia, where malaria remains a significant public health concern [14, 15]. A
household survey in 2002-2003 indicated that less than 1% of children under the age
of five received an antimalarial for fever [15]. Another household survey conducted in
Java in 2006 showed that the public sector was the primary source of malaria treatment
for less than half of those with self-reported malaria [14]. Although several treatment-
seeking surveys have been conducted in Asia [6, 7, 14, 16, 17, 18, 19, 20, 21, 22], almost
no data exists on the associated healthcare costs for P. falciparum and P. vivax malaria
in a co-endemic area as only one reported costs associated with each malarial episode
with little detail on what these costs entailed [14].
The aims of the current study were (1) to describe treatment-seeking behaviour for
fever and (2) to describe the associated costs of P. vivax and P. falciparum infection in
Papua, prior to March 2006, when policy was changed to dihydoartemisinin-piperaquine
(a fixed dose combination therapy) for uncomplicated malaria due to any species of
malaria. A subsequent household survey to determine changes in treatment seeking
and costs was conducted in 2013 and is reported in Chapter 3.
2.2 Methods
2.2.1 Site details
The survey was conducted in Mimika Regency, southern Papua, Indonesia. This district
covers an area of 21,522 km2 with approximately 130,000 people living in 12 districts in
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2004. Most of the population resides in Timika town and the surrounding villages. The
area is inhabited by a variety of ethnic groups which are broadly categorized as lowland
Papuans, highland Papuans or non-Papuans. The demographics, malaria transmission
and health services in this region have been described previously [8].
The area is covered with thick rain forest with both coastal and mountainous
areas. Malaria transmission occurs throughout the year and is restricted to the lowland
area where most of the population lives. Immigration to work at the local mine is
considerable and has the potential both to expose non-immune individuals to malaria
and to introduce malaria from other areas of Indonesia. There are three mosquito
vectors: Anopheles koliensis, Anopheles farauti and Anopheles punctulatus. Based on
the malaria surveillance data, the annual incidence of clinical malaria, is estimated
to be approximately 876 episodes per 1,000 people, with a slight predominance of P.
falciparum infection (46%) compared to P. vivax (39%) [8].
Healthcare provision is provided free of charge at the hospital, 12 Government-funded
Primary Health Clinics (Puskesmas) and, for those employed by a local mining company,
at the malaria control clinics where parasitological diagnosis by microscopy, and rapid
diagnostic test are available. There is also a thriving private sector which includes
clinics, pharmacies and drug stores. Whilst antimalarials are officially prescription
drugs, they can also be purchased over the counter in the private sector [10]. The
malaria surveillance program does not capture the malaria cases seen in the private
sector.
2.2.2 Household sampling strategy
The survey was conducted in the Mimika district between July and December 2005.
The sample size calculation aimed to estimate the true prevalence of households
with someone with a recent history of fever and was based on an estimated prevalence
of 40% and population size of 140,000; a multiplication factor of two was used to take
into account the design effect due to cluster sampling. A sample size of 800 households
was required to achieve an estimate of prevalence with greater than 95% confidence.
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A three-stage cluster sampling procedure was applied to identify 32 clusters of 25
households [23]. Firstly the four most populous subdistricts (Mimika Baru, Mimika
Timur, Kuala Kencana and Tembaga Pura) were chosen from the 12 subdistricts based
on their accessibility by road from the main town of Timika and because they included
the majority (80%) of the districts population. Secondly, the number of clusters in
each subdistrict was apportioned according to their relative populations. The houses
were then assigned numbers according to their geographical location and clusters of
25 houses were identified randomly according to WHO guidelines with the first house
identified by random allocation.
Members of the households were defined as all individuals living under one roof,
who ate from one kitchen and had resided in the study area for at least six months. If a
selected household was empty, the interviewer returned the next day. If still unoccupied,
the next occupied household was sampled instead. Temporary migrants were defined as
individuals who had moved into the area within last six months and did not plan to
stay longer than six months; these were excluded from the survey.
2.2.3 Data collection
The survey was conducted using a structured questionnaire capturing self-reported
household demographic data, income, average monthly food and non-food expenditures,
expenditure on healthcare in the last month, ownership of assets, and bed net ownership
and use. Nearly all surveys were conducted in the local language, Bahasa Indonesian.
The survey was conducted with the head of the household or another suitable adult
and details on all household members gathered. Those members who were present were
asked specific details about recent illness, had a physical examination and were asked
to consent to a blood film as previously described [8].
In order to obtain detailed information about the care-seeking process and cost of
illness, individuals reporting a history of fever in the preceding 30 days were asked
to complete a separate module on treatment seeking, comprising of questions on all
the places that they went to seek treatment, whether they received a blood test and
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the type of medicines they received. They were also asked about direct and indirect
household costs including the cost of treatment, transport, productivity losses due to
illness, and companion, caretaking and substitute labour [21].
An exit survey was also undertaken on patients with confirmed malaria as they left
public facilities in order to collect accurate information on household costs in relation
to type (species) of malaria infection. The exit interviews were carried out over a
period of four months in the hospital, two of the four Puskesmas and three of the eight
malaria control clinics. The number of interviews per type of facility was proportional
to the number of malaria patients each facility saw each month. Any patient with
a parasitological diagnosis of malaria was eligible for inclusion. Patients completed
a questionnaire with the aid of a research nurse to document treatment seeking and
costs of illness. With a shorter time between the event and the survey, these results
were less likely to be confounded by recall bias and enabled a greater certainty about
malaria species diagnosis with the disadvantage of truncating the costs at the end of
the healthcare visit.
2.2.4 Data analysis
Data were analysed using STATA statistical software (version 14) [24] and R (version
3.2.3) [25]. Frequencies and percentages were used for the descriptive data. Percentages
were compared using the chi-square test (X2). Differences in outcome distributions
were tested using Mann Whitney test for two groups and the Kruskal Wallis H test for
more than two groups. Continuous variables were compared using Spearmans rank for
correlation. Simple logistic regression was used to calculate odds ratios (ORs). The
variables that were significant risk factors (p < 0.05) for fever in the past month in the
univariate analysis were included in a multiple logistic regression model. Regression
models involving behaviour of the individuals were adjusted for clustering by households,
since more than one household member could have been present for each household.
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Treatment-seeking behaviour
For the analysis on treatment-seeking behaviour, those who reported that their fever
started in the last two days were excluded in order to ensure that only individuals
who had had sufficient time to seek or not seek treatment were included. For those
included in the treatment-seeking behaviour analysis, the following outcomes were
calculated: the percentage that reported taking any medicines (including at home or
traditional medicine) and percentage seeking treatment outside of the home according
to the number and type of provider, categorised into private providers (private clinics,
pharmacies and drug shops) and public facilities (the hospital, Puskesmas and malaria
control clinics).
In order to explore how patients were managed at each provider in terms of blood
testing and prescriptions of antimalarials, further analysis was undertaken on each
patient-provider interaction (visit). A visit could be inpatient or outpatient. As
antimalarial injections pose the risk of infection to patients and are largely inappropriate
treatments for uncomplicated malaria, individuals were also asked whether they received
an injection or tablets or both.
Socio-economic status
In order to categorise the surveyed by SES, a Discriminant Analysis of Principal
Components [26] was used to analyse the data on reported household ownership of
assets. This approach maximized between group variability while minimising within
group variability, capturing heterogeneity in ownership that was not seen using a
standard principal component analysis [27]. In order to investigate the relationship
between SES and other outcomes captured by the survey, the groups were ranked from
poorest to richest in terms of both income and expenditure per household member.
Costs
Costs were gathered in Indonesian rupiah (IDR), and converted into United States
Dollars (US$) using the average exchange rate for 2005 [28] and then revised to the
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2014 equivalent using the consumer price index for Indonesia [29]. To represent the
cost burden on households, the mean and standard deviation (SD) are reported. As the
data were skewed, the Mann-Whitney test was used for comparisons, and the median
and interquartile range (IQR) are also included. Direct costs, including consultation,
diagnosis, medication, overnight stays, administration and transportation, were reported
according to where treatment was obtained [30]. Indirect costs, including lost wages for
companions, caretakers and substitute labourers, are aggregated into cost per individual
taking treatment. As a result, when multiple companions, caretakers or substitute
labourers were reported for a single individual taking treatment, their times were
summed, resulting in the mean days per individual taking treatment. The mean wage
was calculated for all who reported a wage, including individuals taking treatment,
companions, caretakers and substitute labourers. This wage was applied to all who
reported reducing their activities because they had a fever or were a companion, caretaker
or substitute labourer for someone with a fever. While this may have overestimated the
losses for individuals who are unpaid for their labour (i.e. housework), it attempts to
capture the productivity losses for those individuals and the households that rely on
them. For those who reported reducing some of their usual activities, the days of lost
activity were multiplied by one half day’s wage and included in the total costs.
2.3 Results
Table 2.1 describes the questionnaires, sample sizes and dates included in the surveys.
2.3.1 Household demographics, SES and expenditure
In total 825 households with 5,255 individuals were included in the survey between
July and December 2005 (Figure 2.1). The median household size was six individuals
(IQR, 4−8) with a maximum of 24 in one house. The median duration that a household
had lived at that location was nine years (IQR, 4−15). Thirty four (4%) of households
reported moving into that location less than a year previously. Of the 763 households
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Table 2.1: Surveys, questionnaires included in the surveys, sample sizes and dates.
Survey Questionnaire Sample size Dates
Household Socio-demographic details 825* June to November 2005
Household Household members 5255 June to November 2005
Household Fever in past month & parasite positivity 3896 June to November 2005
Household Treatment seeking 1176 June to November 2005
Household Costs 1176 June to November 2005
Hospital Exit Socio-demographic details 358 May to November 2005
Hospital Exit Treatment seeking 358 May to November 2005
Hospital Exit Costs 358 May to November 2005
* This is the number of households. All other sample sizes are for individuals.
in which income was recorded, 63% (482) reported a total monthly income of less than
US$500.
For the SES, the Discriminant Analysis of Principal Components resulted in house-
holds being split into five groups ranging in size from 111 to 203. Richer households had
electricity and owned electrical items but did not always own a house or land, whereas
poorer households tended to own houses, land and grow crops, but were less likely to
have electricity (Figure 2.2). Household SES was significantly lower in Highland Papuan
household with 47% (101/216) of Highland Papuans in the poorest categories compared
to 12% (22/190) of Lowland Papuans and 4% (16/416) of non-Papuans (p < 0.001).
The household general health expenditure in the previous month was significantly lower
in households with lower SES (p < 0.001; Figure 2.3). The estimated household general
health expenditure was correlated with the number of individuals reporting fever in a
household (ρ = 0.209, p < 0.001).
Only 340 (41%) of households reported owning a bed net, and this was inversely
correlated with SES with 51% (72/140) in the poorest group reported bed net ownership
as compared to 29% (32/111) in the richest (p < 0.001).
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5255 individuals
825 households
1359 individuals not present at interview:
182 reported fever by family 
1177 no report of fever by family 
3896 individuals present at interview
825 households
1631 had fever in the last month
700 households
455 no treatment seeking questionnaire 
available 
2265 individuals reported no fever in the 
last month
1176 were given the treatment seeking 
questionnaire
587 households
1104 included in the analysis
575 households
72 reported fever that started less than 2 
days before surveyed
270 individuals did not take medicines
187 households 
834 took medicines
494 households
325 from public provider 84 drugs from home or neighbor425 from private provider
283 no further 
medicines taken
18 public provider
23 private provider
1 medicines at home
360 no further 
medicines taken
70 no further 
medicines taken
15 public provider
47 private provider
3 medicines at home
6 public provider
8 private provider
0 medicines at home
Figure 2.1: Flow Diagram of household members, interviews, initial location of treatment
taking, and whether took a second treatment.
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Figure 2.2: Results from the Discriminant Analysis of Principal Components to construct
SES groupings for 2005. A) Shows the household income divided by the number of
household members for each group (2014 US$). B) Shows the monthly household
expenditure divided by the household members (2014 US$) for each group. C) Tree
plot of ownership by groups from poorest (black) to richest (lightest grey).
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Figure 2.3: Mean household expenditure on health by SES groups.
37
CHAPTER 2. TREATMENT-SEEKING BEHAVIOUR AND ASSOCIATED COSTS
FOR MALARIA IN PAPUA, INDONESIA
Table 2.2: Demographic characteristics of individuals in surveyed households.
Characteristic
All
household
members
(N=5255)
Present
during
survey
(N=3896)
Reported fever
during previous
month
(N=1631, 42%)
Reported fever starting
>2 days before survey
and took treatment
(N=834, 51%)
Age (years) − n (%)
0-4 870 (17%) 820 (21%) 405 (25%) 205 (25%)
5-14 1101 (21%) 824 (21%) 306 (19%) 148 (18%)
15+ 3284 (62%) 2252 (58%) 920 (56%) 481 (58%)
Sex (Female) − n (%) 2409 (46%) 2019 (52%) 850 (52%) 433 (52%)
Pregnant (Yes) − n (%) 92 (2%) 87 (2%) 39 (2%) 23 (3%)
Place of birth − n (%)
Highland Papuan 1494 (28%) 1045 (27%) 385 (24%) 172 (21%)
Lowland Papuan 1371 (26%) 1024 (26%) 463 (28%) 183 (22%)
Non-Papuan 2390 (45%) 1827 (47%) 783 (48%) 479 (57%)
Resided in lowlands for more
than one year? (Yes) − n (%) 4969 (95%) 3674 (94%) 1547 (95%) 797 (96%)
District − n (%)
Mimika Baru 4401 (84%) 3242 (83%) 1401 (86%) 740 (89%)
Mimika Timur 371 (7%) 286 (7%) 108 (7%) 11 (1%)
Kuala Kencana 331 (6%) 249 (6%) 93 (6%) 65 (8%)
Tembaga Pura 152 (3%) 119 (3%) 29 (2%) 18 (2%)
2.3.2 History of fevers and parasite positivity of household
members
In total 3896 (74%) of individuals were present at the time of interview (Figure 2.1)
of whom 48% (1877) were male, 42% (1644) were under the age of 15 (Table 2.2),
and 53% (2069) were Papuan. In total, 1631 (42%) of individuals from 700 (85%)
households reported having had a febrile illness in the preceding month. Significant
independent risk factors for febrile illness included age, ethnicity, and poor economic
status (Table 2.3).
In those who consented to blood testing, malaria slide positivity was 16% (634/3890)
of whom 46% (290) were infected with P. falciparum, 39% (248) with P. vivax, 11%
(72) with mixed infections and 4% (24) with P. malariae. Individuals in the lower three
SES groups were more likely to be parasite positive than those in the top two SES
groups (OR = 1.33 [95% CI: 1.05−1.68], p = 0.019).
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Table 2.3: Logistic regression analysis of risk factors for reporting a fever in the past
month (N=3896).
Variable OR (95% CI) p value AOR (95% CI) p value
Gender
Male Reference Reference
Female 1.02 (0.90−1.16) 0.756 – –
Age
< 5 years 1.47 (1.26−1.73) <0.001 1.49 (1.27−1.74) <0.001
≥ 5 years Reference Reference
Pregnant
No Reference Reference
Yes 1.13 (0.74−1.73) 0.566 − −
Household size
≤ 7 members 1.16 (0.98−1.38) 0.091 − −
> 7 members Reference Reference
SES groups
Richest Reference Reference
Fourth 1.47 (1.11−1.95) 0.007 1.47 (1.11−1.96) 0.007
Middle 1.33 (1.00−1.76) 0.050 1.40 (1.05−1.87) 0.022
Second 1.17 (0.89−1.53) 0.270 1.35 (1.01−1.80) 0.046
Poorest 1.52 (1.15−2.00) 0.003 2.04 (1.48−2.81) <0.001
Ethnicity
Highland Papuan Reference Reference
Lowland Papuan 1.41 (1.12−1.78) 0.003 1.64 (1.28−2.10) <0.001
Non-Papuan 1.29 (1.06−1.55) 0.009 1.59 (1.26−2.01) <0.001
Resided in lowlands > 1 year?
No Reference Reference
Yes 1.19 (0.86−1.66) 0.292 −
Family sleeps under a bednet?
No Reference Reference
Yes 1.02 (0.86−1.21) 0.792 −
The multiple logistic regression included variables that were significant (p < 0.05) in
the univariate logistic regression.
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2.3.3 Treatment-seeking behaviour of household members
Treatment-seeking behaviour was assessed in 72% (1176/1631) of individuals who
reported fever in the preceding month (Figure 2.1). The analysis of treatment seeking
was restricted to the 94% (1104/1176) of individuals with a fever commencing at least
two days before the survey (Figure 2.1). Three-quarters (76%, 834/1104) reportedly
took some form of medicine. For the 270 (24%) of participants who did not take any
medication, the most common explanation offered was that the disease was not severe
enough to warrant it (169, 63%).
Of those who took some form of medicine, 92% (764/834) sought treatment outside
of the home at some point. Treatment seeking outside of the home was significantly
more likely in those who had a febrile illness lasting two or more days (OR = 2.97 [95%
CI: 2.15−4.09], p < 0.001), were in the richest two SES groups (OR = 1.99 [95% CI:
1.42−2.78], p < 0.001) and were non-Papuan (OR = 2.63 [95% CI: 1.92−3.60], p <
0.001). Treatment seeking was not influenced by age or gender. Of those who sought
treatment outside of the home, 46% (349/764) went to a public provider at least once;
this percentage being greater in those who were female, less than 15 years old, Papuan
ethnicity or from the poorest SES (Table 2.4).
The 764 individuals who sought treatment outside of the home reported a total
of 894 visits to healthcare providers. Further analyses were undertaken on these 894
interactions with providers.
2.3.4 Diagnosis of malaria at healthcare providers
Out of the 894 visits to healthcare providers, a blood test for malaria was reportedly
undertaken in 433 (48%) of these visits (Table 2.5) of which 78% (337) were reportedly
positive: half (167) P. falciparum, 47% (159) P. vivax, 3% (10) mixed infections and
0.3% (1) P. malariae. For 3% (12/433) of visits, no result was reported. Children less
than 14 years old were more likely to have a blood test compared to individuals over
the age of 14 (OR 1.42 [95% CI: 1.10−1.84], p = 0.007), although they were less likely
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Table 2.4: Sociodemographic characteristics associated with whether ever sought treat-
ment at a public provider (N=764).
Source of treatment [% (n)]
Variable
Private provider(s)
only (N=415)
Public provider
ever (N=349)
Univariate odds
ratio (95% CI) p value
Gender
Male 60% (219) 40% (148) Reference
Female 49% (196) 51% (201) 1.51 (1.14−2.02) 0.004
Age group
15+ years 59% (261) 41% (180) Reference
5-15 years 46% (61) 54% (71) 1.69 (1.13−2.53) 0.011
<5 years 49% (93) 51% (98) 1.53 (1.06−2.21) 0.024
Ethnicity
Non-Papuan 67% (288) 33% (142) Reference
Papuan 38% (127) 62% (207) 3.31 (2.31−4.73) <0.001
SES quintile
Highest 76% (100) 24% (32) Reference
Fourth 59% (99) 41% (68) 2.14 (1.17−3.93) 0.013
Middle 58% (100) 42% (73) 2.28 (1.25−4.16) 0.007
Second 46% (80) 54% (95) 3.71 (2.03−6.78) <0.001
Poorest 31% (36) 69% (81) 7.03 (3.82−12.95) <0.001
This is among fever patients who sought treatment outside of the home (includes
inpatient and outpatient visits).
95% CI = 95% confidence intervals.
to have a detectable parasitaemia (OR 0.30 [95% CI: 0.18−0.51], p < 0.001).
2.3.5 Antimalarial treatment at healthcare providers
An antimalarial (alone or with other medicines) was reportedly prescribed during 61%
(547/894) of visits: 86% (471/547) of which were prescribed as tablets, 5% (30/547) as
an injection and 8% (46/547) as both an injection and tablets. Overall, public facilities
were significantly more likely to prescribe antimalarial treatment than private providers
(OR = 1.41 [95% CI 1.07−1.86], p = 0.015); Table 2.5, however, shows that the majority
(92%, 70/76) of antimalarial injections were administered by private clinics or doctors.
In relation to parasitological testing prior to antimalarial prescription as per clinical
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Table 2.5: Percentage of respondents who reported receiving blood tests, antimalarials and associated costs (N=894).
Healthcare provider
Percentage with
blood test for
malaria n (%)
Frequency anti-
malarials were
prescribed n (%)
Visit costs† Transport costs†† Total direct costs
Mean (SD) Median IQR Mean (SD) Median IQR Mean (SD) Median IQR
Private (N=519) 148 (29%) 300 (58%) 11.52 (29.86) 2.80 0.93−8.40 0.93 (1.96) 0.56 0.00−0.93 12.46 (30.25) 3.74 1.49−9.99
Private clinic or doctor (N=240) 124 (52%) 187 (78%) 21.66 (41.44) 7.47 2.80−18.68 1.53 (2.73) 0.84 0.37−1.12 23.19 (41.77) 9.34 3.74−22.69
Pharmacy (N=173) 23 (13%) 87 (50%) 3.76 (5.26) 1.87 0.93−3.92 0.58 (0.39) 0.56 0.37−0.75 4.34 (5.29) 2.61 1.68−5.04
Shop (N=106) 1 (1%) 26 (25%) 1.25 (1.44) 0.75 0.37−1.49 0.15 (0.32) 0.00 0.00−0.19 1.40 (1.57) 0.84 0.37−1.87
Public (N=375) 285 (76%) 247 (66%) 2.63 (13.87) 0.37 0.00−0.75 0.88 (1.66) 0.37 0.00−0.93 3.52 (14.33) 0.93 0.00−1.87
Puskesmas (N=155)* 102 (66%) 94 (61%) 3.40 (11.20) 0.75 0.37−1.42 0.57 (0.69) 0.37 0.00−0.75 3.97 (11.57) 1.21 0.75−2.36
Malaria control clinic (N=149)** 123 (83%) 107 (72%) 0.00 (0.00) 0.00 0.00−0.00 0.57 (1.59) 0.00 0.00−0.56 0.57 (1.59) 0.00 0.00−0.56
Hospital (N=71) 60 (85%) 46 (65%) 6.49 (26.86) 0.37 0.37−0.93 2.24 (2.46) 1.40 0.93−2.05 8.72 (27.41) 1.87 1.31−2.80
p value (Private versus Public) <0.001a 0.015b <0.001c 0.080c <0.001c
All costs are reported in US$.
† Visit costs for inpatient and outpatient visits, including costs of consultation, diagnosis, medications and any other costs directly related
to the care received.
†† Transport cost includes costs for the patient and anyone who accompanied him or her.
a OR = 7.94 [95% CI 5.86−10.76].
b OR = 1.41 [95% CI 1.07−1.86].
c Mann-Whitney test.
* Government-funded primary health clinic.
** Mining company-funded clinic.
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guidelines, 61% (336/547) of the antimalarial prescriptions followed a blood test. The
corresponding figures were 87% (215/247) at public facilities and 40% (121/300) at
private providers (p < 0.001).
Only 10% (17/177) of individuals who reported testing positive for P. falciparum or
mixed infection reported receiving the prevailing first-line treatment of chloroquine with
SP, with the majority receiving primaquine (129; 73%), chloroquine (103; 58%) and/or
quinine (49; 28%). Those reporting a diagnosis of P. vivax were more likely to receive
the correct first line treatment of chloroquine and primaquine [38% (61/159); Table 2.6].
Overall, public facilities were more likely to prescribe the correct drug combinations
(OR = 3.77 [95% CI 2.31−6.14], p < 0.001).
In total, 69% (232/337) of respondents who reported a positive blood test for malaria,
reported being prescribed primaquine. Of those who reported taking primaquine for P.
vivax infection (alone or mixed), 63% (69 /109) reported taking less than seven days of
treatment (Figure 2.4).
2.3.6 Direct costs of treatment seeking
The mean total direct cost to the household per visit at a private provider was US$12.46
(SD = 30.25) compared to US$3.52 (SD = 14.33) at the public sector (p < 0.001).
Table 2.5 shows the mean cost of treatment (including drugs, consultation and diagnosis)
and transport (including patient and any accompanying people) by source of treatment.
No significant difference in direct costs were seen for those diagnosed with P. falciparum
as compared with P. vivax infection. The total direct costs per person according to age
group are presented in Table 2.7.
2.3.7 Indirect costs per fever episode
Overall, 77% (641/834) of those who reported taking treatment stated that at least one
person had reduced his or her usual activities to care for them and 66% (553/834) of
respondents reported having at least one companion journey with them when seeking
treatment. Eight percent (66/834) reported the need for at least one substitute labourer
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Table 2.6: Antimalarial treatment received according to blood test results as reported in the household survey (includes inpatient and
outpatient visits).
Private clinic
or doctor
Pharmacy Shop
All
private
Puskesmas†
Malaria
control clinic††
Hospital
All
Public
Overall
Not tested (N) 116 150 105 371 53 26 11 90 461
% (n) antimalarialsa 69% (80) 49% (73) 25% (26) 48% (179) 43% (23) 35% (9) 0% (0) 36% (32) 46% (211)
Tested negative (N) 16 5 1 22 28 21 13 62 84
% (n) antimalarialsa 19% (3) 0% (0) 0% (0) 14% (3) 0% (0) 5% (1) 0% (0) 2% (1) 5% (4)
P. falciparum (N) 57 11 0 68 29 50 20 99 167
% (n) antimalarialsab 98% (56) 73% (8) – 94% (64) 97% (28) 100% (50) 95% (19) 98% (97) 96% (161)
% (n) chloroquine*b 51% (29) 27% (3) – 47% (32) 79% (23) 88% (44) 5% (1) 69% (68) 60% (100)
% (n) SP*b 5 (9%) 0% (0) – 7% (5) 0% (0) 28% (14) 0% (0) 14% (14) 11% (19)
% (n) primaquineb 68% (39) 27% (3) – 62% (42) 83% (24) 92% (46) 55% (11) 82% (81) 74% (123)
% (n) quinineb 33% (19) 36% (4) – 34% (23) 17% (5) 6% (3) 75% (15) 23% (23) 28% (46)
% (n) antimalarial injectionb 32% (18) 9% (1) – 28% (19) 3% (1) 0% (0) 10% (2) 3% (3) 13% (22)
P. vivax (N) 44 7 0 51 41 43 24 108 159
% (n) antimalarialsab 95% (42) 86% (6) – 94% (48) 100% (41) 98% (42) 100% (24) 99% (107) 97% (155)
% (n) chloroquine*b 34% (15) 71% (5) – 39% (20) 68% (28) 77% (33) 8% (2) 58% (63) 52% (83)
% (n) primaquine*b 34% (15) 0% (0) – 29% (15) 78% (32) 81% (35) 88% (21) 81% (88) 65% (103)
% (n) quinineb 34% (15) 14% (1) – 31% (16) 24% (10) 5% (2) 88% (21) 31% (33) 31% (49)
% (n) antimalarial injectionb 11% (5) 0% (0) – 10% (5) 0% (0) 0% (0) 4% (1) 1% (1) 4% (6)
† Government-funded primary health clinic. †† Mining company-funded clinic.
a Medication categories are not mutually exclusive.
b Includes tablets and injections.
* Recommended treatment regimen.
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Figure 2.4: Histogram of the reported number of days of primaquine treatment for P.
falciparum and P. vivax / mixed infections (n, %).
to perform their usual activities while sick and this was significantly more likely in
non-Papuans (OR = 2.09 [95% CI 1.19−3.65], p = 0.010). Of those who reported a
daily wage, the mean was US$10.92 (SD = 8.22). The days lost by the individual and
his/her companions, caretakers and substitute labourers are shown in Table 2.7 along
with their associated costs. The total mean indirect cost per fever episode requiring
treatment taking was US$31.49 (SD = 35.92) for children and US$53.52 (SD = 58.06)
for adults.
2.3.8 Malaria costs from healthcare facility exit survey
A total of 358 patients were surveyed after exiting six public healthcare facilities (the
hospital, two Puskesmas and three malaria control clinics). The reported diagnosis
was P. falciparum in 55% (196), P. vivax in 38% (136), mixed infection in 4% (12), P.
malariae in 4% (13) and P. ovale in 0.3% (1). The direct and indirect costs related
to visits at public providers for P. falciparum and P. vivax are presented in Table 2.8.
The total costs were similar between the species of diagnosis, however respondents with
P. falciparum infection reportedly spent more money than those with P. vivax for the
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Table 2.7: Reported direct, indirect and total costs (including illness days) per individual taking treatment for fever over the entire fever
episode (N=834).
Category
Child (n=353) Adult (n=481) Overall (N=834)
Mean (SD) Median IQR Mean (SD) Median IQR Mean (SD) Median IQR
Total direct costs (incl. payments for all treatments) 7.34 (25.72) 1.31 0.19−5.04 10.83 (28.38) 1.96 0.41−6.16 9.35 (27.33) 1.87 0.37−5.60
Total indirect costs 31.49 (35.92) 27.31 10.92−38.23 53.52 (58.06) 38.23 16.39−76.46 44.19 (51.05) 32.77 10.92−60.08
Individual taking treatment
Number of days unable to perform all usual activitiesa − − − 1.59 (2.52) 0.00 0.00−3.00 − − −
Number of days unable to perform some usual activitiesab − − − 2.96 (4.23) 2.00 0.00−5.00 − − −
Total cost to the individual due to lost wages − − – 33.47 (33.95) 27.31 10.92−43.69 19.31 (30.63) 0.00 0.00−32.77
All companions
Number of days unable to perform all usual activities 0.17 (0.57) 0.00 0.00−0.00 0.10 (0.38) 0.00 0.00−0.00 0.13 (0.47) 0.00 0.00−0.00
Number of days unable to perform some usual activitiesb 0.73 (0.77) 1.00 0.00−1.00 0.30 (0.61) 0.00 0.00−0.00 0.48 (0.72) 0.00 0.00−1.00
Total cost for companions 5.86 (7.58) 5.46 0.00−5.46 2.78 (5.21) 0.00 0.00−5.46 4.09 (6.50) 0.00 0.00−5.46
All caretakers
Number of days unable to perform all usual activities 0.31 (1.73) 0.00 0.00−0.00 0.23 (1.55) 0.00 0.00−0.00 0.27 (1.63) 0.00 0.00−0.00
Number of days unable to perform some usual activitiesb 4.03 (4.41) 3.00 1.00−5.00 2.36 (4.50) 0.00 0.00−3.00 3.07 (4.54) 1.00 0.00−5.00
Total cost for caretaking 25.45 (31.77) 21.85 5.46−32.77 15.42 (28.92) 0.00 0.00−21.85 19.67 (30.54) 10.92 0.00−27.31
All substitute labourers
Number of days unable to perform all usual activities 0.00 (0.00) 0.00 0.00−0.00 0.06 (0.40) 0.00 0.00−0.00 0.03 (0.30) 0.00 0.00−0.00
Number of days unable to perform some usual activitiesb 0.03 (0.36) 0.00 0.00−0.00 0.22 (1.33) 0.00 0.00−0.00 0.14 (1.04) 0.00 0.00−0.00
Total cost for substitute labour 0.17 (1.95) 0.00 0.00−0.00 1.84 (8.39) 0.00 0.00−0.00 1.13 (6.54) 0.00 0.00−0.00
Total costs 38.82 (46.41) 29.18 16.39−45.35 64.34 (74.43) 40.47 16.39−87.39 53.54 (65.28) 33.75 16.39−66.66
a Not reported by children.
b Days reported as cutting back on some activities were included in the cost calculations as half of the mean wage per day.
46
CHAPTER 2. TREATMENT-SEEKING BEHAVIOUR AND ASSOCIATED COSTS
FOR MALARIA IN PAPUA, INDONESIA
healthcare visit (p = 0.013), personal transportation to the healthcare facility (p <
0.001) and lost wages for the patient (p = 0.001). Individuals with P. vivax infection
spent more money on companion costs (p = 0.034). When the analysis was restricted
to children or adults, the only cost that remained statistically significant was for the
healthcare visit.
Table 2.8: Mean (SD), median and IQR of patient costs in 2014 US$ per visit to a public
provider (inpatient and outpatient) by malaria diagnosis from facility exit surveys.a
P. falciparum (N=196) P. vivax (N=136)
Mean (SD) Median IQR Mean (SD) Median IQR p value
Total direct costs 2.69 (4.67) 1.42 0.84−2.25 2.09 (3.35) 1.31 0.00−2.24 0.056
Visit cost 0.90 (3.08) 1.42 0.00−0.75 0.40 (0.53) 0.37 0.00-0.37 0.013
Transport cost for patient 0.61 (1.41) 0.16 0.00−0.56 0.40 (1.24) 0.00 0.00−0.28 <0.001
Transport cost for companions 1.18 (2.53) 0.56 0.00−1.12 1.28 (2.61) 0.28 0.00−1.17 0.541
Total indirect costsa 45.90 (63.10) 27.31 10.92−60.08 42.41 (44.98) 27.31 10.92−54.62 0.960
Lost wages for patientb 17.23 (29.73) 0.00 0.00−27.31 8.79 (19.59) 0.00 0.00−5.46 0.001
Lost wages for companions 5.46 (7.28) 5.46 0.00−10.92 6.95 (7.33) 5.46 0.00−10.92 0.034
Lost wages for caretakers 22.04 (40.55) 10.92 0.00−30.04 26.51 (36.39) 10.92 0.00−38.23 0.089
Lost wages for substitute labourers 1.25 (6.85) 0.00 0.00−0.00 0.16 (1.87) 0.00 0.00−0.00 0.096
Total costs 48.58 (64.65) 29.51 11.86−65.59 44.50 (46.23) 28.34 10.92−60.73 0.981
a The per day wage was taken from the household survey (US$10.93).
b For children, lost wages are recorded as no cost.
2.4 Discussion
This study from Papua, Indonesia, was conducted in an area with one of the greatest
levels of malaria burden in the region and at a time of high levels of antimalarial
drug resistance to prevailing first-line therapies. It is the first study from eastern
Indonesia reporting household treatment-seeking behaviour and is one of the few studies
comparing household costs of P. vivax malaria with P. falciparum malaria, as well as
self-reported adherence to 14 day primaquine.
There were several significant findings of relevance to malaria control efforts. Firstly
in relation to treatment seeking, almost a third of individuals reporting a fever in the
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last month did not seek treatment outside of the home. This figure is higher than
previous reports from central Java where 88% of households reported seeking treatment
or advice outside of the home for their most recent malaria illness [14]. Over half (54%)
of individuals sought treatment only in the private sector, despite the availability of
free treatment in the public sector. Those who sought care in the private sector were
less likely to report a diagnosis of malaria, but almost 60% still reported receiving
antimalarial treatment. Fifteen percent of individuals with fever reported more than
one source of treatment, a likely consequence of the initial treatment failing to improve
their symptoms. These findings highlight the importance of engaging with the private
sector in malaria control efforts and of the need to understand and address the reasons
underlying patients preferences.
Secondly in relation to antimalarial treatment, of those patients who reported
positive blood tests for malaria, few were prescribed the recommended drug regimen
for the species that they reported and for patients reporting P. vivax infections who
reportedly received primaquine, over half of participants reported taking less than
three days of the recommended 14 day regimen, a duration ineffective in preventing
relapse [31]. Furthermore, primaquine was not recommended for P. falciparum, but the
majority of patients reported receiving it. With such a large proportion of P. falciparum
patients reporting primaquine use, it seems unlikely that this is entirely due to patient
recall bias in terms of the species diagnosed or the drug prescribed. Such discrepancies
in antimalarial policy and actual practice have been described previously in other
settings [32, 33]. There are many possible reasons including lack of provider awareness
or understanding, patient and provider preferences, perceptions and experiences with
regards efficacy and side effects. Understanding and addressing the reasons for these
discrepancies is clearly important, especially in the face of increasing antimalarial drug
resistance.
Thirdly in relation to household costs, the household financial burden of fevers in
this region was substantial and did not differ substantially by the species of malaria.
The mean cost per fever episode reported in the household survey was (US$53.54)
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and included the direct costs of the whole illness episode, including subsequent visits
to treatment providers, as well as any further indirect costs of time incurred after
visits to a healthcare facility. The mean cost of an episode of P. vivax malaria was
US$44.50, compared to US$48.58 P. falciparum. This likely represents an underestimate
of household costs as patients were at public facilities and not at the end of their malaria
episode.
Over 60% of households reported a monthly income less than US$500, indicating that
a fever episode represented at least 11% of the households monthly income. This also
represents nearly five hours of work using the mean reported hourly wage of US$10.92.
Individuals in poorer households were at greater risk of fevers, with additional indirect
costs likely to accumulate in those who do not take effective treatment. These findings
emphasize the enormous economic burden of recurrent P. vivax episodes on the most
vulnerable communities.
Another strength of this study, is the use of Discriminant Analysis of Principal
Components to create meaningful SES categories. In this setting, use of the traditional
asset index would have resulted in misclassification of households into categories which
would have not reflected a useful categorization of households actual status. Re-settled
Papuans had been provided with house and land by the local government resulting in
many of the poorer households having high levels of house and land ownership but little
other disposable income. When the data were analysed using a principal components
analysis, the first component of the principal components analysis only explained 19% of
the variation, but the results with the Discriminant Analysis of Pricipal Components was
able to explain almost all of the differences between groups using only two discriminant
functions. These could then be correlated back to the original variables and extract the
ones that are relevant to explain group differences. Lower SES status was a risk factor
for both recent febrile illness and parasite positivity at the time of the survey. Those
with lower SES status were more likely to ever seek treatment at a public facility, a
likely reflection of the lower costs incurred. This, along with the higher likelihood of
reporting fever in the past month by those with lower SES, highlights the heterogeneity
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of the population in relation to risk of fever and treatment-seeking behaviour.
This study has a number of limitations. Firstly, much time has elapsed since the
collection of the data and the presentation of the results. While it is possible that this
has resulted in some of the loss of some of the finer details of the study, the survey design
and results published by Karyana et al. in 2008 provide a record of the substantive
details of the survey [8]. Many of the older male household members were not present
at the time of the survey and therefore not included in the analysis. In this region it
is often the adult males who are at higher risk of malaria and so it is possible that
we underestimated the true burden of fever episodes. Furthermore, males were more
likely than females to seek treatment at private providers, which would have impacted
the overall results with regards to treatment-seeking behaviour and costs [8]. Another
group excluded from the survey were temporary migrants who had moved into the area
within last six months and did not plan to stay longer than six months. Depending on
where they moved from, these individuals might be more susceptible to malaria than
the general population and more likely to cause malaria outbreaks. The survey was
also undertaken in the four most accessible and populous subdistricts whose population
may not be representative of those in the more remote subdistricts where access to
healthcare is more difficult therefore results may slightly overestimate the proportion
seeking treatment outside the home.
A common issue with all surveys aimed at describing treatment-seeking behaviour
and case management for malaria, is the unknown malaria status of the individuals who
reported having a fever in the past month. Including all fevers in the previous month,
enables the potential capture of entire fever episodes; however, they may also result
in significant recall bias due to the length of time between the episode and the survey.
In order to triangulate these results, healthcare facility exit surveys were undertaken
in which patients were interviewed immediately after their visit, thus minimising the
potential for bias and enabling an examination of costs specific to the type of malaria
diagnosed. Any treatment or indirect costs occurring after the healthcare visit, however,
would not be captured by this survey and thus potentially impact its cost estimates.
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This study was undertaken at a time of very high treatment failure to the recom-
mended first-line antimalarials [11]. The poor efficacy of available treatments may
partly explain the high rates of reported fever in the preceding month and why a third
of respondents did not access treatment outside of the home.
2.4.1 Conclusions
In summary these findings highlight a high level of reported febrile illness, which is
most apparent in young children and those from poor households. Despite the provision
of free treatment in public health facilities, treatment seeking in the private sector
was higher than expected, with considerably higher costs. The household costs of
P. vivax were similar to P. falciparum, and in view of the relapsing and recurrent
nature of malaria in this location, the financial burden of both infections is likely to
be considerable. Antimalarial programmes implementing policy change of first-line
treatment will need to engage both public and private sectors if early diagnosis and
highly effective treatment is to impact on the whole community.
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3.1 Introduction
In Indonesia the greatest prevalence of malaria is in the eastern provinces of Nusa
Tenggara Timur and Papua [1]. Great progress has been made in reducing the burden
of malaria with the majority (74%) of the Indonesian population residing in malaria-free
areas. However, 12% of the population still reside in areas with a malaria incidence
greater than one case per 1000 per year [2], and these individuals are at increased risk of
malaria associated anaemia [3, 4]. Until 2006, the first line policy was chloroquine plus
sulfadoxine-pyrimethamine for uncomplicated P. falciparum malaria, and chloroquine
plus primaquine (total dose 3.5 mg/kg over 14 days) for radical cure for P. vivax
with the exception of infants less than one year of age or below and pregnant or
lactating women for whom chloroquine alone was recommended [5] (Table 3.1). In
2005 clinical trials in Papua, Indonesia highlighted very high levels of antimalarial drug
resistance to the recommended treatment regimens with recrudescent P. falciparum
and recurrent P. vivax infections exceeding 40% by day 28 following treatment [5, 6, 7].
Dihydroartemisinin-piperaquine (DHP) was shown to be highly effective against both
species [8, 9]. In response, national policy was changed in March 2006 to the fixed
dose ACT of DHP for uncomplicated malaria due to any species of malaria [8, 9]. The
recommendation of single dose of primaquine for P. falciparum remained while the dose
of primaquine recommended for P. vivax was increased to a total of 7 mg/kg over 14
days. The policy also stipulated that antimalarial treatment should only be given after
laboratory confirmation, which was not a recommendation before 2006.
Prior to the change in policy, a cross-sectional household survey was undertaken in
2005, which documented that 42% of individuals reported having a febrile illness in the
preceding month, for which they sought treatment multiple times, often at different
healthcare facilities (Chapter 2). Only 46% of these individuals reported seeking
treatment at a public provider, despite provision of treatment for free in the public
sector. The majority of households reported a monthly income less than US$500, hence
each individuals fever episode resulted a cost of at least 11% of the household income
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Table 3.1: Recommended drug treatments for malaria.
Malaria Before March 2006 After March 2006
P. vivax
Uncomplicated Chloroquine with 14 day PQ (3.5mg/kg) DHP with 14 day PQ (7mg/kg)
Second line Quinine and Doxycycline/Clindamycin Quinine and Doxycycline/Clindamycin
Severe Quinine IV Artesunate
P. falicparum
Uncomplicated Chloroquine with SP & single-dose PQ DHP with single dose PQ
Second line Quinine and Doxycycline/Clindamycin Quinine and Doxycycline/Clindamycin
Severe Quinine IV Artesunate
DHP = dihydroartemisinin-piperaquine; PQ = primaquine; SP = sulfadoxine-
pyrimethamine.
(Chapter 2). Following policy change, DHP was provided free of charge at public
health facilities but was also available at a cost in the private sector.
Changes in antimalarial policy can potentially impact on the overall burden and
transmission of malaria, not only through the direct impact of switching to a more
effective treatment but also through increasing the communitys trust in the public
health care system and the subsequent shifts in treatment-seeking behaviour. A second
household survey was conducted in 2013 to investigate the changes in treatment-seeking
behaviour after the policy change. The aim of this study was to describe the changes in
treatment-seeking behaviour for fever and burden of disease in Papua following policy
change to ACT for all species of malaria.
3.2 Methods
Household surveys were conducted in Mimika Regency, southern Papua, Indonesia
in 2005 and 2013. The methods in 2013 were based on the 2005 survey which has
been reported previously (Chapter 2). Minor differences between the questionnaires
included the collection of household income as a range rather than a specific estimate
and information on bed net use by individuals rather than ownership by the household.
The demographics, malaria transmission, and health services in this region have
been described previously [4, 10, 3]. In brief, the district covers an area of 21,522 km2
with a population of approximately 120,457 in 2005 expanding to 202,350 in 2013. Most
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of the population resides in 12 districts, incorporating Timika town and the surrounding
villages. The area is covered with thick rain forest with both coastal and mountainous
areas, inhabited by a variety of ethnic groups which are broadly categorized as lowland
Papuans, highland Papuans or non-Papuans. Malaria transmission occurs throughout
the year and is restricted to the lowland area where most of the population lives. There
are three mosquito vectors: Anopheles koliensis, Anopheles farauti and Anopheles
punctulatus.
Healthcare provision is provided free of charge at public providers, which includes one
hospital, 12 Government-funded Primary Health Clinics (Puskesmas), and 10 malaria
control clinics provided by a local mining company. In 2008 a second hospital was
opened, providing care to approximately 100,000 patients per year. Antimalarials can
also be purchased in the private sector, including clinics, pharmacies and drug stores
[11]. Diagnostic tests for malaria are available in the private sector but usually not in
drug stores.
The household sampling strategy was the same for both surveys with 800 households
sampled using a three-stage cluster sampling procedure to identify 32 clusters of 25
households [12] & (Chapter 2). Firstly the four most populous sub-districts (Mimika
Baru, Kuala Kencana, Iwaka, Kwamki Narama, and Wania) were chosen from the
12 sub-districts based on their accessibility by road from the main town of Timika
and because they included the majority (80%) of the districts population. The 2013
survey took place in similar geographic areas as the 2005 survey but the names of the
subdistricts were different in 2013 due to the renaming of subdistricts after the 2005
survey. Secondly, the number of clusters in each sub-district was apportioned according
to their relative populations. The houses were then assigned numbers according to their
geographical location and clusters of 25 houses were identified.
The 2013 survey was conducted in the months of April through July while the 2005
survey was conducted between the months of July and December. Household members
were defined as all individuals living under one roof and who ate from one kitchen. If a
selected household was empty, the interviewer returned the next day. If still unoccupied,
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the next occupied household was sampled instead. As the recall period for the survey
was fever in the previous month, temporary migrants who had moved into the area
within the preceding month were excluded from the survey.
3.2.1 Data collection
The head of the household or another suitable adult was asked questions about the
household and its members. Those members who were present at the time of the
survey were asked specific details about any recent febrile illness and underwent a
brief examination. Capillary or venous blood samples were collected for blood film
examination. Symptomatic illness was defined as a history of fever in the past 24 hours
or an axillary temperature greater than or equal to 37.5°C when examined. Nearly all
surveys were conducted in Bahasa Indonesian and the remaining in a local Papuan
language. Individuals reporting a history of fever in the preceding 30 days were asked
to complete a separate module on treatment seeking if they were present. This module
comprised of questions on all of the places where they had sought treatment, whether
they had received a blood test, whether they were prescribed antimalarials or other
medicines, and any associated costs to the households.
3.2.2 Data analysis
Data were analyzed using STATA statistical software (version 14.2) [13] and R (version
3.2.3) [14]. A Discriminant Analysis of Principal Components was used to categorize
households by SES by data on reported ownership of assets [15] (Chapter 2). To
ensure that sufficient time had elapsed to capture treatment-seeking behavior, those
individuals reporting fever starting within the preceding two days were excluded from
the analysis of treatment seeking. For the use of diagnostics, laboratory tests, and
antimalarial prescriptions, each patient-provider interaction (“visit”) was analyzed for
public and private healthcare providers.
Frequencies and percentages were used for the descriptive data. Percentages were
compared using the chi-square test (X2). Differences in outcome distributions were
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evaluated with the Mann−Whitney test. Continuous variables were compared using
Spearman’s rank for correlation. When less than five observations were seen in a
category, categorical outcomes were compared using Fischer’s Exact test. Simple
logistic regression adjusted for clustering by households was used to calculate ORs for
comparisons within the 2013 survey. For the analysis of reported fever in the past
month, significant risk factors (P < 0.05) in the univariate analysis were included in a
multiple logistic regression model and significant interactions between age, ethnicity
and significant variables were reported. The 2005 and 2013 surveys were compared
using AORs for age (0-4, 5-14, 15+), gender, household SES and ethnicity (non-Papuan,
highland Papuan, lowland Papuan). The models were adjusted for clustering by
household.
Costs were gathered in Indonesian rupiah, converted into US$ using the average
exchange rates [16, 17] and then revised to the 2014 equivalent using the consumer price
index for Indonesia [18]. The mean cost and SD per fever episode are reported. Direct
costs included transportation for the patient and carer and treatment, which included
consultations, diagnosis, medication, overnight stay and any other payments. Indirect
costs included the amount of time that usual activities were reduced for the individual
and any companions, caretakers, or substitute laborers. This time was valued using the
mean reported wage for all.
3.3 Results
3.3.1 Household characteristics
A total of 800 households with 4,010 individuals were included in the 2013 survey
(Figure 3.1). The baseline characteristics for both the 2005 and 2013 surveys are
provided in (Table 3.2). In 2013 the median household size was five individuals (IQR
= 4−6) with a maximum of 13 in one house. The median duration that heads of
households reported residing at their current location was 13 years (IQR = 6−20),
with 23 (3%) households reporting a move into that location within the previous year.
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Table 3.2: Demographic characteristics of all household members and individuals present
during surveys in 2005 and 2013.
Characteristic − n (%)
2005 2013
All household
members
(N = 5255)
Present during
survey
(N = 3896)
All household
members
(N = 4010)
Present during
survey
(N = 2830)
Age (years)
0-4 870 (17%) 820 (21%) 629 (16%) 559 (20%)
5-14 1101 (21%) 824 (21%) 970 (24%) 666 (24%)
15+ 3284 (62%) 2252 (58%) 2,404 (60%) 1604 (57%)
Not reported − − 7 (0.2%) 1 (0.04%)
Sex (Female) 2409 (46%) 2019 (52%) 2035 (51%) 1668 (59%)
Pregnant (Yes) 92 (2%) 87 (2%) − * 45/2825 (2%)
Place of birth
Highland Papuan 1494 (28%) 1045 (27%) 733 (18%) 539 (19%)
Lowland Papuan 1371 (26%) 1024 (26%) 1039 (26%) 751 (27%)
Non-Papuan 2390 (45%) 1827 (47%) 2238 (56%) 1,540 (54%)
Resided in lowlands for more than 1 year? (Yes) 4969 (95%) 3674 (94%) 3862 (96%) 2711 (96%)
Subdistrict
Banti 152 (3%) 119 (3%) 0 (0%) 0 (0%)
Harapan & Kwamki Lama 901 (17%) 576 (15%) 111 (3%) 80 (3%)
Inauga 521 (10%) 405 (10%) 383 (10%) 291 (10%)
Kamoro Jaya 354 (7%) 273 (7%) 369 (9%) 257 (9%)
Kadun Jaya, Kaugapu & Pigapu 371 (7%) 286 (7%) 267 (7%) 210 (7%)
Limau Asri, Iwaka, Mulia Kencana & Naena Muktipura 136 (3%) 112 (3%) 506 (13%) 334 (12%)
Koperapoka 957 (18%) 729 (19%) 753 (19%) 521 (18%)
Timika Jaya, Kwamki & Kwamki Baru 1,407 (27%) 1,046 (27%) 989 (25%) 696 (25%)
Wonosari Jaya & Nawaripi 122 (2%) 98 (3%) 374 (9%) 267 (9%)
Karang Senang & Bhintuka 334 (6%) 252 (6%) 258 (6%) 174 (6%)
* Not reported.
In 2005 household size was six individuals (IQR = 4−8) with a median duration of
nine years (IQR = 4−15). Of the 781 households in which monthly household income
was reported, 52% (403) estimated US$560 or less. The households were categorized
into five SES groups, with number of households in each group ranging from 91 to
296. Whilst poorer households were more likely to grow their own crops and drink
rain water, richer households were more likely to own motorcycles and large electrical
items and drink bought water (Figure 3.2). The poorest SES group was composed of
a greater percentage of Highland Papuans (32%, 47/145) compared to 19% (35/189)
of Lowland Papuans and 3% (15/465) of non-Papuans (p < 0.001). The estimated
household general health expenditure was correlated with the number of individuals
reporting fever in a household (ρ = 0.488, p < 0.001).
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4010 individuals
800 households
1180 individuals not present at interview:
16 reported fever by family 
1164 no report of fever by family 
2830 individuals present at interview
800 households
117 had fever in the last month 
108 households
2 no treatment seeking questionnaire 
available 
2713 individuals reported no fever in the 
last month
115 were given the treatment seeking 
questionnaire
108 households
108 included in the analysis
103 households
7 reported fever that lasted less than 2 
days
9 individuals did not take medicines
9 households 
99 took medicines
96 households
66 from public provider 3 drugs from home or neighbor30 from private provider
64 no further 
medicines taken
2 public provider
30 no further 
medicines taken
1 no further 
medicines taken
2 private provider
Figure 3.1: Flow diagram of household members, interviews, initial location of treatment
taking, and whether took a second treatment in 2013.
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  Figure 3.2: Results from the Discriminant Analysis of Principal Components to construct
SES groupings for 2013. Tree plot of ownership by groups from poorest (black) to
richest (lightest grey).
3.3.2 History of fever and parasite positivity of household
members
Of the 2,830 (71%) individuals present at the time of the interview in 2013, 41%
(1162) were male, 43% (1225) were under the age of 15, and 46% (1290) were Papuan
(Table 3.2). Overall, 4% (117/2830) of individuals reported having had a febrile illness
in the preceding month compared with 42% (1631/3896) in 2005 (AOR = 0.06 [95% CI:
0.05−0.08], p < 0.001; (Table 3.3)). Non-Papuan participants were at a significantly
higher risk for having had a febrile illness compared with Highland Papuans (AOR =
1.84 [95% CI: 1.05−3.26], p = 0.035; Table 3.4).
Overall 12% (348/2795) of individuals who consented to blood testing in 2013 were
parasitaemic compared to 16% (634/3890) in 2005 (AOR = 0.83 [95% CI: 0.69−0.99], p
= 0.038). The prevalence of parasitaemia which decreased from 5% (200/3890) in 2005
to 1% (21/2795) in 2013 (AOR = 0.16 [95% CI: 0.10−0.26], p < 0.001), whereas the
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prevalence of asymptomatic parasitaemia was similar in both surveys: 11% (434/3890)
in 2005 and 12% (327/2795) in 2013 (AOR = 1.20 [95% CI: 0.98−1.45], p = 0.073).
Individuals reporting a febrile illness in the past month were significantly more likely
to be parasitaemic in the 2005 survey (OR = 3.81 [95% CI: 3.10-4.68], p < 0.001);
however, this was not significant in the 2013 survey (OR = 1.53 [95% CI: 0.89−2.61], p
= 0.123). The prevalence of parasitaemia in each subdistrict is presented in Table 3.5.
3.3.3 Treatment-seeking behaviour
In 2013 treatment-seeking behaviour was assessed in 98% (115/117) of participants
reporting a fever in the preceding month, and in 94% (108/115) of these individuals
the fever commenced at least two days prior to the survey (Figure 3.1). Overall
individuals were more likely to take some form of medicine for their fever in 2013 with
92% (99/108) reporting taking medication, compared to 76% (834/1104) of those whose
fever commenced at least two days prior to the survey in 2005 (AOR = 2.50 [95% CI:
1.23−5.06], p = 0.011). Of the 99 patients reporting taking medication, only 1% (1) did
not seek treatment outside of the home, compared to 8% (70/834) in 2005 (p = 0.004).
In 2013 67% (66/98) of individuals seeking treatment outside of the home attended a
public provider at least once compared to 46% (349/764) in 2005 (AOR = 4.30 [95%
CI: 2.54−7.28], p < 0.001). Furthermore, individuals in the three lower SES groups
were more likely to seek treatment at a public provider at least once compared to those
in the top two SES groups (OR = 6.10 [95% CI: 2.0518.11], p = 0.001); this was also
apparent in 2005 (OR = 2.29 [95% CI 1.59-3.32], p < 0.001). While the percentage
seeking treatment at at the old hospital remained constant at 8% (p = 0.961), the
percentage of visits at any hospital increased significantly from 8% (71/894) in 2005 to
18% (18/100) in 2013 (p = 0.001).
3.3.4 Diagnosis of malaria at healthcare providers
Of the 100 visits to healthcare providers in 2013, 95 (95%) involved a blood test for
malaria compared to 48% (433/894) in 2005 (AOR = 24.42 [95% CI: 9.87−65.43], p <
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Table 3.3: Fever reporting in those who were present during the survey in 2005 and 2013.
Characteristic − n (%)
2005 2013
Reported fever during
previous month
(N = 1631/3896, 42%)
Reported fever starting
> 2 days before survey
and took treatment
(N = 834/1631, 51%)
Reported fever during
previous month
(N = 117/2830, 4%)
Reported fever starting
> 2 days before survey
and took treatment
(N = 99/117, 85%)
Age (years)
0-4 405 (25%) 205 (25%) 23 (20%) 15 (15%)
5-14 306 (19%) 148 (18%) 29 (25%) 26 (26%)
15+ 920 (56%) 481 (58%) 65 (56%) 58 (59%)
Sex (Female) 850 (52%) 433 (52%) 63 (54%) 55 (56%)
Pregnant (Yes) 39 (2%) 23 (3%) 3/116 (3%) 3/98 (3%)
Place of birth
Highland Papuan 385 (24%) 172 (21%) 14 (12%) 11 (11%)
Lowland Papuan 463 (28%) 183 (22%) 28 (24%) 19 (19%)
Non-Papuan 783 (48%) 479 (57%) 75 (64%) 69 (70%)
Resided in lowlands for more than one year? (Yes) 1547 (95%) 797 (96%) 111 (95%) 93 (94%)
Sub-district
Banti 29 (2%) 18 (2%) 0 (0%) 0 (0%)
Harapan & Kwamki Lama 226 (14%) 124 (15%) 4 (3%) 2 (2%)
Inauga 183 (11%) 106 (13%) 5 (4%) 5 (5%)
Kamoro Jaya 107 (7%) 77 (9%) 12 (10%) 10 (10%)
Kadun Jaya, Kaugapu & Pigapu 108 (7%) 11 (1%) 23 (20%) 14 (14%)
Limau Asri, Iwaka, Mulia Kencana & Naena Muktipura 55 (3%) 3 (0.4%) 15 (13%) 15 (15%)
Koperapoka 396 (24%) 127 (15%) 13 (11%) 12 (12%)
Timika Jaya, Kwamki & Kwamki Baru 383 (23%) 262 (31%) 16 (14%) 14 (14%)
Wonosari Jaya & Nawaripi 49 (3%) 39 (5%) 24 (21%) 23 (23%)
Karang Senang & Bhintuka 95 (6%) 67 (8%) 5 (4%) 4 (4%)
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Table 3.4: Multivariable analysis of risk factors for febrile illness in the past month
(N=2890).
Variable OR (95% CI) p value AOR (95% CI) p value
Gender
Female Reference −
Male 1.24 (0.85−1.82) 0.266 −
Age
≥ 15 years Reference –
5−14 years 1.08 (0.68−1.70) 0.746 − −
< 5 years 1.02 (0.61−1.69) 0.951 − −
Pregnant
No Reference −
Yes 1.69 (0.51−5.55) 0.391 − −
Household size
> 7 members Reference Reference
≤ 7 members 2.11 (1.01−4.43) 0.048 2.00 (0.96−4.15) 0.062
SES groups
Richest Reference −
Fourth 0.68 (0.37−1.24) 0.211 − −
Middle 1.32 (0.78−2.23) 0.302 − −
Second 1.05 (0.61−1.80) 0.857 − −
Poorest 0.76 (0.39−1.47) 0.410 − −
Ethnicity
Highland Papuan Reference Reference
Lowland Papuan 1.45 (0.74−2.84) 0.275 1.53 (0.79−2.97) 0.209
Non-Papuan 1.92 (1.08−3.40) 0.025 1.84 (1.05−3.26) 0.035
Resided in lowlands > 1 year?
Yes Reference −
No 1.24 (0.54−2.84) 0.605 − −
Family sleeps under a bednet?
No Reference −
Yes 1.27 (0.86−1.86) 0.226 − −
The multiple logistic regression included variables that were significant (p < 0.05) in
the univariate logistic regression.
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Table 3.5: Changes in parasite prevalence by location (subdistrict).
Subdistrict
2005 2013
Household
members
Total
parasitaemic
N (%)
Species - n (%)
Household
members
Total
parasitaemic
N (%)
Species - n (%)
P. falciparum P. vivax P. malariae
Mixed
infection
P. falciparum P. vivax P. malariae
Mixed
infection
Banti 119 7 (6%) 0 (0%) 7 (100%) 0 (0%) 0 (0%) 0 − − − − −
Harapan & Kwamki Lama 576 136 (24%) 67 (49%) 56 (41%) 2 (2%) 11 (8%) 80 14 (18%) 6 (43%) 4 (29%) 4 (29%) 0 (0%)
Inauga 405 47 (12%) 19 (40%) 23 (49%) 0 (0%) 5 (11%) 290 25 (9%) 10 (40%) 14 (56%) 1 (4%) 0 (0%)
Kamoro Jaya 273 102 (37%) 44 (43%) 24 (24%) 11 (11%) 23 (23%) 254 37 (15%) 17 (46%) 14 (38%) 5 (14%) 1 (3%)
Kadun Jaya, Kaugapu
& Pigapu
285 35 (12%) 10 (29%) 17 (49%) 2 (6%) 6 (17%) 198 60 (30%) 29 (48%) 25 (42%) 1 (2%) 5 (8%)
Limau Asri, Iwaka, Mulia
Kencana & Naena Muktipura
111 5 (5%) 3 (60%) 2 (40%) 0 (0%) 0 (0%) 330 27 (8%) 17 (63%) 9 (33%) 1 (4%) 0 (0%)
Koperapoka 726 100 (14%) 42 (42%) 45 (45%) 1 (1%) 12 (12%) 517 58 (11%) 27 (47%) 31 (53%) 0 (0%) 0 (0%)
Timika Jaya, Kwamki &
Kwamki Baru
1045 133 (13%) 68 (51%) 57 (43%) 1 (0.8%) 7 (5%) 695 60 (9%) 17 (28%) 40 (67%) 2 (3%) 1 (2%)
Wonosari Jaya & Nawaripi 98 15 (15%) 11 (73%) 4 (27%) 0 (0%) 0 (0%) 258 37 (14%) 14 (38%) 16 (43%) 6 (16%) 1 (3%)
Karang Senang & Bhintuka 252 54 (21%) 26 (48%) 13 (24%) 7 (13%) 8 (15%) 173 30 (17%) 12 (40%) 10 (33%) 5 (17%) 3 (10%)
Total 3890 634 (16%) 290 (46%) 248 (39%) 24 (4%) 72 (11%) 2795 348 (12%) 149 (43%) 163 (47%) 25 (7%) 11 (3%)
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0.001; Table 3.6). Malaria testing was positive in 92% (87/95) of cases and in one visit
the result was not reported. P. falciparum was diagnosed in 53% (46/87) of cases, P.
vivax in 43% (37/87), mixed infections in 3% (3/87), and P. malariae in 1% (1/87).
The increase in likelihood of individuals being tested for malaria was most apparent in
the private sector where 29% (148/519) of individuals were tested in 2005 compared to
97% (31/32) in 2013 (p < 0.001).
3.3.5 Antimalarial treatment at healthcare providers
In 2013 an antimalarial (alone or with other medicines) was reportedly prescribed
during 88% (88/100) of visits to healthcare providers. Of these prescriptions, 95%
(84/88) were prescribed as tablets, 1% (1/88) as an injection and 3% (3/88) as both
an injection and tablets. Of the four malaria injections that were reported, two were
at the public hospital and two at private providers. Ninety-nine percent (87/88) of
antimalarial prescriptions followed a blood test as per clinical guidelines; all were
reportedly positive. This was a significant increase compared to 2005 when only 61%
(336/547) of prescriptions followed a blood test (p < 0.001). In 2013 the antimalarial
treatment regimen was prescribed correctly in 74% (64/86) of healthcare encounters in
which P. vivax, P. falciparum or mixed infections were diagnosed, a significant increase
from 2005 when only 23% (78/336) of individuals were correctly treated according to
the prevailing guidelines (AOR = 15.71, [95% CI: 8.18−30.18], p < 0.001; Table 3.6).
These improvements in prescribing habits were apparent in both the public (AOR =
15.93 [95% CI: 6.84−37.14], p < 0.001) and private sectors (AOR = 12.16 [95% CI:
3.42−43.28], p < 0.001).
The reported treatments prescribed for the different species are presented in Table
3.7. In 2013 95% (57/60) of patients diagnosed with malaria in a public facility were
treated with DHP compared to 52% (14/27) of those treated at a private provider
(p < 0.001). Between 2005 and 2013 the percentage of individuals reportedly being
treated with 14 days of primaquine for P. vivax infection (alone or mixed) rose from
9% (16/169) to 63% (25/40); (AOR = 37.49 [95% CI: 9.94−141.41], p < 0.001). Over
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Table 3.6: Percentage of respondents who reported receiving blood tests and antimalarials (including tablets and injections) by survey.
Public Private Overall
2005 2013 AOR (95% CI)* p value 2005 2013 AOR (95% CI)* p value 2005 2013 AOR (95% CI)* p value
Percent of visits that
resulted in a blood test
for malaria
76%
(285/375)
94%
(64/68)
− < 0.001 29%
(148/519 )
97%
(31/32)
− < 0.001 48%
(433/894)
95%
(95/100)
25.42
(9.88-65.42)
< 0.001
Percent of blood tests
that were positive
75%
(213/285)
94%
(60/64)
− <0.001 84%
(124/148)
87%
(27/31)
− 0.790 78%
(337/433)
92%
(87/95)
3.11
(1.29-7.47)
0.012
Percent receiving
correct antimalarial
after testing positive †
32%
(67/212)
85%
(50/59)
15.94
(6.84−37.14) <0.001
9%
(11/124)
52%
(14/27)
12.16
(3.42−43.28) <0.001
23%
(78/336)
74%
(64/86)
15.71
(8.18-30.18)
<0.001
Percent receiving
chloroquine after
testing positive
62%
(133/212)
0%
(0/59)
− <0.001 43%
(53/124)
11%
(3/27)
− 0.002 55%
(186/336)
3%
(3/86)
− <0.001
Percent not receiving
an antimalarial after
testing negative
98%
(61/62)
100%
(3/3)
− −‡ 86%
(19/22)
100%
(4/4)
− −‡ 95%
(80/84)
100%
(7/7)
− −‡
Percent not receiving
an antimalarial if no
blood test given
64%
(58/90)
100%
(4/4)
− −‡ 52%
(192/371)
0%
(0/1)
− −‡ 54%
(250/461)
80%
(4/5)
− 0.383
* Multivariate logistic regression adjusted for age, sex, ethnicity and household SES status if five or more observations. Fischer’s Exact if
less than five observations (no AORs).
† In 2005 local guidelines recommended antimalarial treatment with chloroquine plus sulphadoxine-pyramethamine for P. falciparum and
chloroquine for P. vivax. In those patients with P. vivax (either alone or mixed) primaquine was also recommended. In 2013 correct
treatment regimens were dihydoartemisinin-piperaquine for all species of malaria plus primaquine in those with P. vivax infections (alone
or mixed). P. malariae infections (n = 2) were excluded from this analysis.
‡ 2013 data predicted the outcome perfectly. All individuals had the same level of outcome; hence, no statistical computations can be
performed for the logistic regression − no statistical output is given in software.
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Table 3.7: Reported antimalarial treatment for individuals by reported diagnosis.
2005 (N = 336) 2013 (N = 86)
Private Public Overall Private Public Overall
P. falciparum (N) 68 99 167 14 32 46
Percentage receiving any ACT 0% (0) 1% (1) 1% (1) 50% (7) 97% (31) 83% (38)
Percentage receiving any antimalarial without ACT 88% (60) 94% (93) 92% (153) 36% (5) 3% (1) 13% (6)
Percentage receiving unknown antimalarial 0% (0) 3% (3) 2% (3) 14% (2) 0% (0) 4% (2)
Percentage receiving primaquine (any dose) 62% (42) 82% (81) 74% (123) 71% (10) 59% (19) 63% (29)
Percentage receiving any treatment 94% (64) 98% (97) 96% (161) 100% (14) 100% (32) 100% (46)
Percentage receiving no treatment 6% (4) 2% (2) 4% (6) 0% (0) 0% (0) 0% (0)
P. vivax (N) 51 108 159 12 25 37
Percentage receiving any ACT 0% (0) 0% (0) 0% (0) 50% (6) 96% (24) 81% (30)
Percentage receiving any antimalarial without ACT 75% (38) 94% (102) 88% (140) 25% (3) 0% (0) 8% (3)
Percentage receiving unknown antimalarial 20% (10) 5% (5) 9% (15) 25% (3) 4% (1) 11% (4)
Percentage receiving primaquine (any dose) 29% (15) 81% (88) 65% (103) 58% (7) 72% (18) 68% (25)
Percentage receiving any treatment 94% (48) 99% (107) 97% (155) 100% (12) 100% (25) 100% (37)
Percentage receiving no treatment 6% (3) 1% (1) 3% (4) 0% (0) 0% (0) 0% (0)
Mixed infections (N) 5 5 10 1 2 3
Percentage receiving any ACT 0% (0) 0% (0) 0% (0) 100% (1) 50% (1) 67% (2)
Percentage receiving any antimalarial without ACT 80% (4) 60% (3) 70% (7) 0% (0) 0% (0) 0% (0)
Percentage receiving unknown antimalarial 0% (0) 40% (2) 20% (2) 0% (0) 50% (1) 33% (1)
Percentage receiving primaquine (any dose) 60% (3) 60% (3) 60% (6) 100% (1) 50% (1) 67% (2)
Percentage receiving any treatment 80% (4) 100% (5) 90% (9) 100% (1) 100% (2) 100% (3)
Percentage receiving no treatment 20% (1) 0% (0) 10% (1) 0% (0) 0% (0) 0% (0)
the same period, the percentage of patients with P. falciparum reporting treatment
with a single dose primaquine rose from 19% (31/167) in 2005 to 50% (23/46) in 2013
(AOR = 6.27 [95% CI: 2.68−14.68], p < 0.001).
3.3.6 Cost burden of fever
In 2013 a total of 100 visits to healthcare providers were reported by 98 individuals;
hence, nearly all patients reported requiring only one visit compared to 14% (107/764)
of individuals who reported seeking medical care at two or more providers before the
policy change (p < 0.001). In 2013 the mean total direct cost to the household per
visit was US$16.8 (SD = 19.0) at a private provider and US$4.1 (SD = 14.4) at the
public sector (p < 0.001). The mean daily wage in 2013 was US$18.2 (SD = 12.5),
with a total mean indirect cost per fever episode of US$52.5 (SD = 41.4) for adults and
US$7.3 (SD = 16.4) for children.
Table 3.8 shows the cost per fever episode resulting in treatment seeking in 2005 and
2013. While the direct costs were similar (p = 0.119), a significant decrease in indirect
costs was evident from US$44.2 (SD = 51.0) before the policy change to US$33.8 (SD
72
CHAPTER 3. TREATMENT SEEKING AFTER SWITCH TO UNIFIED
MALARIA TREATMENT IN PAPUA
Table 3.8: Reported direct, indirect and total costs per individual taking treatment for
fever over the entire fever episode (2014 US$).
2005 (N = 834) 2013 (N = 99)
Category Mean (SD) Median (IQR) Mean (SD) Median (IQR) p value*
Total direct costs † 9.4 (27.3) 1.9 (0.4−5.6) 8.1 (17.0) 1.7 (1.0−8.1) 0.119
Total indirect costs 44.2 (51.0) 32.8 (10.9−60.1) 33.8 (40.1) 18.2 (0.0−54.6) 0.006
Total cost to the individual taking
treatment due to lost wages
19.3 (30.6) 0.0 (0.0−32.8) 28.4 (38.3) 9.1 (0.0−45.5) 0.010
Total cost for companions 4.1 (6.5) 0.00 (0.0−5.5) 3.2 (7.6) 0.0 (0.0−0.0) 0.001
Total cost for caretaking 19.7 (30.5) 10.9 (0.0−27.3) 2.0 (9.1) 0.0 (0.0−0.0) <0.001
Total cost for substitute labor 1.1 (6.5) 0.0 (0.0−0.0) 0.2 (1.8) 0.0 (0.0−0.0) 0.072
Total costs 53.5 (65.3) 33.8 (16.4−66.7) 41.9 (44.3) 27.3 (8.1−64.7) 0.104
* Mann-Whitney rank test.
† Includes payments made by the household for all treatments including diagnostics
and transport.
= 40.1) in 2013 (p = 0.006). In 2013 only 29% (29/99) of individuals reported that
someone had to cut back on their usual activities to care for them, a decrease from
77% (641/834) in 2005 (OR = 0.12 [95% CI: 0.08−0.20], p < 0.001). There was also a
reduction in the number of individuals requiring a substitute laborer from 8% (66/834)
in 2005 to 1.0% (1/99) in 2013 (p = 0.007). There was no significant difference in
the proportion of individuals having at least one companion accompany them to seek
treatment (66% [553/834] in 2005 versus 73% [72/99] in 2013; p = 0.200). Overall, the
mean cost per fever episode was US$41.9 (SD = 44.3) in 2013 compared to US$53.5
(SD = 65.3) in 2005 (p = 0.104).
3.4 Discussion
The results of the household surveys undertaken before and after implementation of
ACT after confirmed diagnosis in Papua, Indonesia highlight several important changes
in treatment-seeking behaviour, diagnosis of malaria and adherence to antimalarial
drugs. Only one individual (1%) did not seek treatment outside of the home, compared
to 8% in 2005 when less efficacious treatments were available in both the public and
private sectors. This shift in treatment seeking was associated with more individuals
attending public providers at least once, rising from 46% in 2005 to 67% in 2013. Those
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from households with lower SES were still more likely to seek treatment at public
providers than those with higher SES.
Before the implementation of ACT, more than 40% of patients failed antimalarial
treatment within 42 days, with almost half of these patients doing so within seven days
[5]. The introduction of a three-day regimen of DHP resulted in rapid parasite clearance
and symptom recovery with less than 5% of patients having recurrent malaria, most
of which occurred after 28 days [9]. Hence, the observed changes in treatment-seeking
behaviour likely reflect community awareness of such highly effective treatments and
their availability initially in the public sector and subsequently in the private sector.
In parallel with the shift in where patients sought treatment there were also significant
changes in the way in which healthcare services were provided, particularly the emphasis
on only treating malaria after lab confirmation and adherence to antimalarial policy.
RDTs were introduced at public health facilities without microscopists in 2006-07 and
were used for half of the outpatient visits to one of the hospitals, whereas microscopy
remained the main diagnostic for patients requiring admission to hospital. In 2013
individuals who attended healthcare facilities were nearly twice as likely to have a blood
test for malaria compared to those in 2005, and this was particularly prominent in the
private sector where almost all patients were offered a blood test in 2013. Considering
that dissatisfaction with the public sector is common [19] and studies in Southeast Asia
have shown that a large proportion of individuals seek treatment in the private sector
[20, 21], improvement of both sectors is vital to ensuring public health benefits [22].
Our findings also demonstrate that those diagnosed with malaria in 2013 were three-
fold more likely to receive the recommended treatment regimen. Importantly, both
the public and private sectors implemented the policy change to ACT, with reductions
in prescriptions of non-ACT antimalarials apparent in both sectors. This included an
eight-fold decline in chloroquine prescriptions. Furthermore, better prescribing practices
were also observed for primaquine, which is encouraged as a single dose for reducing the
transmission potential of P. falciparum and as a 14 day regimen for the radical cure of
P. vivax.
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The survey results also highlight a modest fall in the prevalence of parasitaemia
from 16% to 12%, although individuals who were parasitemic were six-fold less likely
to be symptomatic. Furthermore, a 10-fold reduction (from 42% to 4%) was observed
in those reporting fever in the preceding month. Before policy change, individuals
reporting recent fever were three times more likely to be parasitaemic at the time of the
survey than those with no recent febrile illness. Since the risk of an infected mosquito
bite within 28 days in this region is low (<8%), the most likely explanation for this
is that prior to 2006 treatment with partially effective treatment often failed to clear
parasitaemia by the time of the survey, whereas this was no longer apparent after the
change in policy to highly effective treatment with ACT. In contrast no reduction was
observed in the prevalence of asymptomatic parasitaemia between 2005 and 2013, a
likely reflection of these patients not being unwell enough to seek treatment [23].
The first survey was conducted between July and December, whereas the second was
undertaken from April through July. While seasonal variation in either malaria or other
causes of fever could therefore have influenced our observations, malaria transmission in
this area occurs throughout the year with minimal seasonality [23]. Other factors that
could have affected our results include fluctuations in the demography and an increase
in the supply of care by public providers through the second hospital. Between 2005
and 2013 the population grew from 120,000 to 172,000, and this was complemented
with a slight increase in the proportion of non-Papuans, who are generally less immune.
But this was countered by individuals reporting having lived in the area longer which
would facilitate greater asymptomatic infections. In 2013 the only significant risk factor
for recent febrile illness was being non-Papuan (Table 3.4). Whereas in 2005 Lowland
Papuans, children less than five years old, and those from lower SES household were all
at greater risk (Chapter 2). The changes in treatment-seeking behaviour therefore
likely reflect a complex shift in population dynamics coupled with the impact of better
treatment regimens and healthcare provision.
The observed changes in treatment seeking had important implications for the
household costs incurred by malaria. While the mean cost for each febrile episode
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decreased from US$53.5 to US$41.9, reported monthly income in households increased
from 60% with less than US$500 in 2005 to 49% with less than US$560 in 2013.
Furthermore, in 2005 households more frequently reported multiple household members
with fevers in the past month and those household members reported more repeat visits
as compared to 2013. Considering the decrease in symptomatic individuals who were
parasite positive, it is likely that many of these changes in treatment-seeking behaviour
are a result of effective treatment.
This study has a number of limitations. Firstly, a degree of recall bias is likely due to
the time between the fever episode and the survey, though this bias would be expected
to be similar for both surveys. Due to differences in the phrasing of the questionnaires,
we were unable to explore how use of bed nets had changed over time. As with the
previous survey, many older male household members were not present at the time of
the interviews and temporary migrants were excluded.
Another key limitation is the eight year gap between surveys. While the cross-
sectional design quantified the changes in parasitaemia, treatment-seeking behaviour
and costs from 2005 to 2013, the time interval between surveys increases confounding
from other changes besides the policy change including demographic dynamics, such
as smaller households, greater representation of females, and duration residing in the
study area. As reflected in the above discussion, this gap makes it more challenging to
infer a direct policy impact; however, public health and malaria control activities aimed
at changing behaviour remained similar over this time period. Had it been possible to
include a control group, an impact evaluation may have been a better result.
In conclusion, the policy change in March 2006 to a unified treatment of malaria
with DHP had a significant impact on treatment-seeking behavior, resulting in more
patients attending healthcare facilities where better case management was provided.
These changes had a significant impact on the burden of malaria with fewer patients
reporting febrile illness; however, asymptomatic infections increased. Further reductions
in malaria and its ultimate elimination will require implementing more effective radical
cure of P. vivax alongside active case detection or presumptive interventions.
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Chapter 4
Using G6PD tests to enable the
safe treatment of P. vivax
infections with primaquine on the
Thailand-Myanmar border: A
cost-effectiveness analysis
This chapter been published as Devine A, Parmiter M, Chu CS, Bancone G, Nosten F,
Price RN, Lubell Y, Yeung S. Using G6PD tests to enable the safe treatment of
Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A
cost-effectiveness analysis. PLoS Negl Trop Dis. 2017;11(5):e0005602.
https://doi.org/10.1371/journal.pntd.0005602 PMID: 28542194.
4.1 Introduction
P. vivax is an important public health concern, particularly in Asia and South
America, where it is now responsible for the majority of malaria cases. While
traditionally regarded as a benign disease, P. vivax malaria has been associated with
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severe and fatal outcomes [1, 2]. As countries move toward malaria elimination and the
overall incidence of malaria declines, the proportion of cases that are due to P. vivax
infections increases [3, 4]. A single infection of P. vivax can lead to multiple relapses
due to its ability to form dormant liver stage parasites called hypnozoites. These
relapses are indistinguishable from new infections and repeated episodes can lead to a
cumulative risk of anaemia and malnutrition [5, 6]. In short latency relapse settings,
the majority of P. vivax cases are thought to be due to relapses [7].
Primaquine is the only drug currently licensed for the radical cure of P. vivax ; however,
it can cause severe haemolysis in individuals with G6PD deficiency, a common genetic
disorder [8] that is positively associated with P. vivax incidence [9]. The prevalence of
G6PD deficiency varies from less than 1% to more than 30%, with a mean of 8% in
countries where malaria is endemic; equivalent to 350 million people worldwide [10].
G6PD deficiency is largely asymptomatic until individuals are exposed to oxidative
stress from an external source, including certain drugs, such as primaquine, and foods,
most notably fava beans [9]. The degree of enzyme deficiency varies widely depending
upon the genotypic variant which varies with geographical region. A recent review
found only 14 documented deaths attributable to primaquine use [11]; however,
fatalities may have gone unreported [12].
The WHO recommends that primaquine be used for the radical cure of P. vivax
infected patients who can be tested for G6PD deficiency [13]. The gold standard for
diagnosing G6PD deficiency is the spectrophotometric assay, a test that requires a
laboratory setting and specialised staff [14, 15]. The fluorescent spot test (FST), which
is the most widely used assay for G6PD deficiency, is easier to perform but requires
basic laboratory equipment, electricity and a cold chain, rendering it difficult to use in
remote settings. Thus, routine testing for G6PD deficiency prior to prescribing
primaquine generally is not part of antimalarial policy in most countries [16]. Recently,
the CareStart G6PD (Access Bio, Somerset, NJ, USA) lateral flow RDT has become
available for point-of-care testing. This phenotypic test has high sensitivity for an
enzyme activity cut off of 30% [17, 18]; hence false negative results would rarely lead to
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a G6PD deficient individual receiving primaquine with an attendant risk of haemolysis.
Unlike the other G6PD RDT by BinaxNOW (Alere, Orlando, FL, USA), the CareStart
RDT can be used in settings where the temperature is above 25°C, a common necessity
in P. vivax endemic settings [19, 20].
The availability of point-of-care G6PD tests is of clinical and public health importance
so that P. vivax patients have safe access to primaquine treatment for the prevention
of relapses and the resulting health complications [20]. Here I evaluate the
cost-effectiveness of using G6PD RDTs on the Thailand-Myanmar border and present
our model as an interactive web tool that can be adapted to other settings.
4.2 Methods
4.2.1 Base case analysis
A cost-effectiveness analysis [21] using a health care provider perspective was
conducted with decision tree models for P. vivax infections using R statistical software
[22] over a one year time horizon. The model was parameterised for the north-western
border of Thailand with Myanmar (Tak Province), with the benefit of data on
recurrences from a recent clinical trial at the Shoklo Malaria Research Unit (SMRU),
which provides free of charge care to migrants and refugees [23, 24]. This study was
chosen as it compared chloroquine with chlorquine plus high-dose primaquine and
followed patients for one year following their initial episode. Few previous studies can
provide information over such a long time period [25].
In this population of migrants and refugees, the prevalence of G6PD deficiency was
documented to be 9-18% [26]. The most common genetic variant was the Mahidol
variant (88%) with Chinese-4, Viangchan, Aores, Seattle, and Mediterranean variants
also present [26]. Low, unstable P. vivax transmission is seen in this area [3] with a
frequent relapse pattern [27]. In recent years, the overall number of malaria cases has
been decreasing while the prevalence of P. vivax in the population has remained
relatively stable at 9% [3]. Routine practice along the border is to administer 14 days
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of supervised therapy with or without G6PD screening to patients able to attend the
clinic; in practice this is a small proportion of the patients.
The testing of G6PD status with CareStart G6PD RDT before administering
primaquine (“screening strategy”) was compared to a strategy in which no G6PD test
is performed and primaquine is not used at all (“chloroquine strategy”). In addition,
the screening strategy is compared with a strategy where primaquine is given to all
patients without testing for G6PD deficiency (“primaquine strategy”) (Table 4.1). The
chloroquine strategy and primaquine strategy were not directly compared to each other
because (1) it is unlikely that in settings where the chloroquine strategy is used
switching to the primaquine strategy would be a viable option due to the evident
concerns about safety and (2) it is unlikely that settings where the primaquine strategy
is used would consider changing to the chloroquine strategy due to its inability to
achieve radical cure. While this is a deviation from standard practice for economic
evaluations, it isolates the options that countries are considering, allowing a focus on
the information relevant to their policy decisions.
Recurrences were recorded over a one year time period in patients who were treated
with chloroquine alone, as compared with those who were treated with chloroquine
plus 14 days of supervised primaquine for each P. vivax episode (0.5 milligrams
(mg)/kilogram (kg)/day) [23, 24]. The relative risk of having at least one recurrence
following primaquine treatment was 0.22 as compared to those receiving chloroquine
alone. For those who had at least one recurrence, the mean number of recurrences was
3.54 in the chloroquine arm and 1.16 in the primaquine arm. The model applies the
inclusion criteria of the clinical trial, which was restricted to patients who were six
months and older, not pregnant and presenting with uncomplicated P. vivax malaria
[23]. The mean age in the clinical trial was 21 years; this was used for the
disability-adjusted life-year (DALY) calculations for years of life lost [24].
The analysis and results were completed separately for males (Figure 4.1) and females
(Figure 4.2) to account for their differences in risks and outcomes. Firstly, as pregnant
females would not be prescribed primaquine due to the unknown G6PD status of the
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Table 4.1: Summary of key components of each strategy.
Chloroquine strategy Primaquine strategy Screening strategy
Initial visit
Treatment Chloroquine given
to all.
Chloroquine and supervised
primaquine therapy (14 day)
given to all. All individuals
with severe G6PD deficiency
stop primaquine therapy early.
Females with intermediate
G6PD deficiency who do not
have severe haemolysis
complete primaquine therapy.
Chloroquine and supervised
primaquine therapy (14 day)
given to those who test G6PD
normal. Chloroquine and weekly
primaquine given to those who
test G6PD abnormal. Individuals
with severe G6PD deficiency who
are inadvertently given 14 day
primaquine will stop therapy
early. Females with intermediate
G6PD deficiency who do not have
severe haemolysis complete
primaquine therapy.
Recurrences (all costs and DALYs are weighted by the proportion of severe cases)
Costs Cost per recurrence. Cost per recurrence.
Supervised primaquine (14
day) for those who are G6PD
normal.
Cost per recurrence. Includes G6PD
RDT. Supervised primaquine (14 day)
for those who are G6PD true normal.
Supervised primaquine (8 weekly)
for those who test G6PD abnormal
and false normal.
Effects All have the number
of recurrences for
chloroquine treatment.
G6PD abnormal individuals
have the number of recurrences
for chloroquine treatment.
G6PD normal individuals have
the number of recurrences
for primaquine treatment.
Those who test G6PD false normal
have the number of recurrences for
chloroquine treatment. All other
individuals have the number of
recurrences for primaquine
treatment.
fetus, the screening and primaquine strategies modelled the inclusion of a pregnancy
test for all women of childbearing age who were unaware that they were pregnant.
Those who were identified or known to be pregnant would be treated with chloroquine
only and would not have a G6PD RDT. Secondly, since G6PD is an X-linked disorder,
males who have deficiency are hemizygous while females can be either homozygous or
heterozygous with a range of G6PD expression levels. Accordingly, G6PD deficiency
was divided into two groups: severe (<30% enzyme activity) and intermediate (30-69%
enzyme activity). Only females can have intermediate deficiency and the outcomes in
this group were taken from heterozygotes. Studies have shown that the G6PD RDT
with a cut off of 30% activity does not detect heterozygous females with intermediate
activity [16, 18]; accordingly, some women with intermediate deficiency who are
identified as G6PD normal with currently available RDTs could be at risk of severe
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Figure 4.1: Model diagram of strategies for P. vivax treatment in males.
haemolysis when prescribed haemolytic drugs.
Table 4.2 shows the parameters used in the model. Both the screening and primaquine
strategies include the cost of supervised therapy in order to reflect the additional costs
required for the gains in effectiveness seen in the clinical trial. For the screening
strategy, weekly supervised primaquine therapy for eight weeks was given to those who
tested G6PD abnormal [28] and the effectiveness was taken from the trial results for 14
day therapy [24]. For each recurrence, the cost and DALY value used were taken from
clinical episodes, severe malaria episodes and episodes that resulted in death and
weighted proportionally. The probability for severe P. vivax was taken from a meta
analysis of clinical studies using those with severe anaemia, but other symptoms due to
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Figure 4.2: Model diagram of strategies for P. vivax treatment in females.
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severe P. vivax were not included [2].
The probability of having a haemolytic episode that requires a transfusion in
individuals with severe and intermediate G6PD deficiency treated with primaquine was
taken from a study of children treated with dapsone in Africa [29]. While this
population may be different in terms of age and G6PD variant from those being
treated with primaquine on the northwestern border of Thailand with Myanmar, this
was the best available data on transfusion risk. The probability of haemolysis requiring
transfusion for severe G6PD deficiency was taken from the proportion of hemizygotes
and homozygotes in the study while the probability for females with intermediate
deficiency was taken from the proportion of heterozygotes. It was assumed that 10% of
patients requiring a transfusion did not receive one; of those, 10% died as a result of
not receiving a transfusion. It was assumed that the decision to give a transfusion was
made by a physician and that the costs are included in the cost of transfusion.
Costs of commodities and service delivery were taken from Myanmar and Thailand and
supplemented by international sources when needed. Costs are reported in 2014 US$.
The cost of supervised therapy was taken from data on annual costs of a community
health worker in Myanmar [34], assuming one half-day of pay per observation. The
cost of hospitalisation for a blood transfusion was included for severe haemolytic
episodes which did not lead to death. Table 4.1 describes the costs for recurrences.
The DALY weights were taken from the 2010 Global Burden of Disease Study [40].
These weights were combined with life tables for Myanmar [38] and assumptions about
the length of illness to calculate the DALY burden for each strategy.
In instances where the screening strategy averted DALYs while costing more money
the incremental cost-effectiveness ratios (ICER) was calculated:
ICER =
Costs − Costb
DALYb −DALYs
Where Cost is the total cost of the strategy and DALY is the total DALYs of the
corresponding strategy. While the gross domestic product per capita for Myanmar is
approximately US$1,200 [41], it has been argued that a lower WTP threshold may be
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Table 4.2: Model parameters and sources (2014 US$).
Base case (low, high) Distribution
(Parameters*)
Sources
Proportion of males with severe G6PD deficiency 0.137 ± 50% Beta (13.50, 85.05) [26]
Proportion of females with severe G6PD deficiency 0.050 ± 50% Beta (15.17, 288.18) Females with <30% activity (Section 4.6)
Proportion of females with intermediate G6PD activity 0.158 ± 50% Beta (12.96, 69.04) Females with 30-69% activity (Section 4.6)
Sensitivity of CareStart G6PD RDT for severe
deficiency
0.99 (0.9−1.00) Beta (9.39, 0.09) [18] (Low range from [16])
Sensitivity of CareStart G6PD RDT for intermediate
deficiency
0.44 ± 50% Beta (7.97, 10.14) [18]
Specificity of CareStart G6PD RDT for males 0.99 (0.75−1.00) Beta (3.01, 0.03) [18] (Low range from [16])
Specificity of CareStart G6PD RDT for females 0.97 (0.68−0.99) Beta (2.59, 0.08) [18] (Low range from [16])
Proportion who have at least one recurrence in the
following year if treated with CQ
0.732 – [24]
Relative risk of having at least one recurrence in the
following year if treated with CQ + PQ
0.219 (0.158−1) Lognormal (-1.52,
0.47)
[23, 24]
Mean number of recurrences in those treated with
CQ who have at least 1 recurrence
3.537 (1−8) Bootstrapped data [23, 24] Each PSA iteration is the mean of
100 bootstrapped data points.
Mean number of recurrences in those treated with
CQ + PQ who have at least 1 recurrence
1.156 (1−2) Bootstrapped data [23, 24] Each PSA iteration is the mean of
100 bootstrapped data points.
Proportion who need a blood transfusion after taking
primaquine if have severe G6PD deficiency
0.109 (0.007−0.15) Beta (10.40, 85.01) [29]
Proportion who need a blood transfusion after taking
primaquine if have intermediate G6PD deficiency
0.005 (0.001−0.05) Beta (0.09, 18.72) [29, 30] Results for female heterozygotes
Proportion who need a transfusion due to haemolysis
but do not receive it
0.100 (0.010−0.150) Beta (8.77, 78.90) Assumption for both severe and intermediate
deficiency
Mortality due to not receiving a needed transfusion 0.100 (0.010−0.500) Beta (2.22, 19.95) Assumption for both severe and intermediate
deficiency
Proportion of females who are pregnant 0.11 ± 50% Beta (14.05, 113.65) Assumption
Proportion of females who need to take a
pregnancy test
0.50 ± 50% Beta (6.92, 6.92) Assumption. All women of childbearing age are
tested unless they disclose pregnancy
COSTS
CareStart G6PD RDT 1.75 (0.88−10.00) Gamma (0.38, 4.64) RDT (1.50) [31] and administration (0.25) [32]
Primaquine pill 0.06 ± 50% Gamma (24.71, 0.00) [33] 14 days of 30mg/day; 8 weeks of 45mg/
week. Assumed weight = 60kg.
One session of supervised primaquine therapy by a
community health worker
1.67 ± 50% Gamma (16.15, 0.10) [34] One-half day of work for a medium
accessible area with no incentives per
supervision
Initial episode and clinical P. vivax recurrence 7.86 ± 50% Gamma (16.10, 0.49) [35] Outpatient visit, excluding screening and
treatment costs
Severe P. vivax recurrence 196.22 (95% CI:
135.08−271.39)
Gamma (31.48, 6.23) [36] Inpatient visit for severe P. falciparum
Haemolytic episode requiring transfusion 320.71 (166.03−401.53) Gamma (32.55, 9.85) One unit of blood (25.31) [37] and 7 day
inpatient stay (295.40) [35]
Pregnancy test 0.10 ± 50% Gamma (16.10, 0.01) SMRU clinic records
DALYS
Proportion of P. vivax cases that are severe 0.020 (95% CI: 0.013
−0.027)
Beta (31.41,
1539.05)
[2]
P. vivax mortality 0.0001 (95% CI:
0−0.001)
Beta (0.09, 929.01) Assumption
Life expectancy for males aged 20−24 in Myanmar 48.9 ± 20% Gamma (96.79, 0.51) [38]
Life expectancy for females aged 20−24 in Myanmar 52 ± 20% Gamma (96.79, 0.54) [38]
Length disability: clinical malaria 0.008 (0.003−0.019) Beta (3.27, 404.86) 3 days (range 1−7)
Length disability: moderate anaemia due to clinical
malaria
0.083 (0.04−0.17) Beta (5.39, 59.33) [39] 1 month (range 0.5−2)
Length disability: severe malaria 0.019 (0.008−0.027) Beta (16.91, 872.94) 7 days (range 3−10)
Length disability: severe anaemia due to severe
malaria or haemolysis
0.250 (0.083−0.500) Beta (3.59, 10.76) 3 months (range 1-6)
Disability weight for clinical malaria 0.053 (0.033−0.081) Gamma (18.12,
0.003)
[40] infectious disease: moderate acute episode
Disability weight for moderate anaemia due to
clinical malaria
0.058 (0.038−0.086) Gamma (21.70,
0.003)
[40]
Disability weight for severe malaria 0.210 (0.139−0.298) Gamma (26.50,
0.008)
[40] infectious disease: severe acute episode
Disability weight for severe anaemia due to severe
malaria or haemolysis
0.164 (0.112−0.228) Gamma (30.37,
0.005)
[40]
* Parameters: Beta (alpha, beta), Lognormal (log (mean), log (standard deviation))
and Gamma (shape, scale)
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appropriate for lower income countries [42]; consequently, a threshold of US$500 was
chosen to reflect the resource limitations of healthcare facilities serving migrant and
refugee communities.
4.2.2 Sensitivity analyses
A one-way sensitivity analysis was conducted to examine the impact of parameter
values on the overall outcome. Low and high values were taken from 95% CIs when
available. When not available, the point estimate was varied by 50% and given wider
intervals when necessary to reflect the uncertainty (Table 4.2). Results that varied
from the base case by more than US$0.05 or 0.0002 DALYs averted were reported.
A probabilistic sensitivity analysis (PSA) was conducted to incorporate the uncertainty
of all parameters over 1000 sampling iterations using the parameter ranges used in the
one-way sensitivity analysis. Table 4.2 lists the distributions used in the PSA. The sum
of squared differences was minimised from the specified ranges to produce the shape
values for the beta and gamma distributions and random numbers were generated from
these distributions. The mean number of recurrences for each iteration was calculated
from 100 bootstrapped data points that were randomly sampled from the data set with
replacement [24]. The PSA produced a mean estimate and 95% credible intervals
(CrIs) for the costs, DALYs and incremental results.
A key concern is adherence to primaquine regimens by the patients as well as
compliance to guidelines by prescribers, which is collectively referred to as adherence
here. In order to account for this, a two-way sensitivity analysis examined the interplay
of costs and benefits depending on adherence to the primaquine strategy (whether
primaquine was administered to the patient and the full course taken) and screening
strategy (whether a G6PD RDT plus primaquine was administered to the patient and
the full course taken). This cohort analysis assumed that at 0% adherence all
individuals have a relative risk and mean number of recurrences equivalent to receiving
chloroquine only. The proportion of individuals in the population who are adherent
increases steadily until 100% adherence, which assumes that recurrences are equivalent
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to the base case. Costs of supervised primaquine and G6PD screening were also varied
accordingly. Assumptions about adherence in individuals with G6PD deficiency who
receive 14 day primaquine remain the same as the base case analysis.
4.3 Results
4.3.1 Comparison with the chloroquine strategy
Costs and DALYs for each strategy are shown in Table 4.3 and the cohort results are
in Table 4.4. On the Thailand-Myanmar border, the screening strategy averted more
DALYs than the chloroquine strategy: 0.026 for males and 0.024 for females. These
gains were produced for similar costs. The base case ICERs were US$6.3 and US$11.7
per DALY averted for males and females respectively.
Figure 4.3 shows the results of the one-way sensitivity analysis. The screening strategy
always averted more DALYs than the chloroquine strategy (Figure 4.3C-D). Costs for
the screening strategy were highest when radical cure had a low impact on recurrences,
when the costs of supervised therapy and the G6PD RDT were increased, and also
when the cost of a recurrence was decreased (Figure 4.3A-B). The only assumptions
that made the screening strategy cost over US$500 per DALY averted were lowering
the number of recurrences after chloroquine to one (US$3,678.7 in males and
US$3,724.5 in females) and assuming the same relative risk of having at least one
recurrence in females (US$1,223.6).
The mean costs and DALYs and CrIs estimated by the PSA are shown in Table 4.3.
The screening strategy cost more than the chloroquine strategy with mean incremental
cost of US$0.8 (95%CrI: 17.4 to 19.7) and 0.026 DALYs averted (95%CrI: 0.007 to
0.117) per male (Figure 4.4A). At a WTP threshold of US$500, the screening strategy
had an 81.2% probability of being cost-effective (Figure 4.5A). The PSA resulted in a
mean incremental cost of US$0.75 (95%CrI: 15.0 to 20.0) with 0.023 DALYs averted
(95%CrI: 0.006 to 0.122) per female (Figure 4.4C) and a 77.6% probability of being
cost-effective at a WTP threshold of US$500 (Figure 4.5C). The ICERs were US$31.3
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Figure 4.3: One-way sensitivity analysis results on costs and DALYs for the comparison
between the screening strategy and the chloroquine strategy for males (A & C) and
females (B & D). The ranges used are specified in Table 4.2.
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Table 4.3: Costs and DALY results over one year per primary episode treated in the
base case analysis and PSA. All costs are in 2014 US$.
Mean costs Mean DALYs
Base case PSA (95% CrI*) Base case PSA (95% CrI*)
Males
Chloroquine strategy 38.0 37.8 (24.6−55.5) 0.034 0.034 (0.009−0.137)
Primaquine strategy 45.3 45.8 (31.6−62.6) 0.019 0.019 (0.007−0.050)
Screening strategy 38.2 38.6 (25.2−55.3) 0.007 0.008 (0.003−0.018)
Females
Chloroquine strategy 38.0 38.3 (24.0−54.4) 0.034 0.034 (0.009−0.155)
Primaquine strategy 40.5 41.2 (28.3−59.0) 0.015 0.015 (0.006−0.040)
Screening strategy 38.3 39.1 (25.6−57.3) 0.011 0.011 (0.004−0.030)
* Credible interval.
per DALY averted for males and US$32.4 for females.
4.3.2 Comparison with the primaquine strategy
Again, the screening strategy resulted in better health outcomes in the base case with
0.011 DALYs averted in males and 0.004 in females (Table 4.3). The health gains in
females were more modest due to their overall lower probability of haemolysis requiring
transfusion. In addition, the screening strategy produced cost savings of US$7.1 and
US$2.2 per male and female initially treated, respectively (Table 4.3). The simulation
output indicated that one death due to haemolysis would be expected for every 6,682
males and 15,994 non-pregnant females treated using the primaquine strategy. This
would be reduced to one death per 668,164 males and 201,198 non-pregnant females
treated with the screening strategy (Table 4.4).
The one-way sensitivity analysis showed that changes in the parameter values had a
smaller impact on the costs when comparing screening and primaquine strategies,
especially for females, and results that consistently averted DALYs (Figure 4.6). The
parameters related to mortality, the need for transfusion and the prevalence of G6PD
deficiency had the highest impact on DALY results (Figure 4.6A-B). The screening
strategy was cost saving with the exception of raising the G6PD RDT cost to US$10.0,
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Figure 4.4: Cost-effectiveness plane showing the incremental costs and DALYs averted
from the PSA. Results show the screening strategy versus: A) the chloroquine strategy
in males, B) the primaquine strategy in males, C) the chloroquine strategy in females
and D) the primaquine strategy in females.
Figure 4.5: Cost-effectiveness acceptability curves. Results show the screening strategy
versus: A) the chloroquine strategy in males, B) the primaquine strategy in males, C)
the chloroquine strategy in females and D) the primaquine strategy in females.
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Table 4.4: The table shows simulated outcomes for 1,000 P. vivax malaria patients of undetermined G6PD status at attendance, if they
were managed according to each of three strategies (chloroquine, primaquine and screening) according to G6PD status, treatment given
and the test result if screened.
Males Females
Strategy Strategy
Initial treatment by G6PD status Chloroquine Primaquine Screening Chloroquine Primaquine Screening
G6PD normal who get primaquine and have no recurrences – 725 718 – 592 592
G6PD normal who get primaquine and have at least one recurrence – 138 137 – 113 113
G6PD normal who get chloroquine only and have no recurrences 231 – 2 212 – –
G6PD normal who get chloroquine only and have at least one recurrence 632 – 6 580 – –
G6PD deficients* who get chloroquine only 137 – – 208 – –
G6PD deficients* who get weekly primaquine – – 136 – – 106
Severe G6PD deficients who get 14 day primaquine, do not complete treatment but do not require a transfusion – 122 1 – 40 0.40
Intermediate G6PD deficients who get 14 day primaquine and complete treatment – – – – 140 78
G6PD deficients* who get primaquine, haemolyse and receive a required transfusion – 13 0.13 – 5 0.40
G6PD deficients* who get primaquine, haemolyse, do not receive a required transfusion and live – 1 0.01 – 0.50 0.04
G6PD deficients* who get primaquine, haemolyse and die due to not receiving a transfusion – 0.15 0.001 – 0.06 0.004
Do not receive primaquine due to pregnancy – – – – 110 110
* For women, this includes both severe and intermediate G6PD deficiency.
95
CHAPTER 4. COST-EFFECTIVENESS OF USING G6PD TESTS BEFORE
PRIMAQUINE TREATMENT FOR P. VIVAX
 
Figure 4.6: One-way sensitivity analysis results on costs and DALYs for the comparison
between the screening strategy and the chloroquine strategy for males (A & C) and
females (B & D). The ranges used are specified in Table 4.2.
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which caused an incremental cost for the screening strategy of US$235.9 and
US$1,602.1 for males and females, respectively (Figure 4.6A-B). The screening strategy
remained cost saving even at low levels of G6PD deficiency (7%) (Figure 4.6A-B).
The PSA showed a mean cost savings of US$7.3 (95%CrI: -15.4 to 3.4) and 0.012
DALYs averted (95%CrI: 0.001 to 0.113) in males (Figure 4.4B), and a mean cost
savings of US$2.2 (95%CrI: 6.2 to 6.7) and 0.004 DALYs averted (95%CrI: 0.000 to
0.029) in females (Figure 4.4D). The screening strategy had a 97.7% probability of
being cost-effective for males at a WTP threshold of US$500.0 (Figure 4.5B). For
females, the probability was 91.1% (Figure 4.5D). Table 4.3 shows the cost and DALY
estimates from the PSA.
The two-way analysis (Figure 4.7) demonstrated that the screening strategy would be
cost-effective in scenarios where it is used to maintain or increase the number of
patients who are adherent to their primaquine regimens. The impact of switching to
the screening strategy was slightly less in females due to the exclusion of pregnant
women from primaquine treatment and the low sensitivity of the G6PD RDT in
women with intermediate G6PD deficiency.
4.3.3 Web-based application
Due to the extensive heterogeneity and parameter uncertainty around key parameter
estimates, notably relapse patterns [27], G6PD variants and prevalence [10] and costs,
a web-based interface was built using the R-Shiny application so that the model could
be adapted to other settings as need be. See website
(https://malaria.shinyapps.io/g6pd_screening/).
4.4 Discussion
Point-of-care G6PD RDTs offer the opportunity for the safe uptake of primaquine for
the prevention of recurrences. Our findings suggest that on the Thailand-Myanmar
border the use of G6PD RDTs to identify patients with G6PD deficiency before
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Figure 4.7: Two-way sensitivity analysis results showing the impact of changes in the
level of adherence to primaquine regimens. The left column is for males and the right
column is for females. Green represents DALYs averted by the screening strategy for a
cohort of 1,000 individuals. For costs, yellow indicates increased costs and blue indicates
cost savings for the screening strategy for one individual. For net monetary benefit
(NMB), purple indicates scenarios where the screening strategy would be cost-effective
at a threshold of US$500 (T ) where NMB = T ×∆DALY s−∆Costs.
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supervised primaquine is likely to provide significant health benefits (equivalent to
between one and nine days of perfect health) compared to giving chloroquine alone or
giving 14 day primaquine without G6PD testing. Furthermore, the use of point-of-care
G6PD RDTs will potentially save costs or, at most, increase them moderately. While
policy decisions primarily impact the public sector, it is hoped that the effect could
spillover to the private sector as seen in Chapter 3. If the population was aware of
the importance of both radical cure to prevent future relapses and of G6PD screening
to prevent unnecessary side effects, then the demand for these things could be sufficient
to incentivise the private sector to implement a similar policy.
Primaquine is currently the only licensed hypnozonticidal drug, but healthcare
professionals who treat P. vivax cases are often more concerned with avoiding the
immediate risk of haemolysis than with protecting the patient from the risks associated
with future relapses. The fear of haemolysis incentivises healthcare providers to avoid
using primaquine. In other settings, primaquine may be administered without G6PD
testing, putting individuals with G6PD deficiency at risk of severe haemolysis, although
the degree of risk will depend upon local G6PD variants and their prevalence. The
providers in these settings may not implement G6PD screening due to the perception
that the risk of haemolysis is too low to justify the use of G6PD tests or they may be
motivated by the short-term cost savings from not screening for G6PD deficiency.
In the scenario presented, the use of G6PD RDTs will save costs while averting DALYs
compared to a policy in which primaquine is administered without G6PD testing.
While our results give a high probability of cost savings when switching from the
primaquine strategy to the screening strategy, this should not deter radical cure
without screening in settings where screening is unavailable as the primaquine strategy
averted more DALYs than the chloroquine strategy.
Our model is based on supervised primaquine therapy aned hence our findings may not
be applicable to other settings where unsupervised primaquine is the norm and
adherence to a complete course of treatment and thus effectiveness may be low [43].
Patients feel better after the first few days of treatment, giving them little incentive to
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complete their primaquine regimen unless educated about its importance in preventing
future P. vivax episodes. While the assumption that adherence is perfect is ambitious,
it was necessary to reflect the clinical trial outcomes, which were the result of
supervised treatment. Future research investigating the relationship between adherence
to primaquine therapy and effectiveness would enable better cost-effectiveness studies.
The two-way analysis on adherence (Figure 4.7) enabled comparison between settings
with varying adherence and how this impacts upon cost effectiveness. The screening
strategy averts more DALYs than the primaquine strategy, even at relatively high
primaquine strategy adherence and low screening strategy adherence. Shorter drug
courses, such as seven day primaquine and tafenoquine, should contribute to higher
adherence levels and reduced costs for the primaquine and screening strategies. Other
options include but are not limited to text message reminders, observed therapy by
family members, and increased education of health care workers and patients on the
importance of adherence.
Overall, the screening strategy was less cost-effective in women as compared to men.
This reflects a greater proportion of women who are excluded from receiving
primaquine due to pregnancy and the lower risk of severe haemolysis in females with
intermediate G6PD deficiency. Since men represented 65% of patients in the trial that
the recurrence data were derived from [24], the overall cost-effectiveness estimates per
person presenting with P. vivax malaria would likely be closer to the results for males.
The cost-effectiveness of using G6PD RDTs is also dependent on the diagnostic
accuracy of the test. Our model draws on studies conducted on the Thailand-Myanmar
border, which demonstrated a high sensitivity in healthy volunteers. While other
studies have shown similar results [16, 17] in healthy volunteers, a recent study in
Brazil found that the sensitivity of the CareStart G6PD RDT dropped to 50% in
patients with malaria compared to 80% in those who did not [15]. A recent
cost-effectiveness analysis of male patients with P. vivax malaria in Brazil used a low
sensitivity for the CareStart G6PD RDT (46%) but still found it to be more
cost-effective than both the BinaxNOW test and routine care; where the analysis also
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involved the prescription of primaquine without having a G6PD test [44]. This study,
however, used the endpoints ‘adequately diagnosed case’ and ‘hospitalisation avoided’
instead of DALYs. The Brazilian population was given a 94% probability of
hospitalisation when primaquine was given to G6PD deficient men. Our model differs
in that we assume a lower rate of hospitalisation due to severe haemolysis. We also
include results for both genders and report DALYs, enabling comparisons with
interventions for other diseases.
Our study has a number of limitations, mostly related to the model assumptions. The
cost-effectiveness of the screening strategy would be increased if it included the onward
transmission of P. vivax, societal costs, or the longer term impact of repeated episodes,
such as anaemia, malnutrition and all-cause mortality. This is particularly relevant in
areas such as the Thailand-Myanmar border where the estimated proportion of
recurrences due to relapses is estimated to be 78% [24]. The cost-effectiveness may
decrease if some individuals were not able to metabolise primaquine, if healthcare
workers were not able to utilise G6PD RDTs or supervise primaquine regimens, if the
prevalence of G6PD deficiency in those presenting with P. vivax was lower than that in
the general population, if the diagnostic accuracy of the G6PD test were lower, if
healthcare facilities providing care for haemolytic episodes were not accessible or if the
operational costs of implementing a switch to the screening strategy were included.
These parameter limitations are similar to those highlighted in a recent review of the
costs and cost-effectiveness of P. vivax control and elimination [45].
Finally, the model is limited by the paucity of data available in the literature for some
parameter values, including the mortality rate for those who have a
primaquine-induced haemolytic episode requiring transfusion but do not receive them.
These were influential parameters in the comparison between the screening strategy
and the primaquine strategy. Our assumptions of primaquine induced mortality were
derived from previous risks of mortality in patients treated with dapsone in Africa and
equated to a population risk of one in 6,682 administrations to males and one in 15,994
administrations in females. These risks are significantly higher than the risks
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documented in a previous review [11] but the screening strategy averted more DALYs
than the primaquine strategy at a lower level of primaquine-induced mortality, though
this is likely due to the utilisation of weekly primaquine by the screening strategy. In
order to reflect this uncertainty, wide distributions were used in the sensitivity analyses
for parameters that were considered to be less reliable. Other variables, such as the
prevalence of G6PD deficiency, will vary greatly depending on the epidemiological
setting. Unit costs were not collected alongside the trial, requiring cost data to be
gathered from various sources. This is a limitation, particularly as the one-way
sensitivity analysis showed that the cost parameters had a large influence on the
results. The online model (https://malaria.shinyapps.io/g6pd_screening/)
could be used to investigate the results when more robust cost data are available.
Whilst it would be beneficial to gather more robust parameter estimates on which to
base informed policy decisions, this should be tempered by the feasibility of gathering
such data and the potential benefits of implementing appropriate policies sooner,
especially in the context of elimination.
Although our model is relatively simple, it provides a useful starting point for
policymakers to compare the risks and benefits of using G6PD RDTs to enable the safe
and effective use of primaquine. To assist in this process, an online tool is provided
(https://malaria.shinyapps.io/g6pd_screening/). This model enables
policymakers and healthcare providers the opportunity to vary the assumptions made
in the model to reflect their local scenario. In this way, decision makers can begin to
think about whether the model might be cost-effective in their setting. While every
attempt has been made to keep a plausible range of settings, it may be necessary for
further consultation with a health economist before implementing policy decisions. In
addition, the model can be adjusted to reflect any additional data as it becomes
available. A new online tool may need to be developed if new screening and treatment
options are available.
As the only licensed antimalarial for the radical cure of P. vivax infections, primaquine
will be a critical tool for the elimination of all malaria [46] and for the health gains
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provided to patients. The currently available G6PD RDTs can identify G6PD deficient
males, making the screening strategy an attractive option regardless of current practice.
In situations where blood transfusions are not accessible, further information may be
required on the prevalence of G6PD deficiency and associated risk of haemolysis in
females with intermediate G6PD deficiency who test normal by current G6PD RDT
methods. Despite the initial cost, point-of-care RDTs avert DALYs by reducing
recurrences while diminishing the haemolytic risk in G6PD deficient patients.
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4.5 Appendix: Study description for determining
G6PD activity in females
4.5.1 Study population and samples
Healthy women were enrolled over a four month time period as part of an ongoing project by
the SMRU among the female migrant and refugee population living at the
Thailand-Myanmar border with a target enrolment of 300. No exclusion criteria specific to
G6PD status were applied; therefore, the sample is believed to represent the general female
population of the area. A venous blood sample was taken from each participant and
transported within eight hours to the central laboratory for analyses.
4.5.2 Laboratory methods
Screening for G6PD deficiency using the FST (R&D Diagnostic, Greece). Five microliters of
blood were mixed with reagents, spotted on filter paper after 10 minutes of incubation and
allowed to air-dry over 20 minutes. Spots were visualized under ultraviolet light and normal
or deficient phenotype assigned based on fluorescence. Quantitative phenotype was assessed
by spectrophotometry according to WHO protocol on whole blood depleted of white blood
cells [47]. G6PD activity was calculated after normalisation with hemoglobin (Hb)
concentration and expressed as percentage of the population median which was previously
established using the same technique.
4.5.3 Statistical analysis
Three categories of G6PD activity were chosen: <30%, 30-69% and >70%. The percentage of
women in each of those categories was calculated using R statistical software [22].
4.5.4 Results
322 women were enrolled in the study. Of those who were enrolled, 5.0% (16/322) had less
than 30% G6PD activity and 15.8% (51/322) tested as having between 30 and 69% G6PD
activity.
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Chapter 5
Economic costs of P. vivax
episodes: A multi-country
comparative analysis using primary
trial data
5.1 Introduction
Outside of Sub-Saharan Africa, P. vivax is now the dominant species causing malaria
with an estimated 12.6 million episodes in 2015 [1]. P. vivax malaria differs from P.
falciparum in that an infectious bite can result in dormant liver stages of the parasites
(hypnozoites) which can relapse months or even years after the primary infection. Hence,
one infected mosquito bite can result in multiple clinical episodes, with the risk and
frequency of relapses varying by geographical location. The clinical management of a
patient with P. vivax therefore should involve radical cure with a drug regimen that
clears both the blood and liver stages of the parasite.
The only licensed drug with activity against hypnozoites is primaquine, an 8-
aminoquinoline, which can cause haemolysis when administered to individuals with
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G6PD deficiency. While a single dose of primaquine is used without screening for G6PD
deficiency to block P. falciparum transmission, WHO guidelines recommend that all
patients should be tested for G6PD deficiency before a high dose of primaquine is
prescribed for radical cure of vivax malaria [2]. Few settings routinely offer screening
for G6PD deficiency to vivax patients due to operational constraints (Chapter 1), but
new point-of-care tests for G6PD deficiency have been developed to facilitate bedside
testing. For individuals identified as G6PD deficient, an eight week course of weekly
primaquine doses is recommended [3], with monitoring for anaemia, now feasible using
a hand held device (HaemocueTM). G6PD normal patients with malaria should be
treated with a course of primaquine usually prescribed as a once daily regimen for 14
days; however, patient adherence to completing a full treatment course varies by setting
and patient population [4] and in practice effectiveness can be very poor [5]. Primaquine
efficacy is dependent upon the total mg/kg dose administered, so adherence and thus
effectiveness can be improved by reducing the duration of treatment. One option is to
administer the same total dose over seven days instead of 14, but this high daily dose
of primaquine increases the risk of gastrointestinal and haematological adverse events.
The safe and effective radical cure of P. vivax can be achieved with a variety of
diagnostic and treatment strategies, which can be evaluated using cost-effectiveness
analyses to determine the most efficient provision of healthcare. In order to do this,
information needs to be gathered on the costs related to P. vivax and its treatment;
to date, little research has been done in this important area [6] (Chapter 1). These
challenges are highlighted in Chapter 4 which relied on cost data from disparate
sources [7, 8, 9, 10, 11, 12, 13], since many of the vivax-specific cost data available were
from studies outside of Asia [14, 15, 16, 17].
A recent clinical trial comparing a seven day primaquine regimen with a 14 day
regimen included costing surveys for households and health facilities within the study
design [18], enabling rich insights into the household costs associated with P. vivax
infection and the healthcare costs of providing the radical cure of malaria. The
costs of vivax malaria, and different screening and treatment options, will inform the
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cost-effectiveness of different radical cure strategies to prevent relapses and onward
transmission of the parasite.
The aim of this study is to describe the costs of uncomplicated P. vivax malaria
infection, including the direct health expenditure for both healthcare providers and
households, and the indirect cost to households due to lost productivity, and to compare
these between different countries in the Middle East, Africa and Asia.
5.2 Methods
5.2.1 Clinical trial details
The Improving the radical cure of vivax malaria (IMPROV) study has been described
previously [18]. In short, patients at sites in Afghanistan, Ethiopia, Indonesia and
Vietnam were enrolled in a three-armed trial with the following comparators:
• Standard blood treatment plus 14 days of supervised primaquine (total dose 7.0
mg/kg)
• Standard blood treatment plus 7 days of supervised primaquine (total dose 7.0
mg/kg) followed by 7 days of placebo
• Standard blood treatment plus 14 days placebo
Standard medical care and treatment for the blood-stage infections were in alignment
with local malaria policies. Patients were screened for G6PD deficiency prior to enroll-
ment. Individuals with G6PD deficiency were excluded from the randomised study;
instead, they were offered enrolment in a single-arm observational study where they
received standard treatment for blood-stage infections plus eight doses of weekly pri-
maquine (total dose 6 mg/kg). After P. vivax was diagnosed, patients were approached
for informed consent. For any tests that were not routine for the study site, consent
and assent were obtained from the patient before these tests were performed. Patients
were followed up for 12 months following enrollment. The cost to the households and
the healthcare providers were collected alongside the trial.
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5.2.2 Household cost collection
Household costs for individuals with P. vivax malaria were collected using standardised
surveys translated into local languages; these reflect the cost of the patient’s illness.
Patients (or informants on the patients behalf) were interviewed by study staff at the
initial visit (day 0) when recruited into the study and at a follow up visit 13 days after
treatment for G6PD normal or 14 days after treatment if G6PD deficient. While the
patients were followed up for 12 months, only the initial recruitment episode costs are
reported to minimise any bias that could arise due to changes in treatment-seeking
behaviour as a result of being enrolled in the study.
Direct costs reported in local currencies included the out of pocket expenditure for
the entire episode from the patient’s perspective. The location and cost of treatment
seeking and transport to other healthcare facilities for the malaria episode were also
included. Payments for treatment (medications, tests and fees) were included along
with the cost of transportation to the healthcare facility, which was multiplied by two
to account for the return journey. The costs of visiting the healthcare facility for the
purpose of follow up visits for the clinical study were excluded.
Indirect costs included productivity losses due to illness. Patients reported the
length of time that they could not perform usual activities due to illness and the length
of time that the patient required a caregiver to stop doing usual work in order to care
for them. The number of days reported at the initial and recurrent visits were summed
and multiplied by the GDP per capita per day for 2016 to calculate the total indirect
costs of illness [19].
5.2.3 Provider cost data collection
The costs of providing care from the healthcare provider perspective were taken from
IMPROV study sites in Ethiopia (Arba Minch), Indonesia (North Sumatra) and Vietnam
(Dak-O). Since the site in Ethiopia was a research facility, inputs were adjusted to
reflect a routine clinical care setting. Micro-costing was used to collect costs for patient
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registration, physical exam, blood draw, malaria diagnosis, treatment, G6PD RDT,
fluorescent spot test (FST) and the HaemocueTM test. Cost data were collected by
local trial staff using a standardised tool.
The cost of usual care for P. vivax included the site-specific costs of diagnosis and
treatment. Depending on the site, venous blood draw, finger prick blood draw, malaria
RDT and microscopy were included in the usual care costs. One blood draw was taken
for all tests undertaken for each patient. In Ethiopia usual care included the cost of
a finger prick blood draw and microscopy. In Indonesia usual care included a finger
prick blood draw and malaria RDT. In Vietnam, malaria RDT and microscopy are
used together so the costs for both tests were included. Usual care for primaquine was
also included: this was 0.25 mg/kg in Indonesia and Vietnam. In Ethiopia primaquine
is not routinely prescribed.
Routine G6PD testing was not done at any of the sites, so the cost of RDT and
FST were calculated as additional test costs. These tests needed to be repeated for
some patients, so FST and G6PD RDT costs are presented as both per patient and
per test. As throughputs were low, it was assumed that the FST would be used as a
point-of-care test (i.e. only one test run in a batch). In addition, it was assumed that
the storage of FST consumables would be in a freezer (or a fridge with a −20°C freezer
compartment) as this offered a more conservative estimate of costs.
Information on capital and recurrent costs were collected by direct observation and
health staff interviews. Equipment costs were annuitised based on useful life estimates
using the standard depreciation rate of 3% [20] and divided by the number of malaria
patients or total patients who attend the facilities annually. Overhead costs were
collected for each facility using the best available data and reported as monthly costs
alongside the average number of patients the facility treated for all diseases. Personnel
time were measured through time and motion studies. The time needed for both malaria
and G6PD RDTs was assumed to be the same. The timing of FST testing was averaged
from Indonesia and Vietnam.
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5.2.4 Analysis
All costs are reported in 2016 US$. Costs collected in other years were inflated using
GDP deflators [21] and then converted using the mid-year (1 July) exchange rates from
2016 [22]. For unit costs from 2017, a consumer price index (CPI) deflation factor of
2% was applied after converting to US$ using the mid-year rate [23]. The midpoint
of recruitment was used as the cost year for the data collection. To aid comparisons
between countries in terms of the ability of each currency to buy the same amount
of goods and services, the appendix contains the costs in international dollars (I$)
converted using Purchasing Power Parity (PPP) conversion factors [24].
The patient-level data were analysed using STATA 14.2 [25]. Patients who did not
return at day 13 were excluded from the analysis. For those who did fill out surveys,
missing data for costs were minimal (< 0.1%) and assumed to be zero. For missing
data on duration of illness, five days was assumed for anyone who stated being ill for
more than four days but did not specify the length of time.
The mean, SD, median and interquartile range are reported for the household costs.
Mann-Whitney and Kruskal-Wallis tests were used for comparisons. For the provider
costs, only point estimates were available so uncertainty cannot be ascertained. All
components of the provider costs are reported as per patient costs unless otherwise
noted. The incremental cost of switching from usual care to 0.5mg/kg primaquine
is reported as well as the incremental cost for switching from FST to G6PD RDT.
Visit costs excluding the vivax-specific costs of drugs and diagnosis are included to aid
comparisons with the standard visit costs reported by WHO [9].
5.3 Results
5.3.1 Patient characteristics
Results were available from a total of 2,008 patients, representing 93% (2,008/2,168) of
those enrolled in the IMRPOV trial Figure 5.1. In total 37% (745) of patients were
118
CHAPTER 5. ECONOMIC COSTS OF P. VIVAX EPISODES: A
MULTI-COUNTRY COMPARATIVE ANALYSIS USING PRIMARY TRIAL DATA
Figure 5.1: Flow diagram of patient recruitment to the trials and inclusion in the
household cost study.
female. This bias was attributable mostly to the Vietnam site where 86% (283/330) of
patients were male. The age of the patients ranged from nine months to 94 years, with
42% of patients being children under 15 years old. The proportion of children under
15 varied by country with 14% (45/330) in Vietnam, 37% (134/363) in Ethiopia, 47%
(449/964) in Indonesia and 59% (208/351) in Afghanistan. In the 2,007 patients who
reported the duration of illness before attending the health centre, the mean number of
days of illness was 2.5 (SD = 2.3), ranging from 1.6 days (SD = 1.3) in Vietnam to 3.3
days (SD = 2.7) in Indonesia.
5.3.2 Indirect household costs and usual activities
At the initial visit, the number of days in which usual activities were not possible were
consistently reported as being shorter than days of illness with a mean of 1.4 (SD =
1.6). This figure increased to 3.3 days (SD = 3.0) for the entire episode (Table 5.1). For
carers, the mean number of days of usual activity missed was 2.8 (SD = 2.9). Patients
in Indonesia reported the highest number of days missed from usual activities (mean =
3.9) and days required by a carer (mean = 2.7), compared to 2.3 and 1.2 in Afghanistan,
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Table 5.1: Days unable to do usual activities and days a caretaker is required by country
and associated indirect costs (2016 US$).
Country
Patients
enrolled
N
Patients
included
n (%)
Patient days lost Carer days lost Mean costs
for patients
(SD)
Mean costs
for carers
(SD)
Mean
(SD)
Median
(IQR)
Mean
(SD)
Median
(IQR)
Afghanistan 438 351 (80%) 2.3 (1.3) 2 (1.5−3) 1.2 (1.2) 1 (0−2) 3.4 (2.0) 1.8 (1.8)
Ethiopia 380 363 (96%) 3.4 (2.6) 2.5 (2−4) 2.3 (2.9) 1.5 (0−3) 6.6 (5.1) 4.4 (5.7)
Indonesia 1008 963 (96%) 3.9 (3.7) 3 (0.5−5) 2.7 (3.6) 1 (0.5−4) 37.8 (36.6) 26.8 (35.5)
Vietnam 342 330 (96%) 2.8 (1.9) 2.5 (1.5−3.5) 0.9 (1.2) 0.5 (0−1.5) 16.5 (11.1) 5.5 (7.1)
Overall 2,168 2,008 (93%) 3.3 (3.0) 2.5 (1−4) 2.8 (3.0) 1 (0.5−3) 22.7 (29.9) 14.9 (27.4)
Table 5.2: Usual activities for patients and their carers − % (n).
Usual activity Afghanistan Ethiopia Indonesia Vietnam Overall
Patient − N 351 363 964 330 2,008
Housework (unpaid) 14% (49) 7% (27) 13% (124) 8% (28) 11% (228)
Subsistence farming (unpaid) 13% (47) 1% (3) 2% (21) 77% (253) 16% (324)
Attending school 54% (189) 53% (191) 48% (467) 9% (31) 44% (878)
Paid employment 3% (10) 22% (81) 4% (37) 2% (5) 7% (133)
Other 16% (56) 17% (61) 33% (315) 4% (13) 22% (445)
Carer − N 212 239 821 180 1450
Housework (unpaid) 39% (83) 30% (71) 65% (535) 33% (60) 52% (749)
Subsistence farming (unpaid) 23% (48) 4% (10) 4% (29) 66% (118) 14% (205)
Attending school 9% (20) 18% (43) 3% (23) 1% (1) 6% (87)
Paid employment 8% (18) 32% (76) 4% (36) 1% (1) 9% (131)
Other 20% (43) 16% (39) 24% (198) 0% (0) 19% (280)
3.4 and 2.3 in Ethiopia, and 2.8 and 0.9 in Vietnam (p < 0.001 for both comparisons).
Overall, 44% (878/2008) of patients reported that they would normally be attending
school. In Vietnam, where patients were older, only 9% of individuals reported that
they were missing school, but the majority (77%, 253/330) reported missing their work
as a subsistence farmer. Carers were required to cut back on usual activities for 72%
(1,450/2,008) of patients. While 52% of carers (749/1,450) reported being unable to do
housework, 14% (205) were unable to farm, 9% (131) missed paid employment and 6%
(87) missed another activity. Table 5.2 details what usual activities entailed in each
country.
5.3.3 Treatment-seeking behaviour and associated costs
In three of the four study countries the majority of patients reported having not sought
treatment elsewhere: 91% (319/351) in Afghanistan, 95% (345/362) in Ethiopia and
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Figure 5.2: Patterns of treatment-seeking among trial participants prior to enrolment
in the study. Only the first two treatment seeking destinations are shown here. Arrow
sizes are in proportion to the percentage seeking treatment in that country with labels
for patient flows involving more than 5% of the patient population.
79% (260/330) in Vietnam (Figure 5.2). Of the 70 patients who sought treatment
prior to enrolment in Vietnam, 64 (91%) had visited a drug shop. In Indonesia only
34% (329/963) of patients were seeking treatment for the first time with 1% (13/963)
reporting that they sought treatment three times before study enrolment. The mean
costs for treatment seeking at locations other than the study facility up until day 13 in
Afghanistan, Ethiopia and Vietnam were less than a dollar as compared with Indonesia
where the mean treatment and transport costs were US$1.4 (SD = 6.4) and US$0.5
(SD = 0.9), respectively (Table 5.3).
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Table 5.3: Direct, indirect and total household costs in 2016 US$ per patient with vivax
malaria (N = 2007). Other treatment and other transport include all costs of treatment
seeking at other locations up to day 13.*
Country
Direct costs Indirect costs Total costs
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Afghanistan total 3.1 (2.2) 2.9 (1.8−3.8) 5.3 (3.0) 5.4 (3.1−6.2) 8.4 (4.2) 7.9 (4.8−10.5)
Other treatment 0.3 (1.6) 0.0 (0.0−0.0)
Other transport 0.1 (0.4) 0.0 (0.0−0.0)
Visit cost 0.0 (0.2) 0.0 (0.0−0.0)
Transport cost 2.8 (1.5) 2.6 (1.8−3.8)
Ethiopia total 2.4 (1.6) 2.3 (1.7−2.9) 11.1 (9.3) 7.8 (4.9−14.6) 13.5 (9.67) 10.3 (7.1−17.1)
Other treatment 0.1 (1.0) 0.0 (0.0−0.0)
Other transport 0.0 (0.2) 0.0 (0.0−0.0)
Visit cost 0.5 (0.7) 0.3 (0.0−0.5)
Transport cost 1.8 (0.9) 1.8 (0.9−2.3)
Indonesia total 4.0 (7.3) 2.7 (1.5−4.9) 64.6 (64.5) 48.9 (14.7−97.8) 68.6 (66.8) 51.4 (18.2−99.4)
Other treatment 1.4 (6.4) 0.1 (0.0−1.5)
Other transport 0.5 (0.9) 0.0 (0.0−0.8)
Visit cost 0.5 (1.0) 0.0 (0.0−1.1)
Transport cost 1.6 (1.4) 1.4 (0.8−1.5)
Vietnam total 3.7 (2.6) 2.7 (2.7−4.0) 22.0 (15.7) 18.0 (12.0−30.0) 25.7 (16.4) 21.6 (14.7−33.2)
Other treatment 0.8 (2.1) 0.0 (0.0−0.0)
Other transport 0.2 (0.6) 0.0 (0.0−0.0)
Visit cost 0.0 (0.0) 0.0 (0.0−0.0)
Transport cost 2.7 (1.0) 2.7 (1.8−3.6)
Overall total 3.5 (5.3) 2.7 (1.8−4.1) 37.5 (52.7) 14.7 (6.2−48.9) 41.1 (54.2) 18.6 (10.0−51.5)
* See Appendix Table 5.9 for values converted using the PPP conversion factor.
5.3.4 Direct and indirect costs to patients from the
enrolment up to the follow up visit
The mean total direct cost to patients ranged from US$2.4 (SD = 1.6) in Ethiopia to
US$4.0 (SD = 7.3) in Indonesia (Table 5.3). The mean cost of transportation ranged
from US$1.6 (SD = 1.4) in Indonesia to US$2.8 (SD = 1.5) in Afghanistan (Table 3).
Overall, 93% (1,869/2,005) of patients reporting a journey of less than one hour. The
majority of those reporting long travel times were in Afghanistan where 28% (99/351),
taking longer than one hour to get to the clinic. In Afghanistan differences in indirect
costs were apparent by age and differences in direct and total costs were apparent by
gender (Table 5.4). In Ethiopia and Indonesia, differences in indirect and total costs
were apparent by age (Table 5.4).
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Table 5.4: Median costs (IQR) for each country compared by age and gender using the
Mann-Whitney test (2016 US$).*
Gender Age
Male Female p value 15+ years <15 years p value
Afghanistan − N (%) 239 (68%) 112 (32%) 143 (41%) 208 (59%)
Direct costs 2.9 (1.8−3.8) 3.8 (2.1−3.8) 0.005 2.9 (1.8−3.8) 2.9 (1.8−3.8) 0.861
Indirect costs 4.6 (3.1−6.2) 6.2 (3.1−7.7) 0.007 4.6 (3.1−6.2) 6.2 (3.1−6.2) 0.019
Total costs 7.4 (4.5−10.0) 10.0 (5.9−11.5) 0.004 6.9 (4.6−10.6) 9.1 (5.3−10.4) 0.191
Ethiopia − N (%) 212 (58%) 151 (42%) 229 (63%) 134 (37%)
Direct costs 2.1 (1.7−2.9) 2.3 (1.8−3.0) 0.615 2.3 (1.8−2.9) 2.2 (1.7−3.0) 0.981
Indirect costs 7.8 (3.9−13.6) 9.7 (5.8−15.5) 0.056 7.8 (3.9−13.6) 10.2 (5.8−16.5) < 0.001
Total costs 9.7 (6.9−16.1) 12.0 (7.5−17.8) 0.093 9.6 (6.6−15.2) 12.6 (8.7−18.9) 0.001
Indonesia − N (%) 529 (55%) 435 (45%) 515 (53%) 449 (47%)
Direct costs 2.7 (1.5−5.0) 2.7 (1.5−4.8) 0.750 2.8 (1.5−5.2) 2.6 (1.5−4.6) 0.256
Indirect costs 44.0 (9.8−97.8) 58.7 (14.7−97.8) 0.064 34.2 (9.8−78.2) 58.7 (19.6−97.8) < 0.001
Total costs 51.4 (18.2−99.2) 59.4 (21.1−100.6) 0.096 40.0 (14.4−82.2) 61.4 (24.4−104.3) < 0.001
Vietnam − N (%) 283 (86%) 47 (14%) 285 (86%) 45 (14%)
Direct costs 2.7 (1.8−3.6) 3.6 (2.7−5.4) 0.073 2.7 (2.2−3.6) 2.7 (2.7−4.5) 0.222
Indirect costs 18.0 (12.0−27.0) 24.0 (12.0−35.9) 0.104 18.0 (12.0−30.0) 18.0 (12.0−30.0) 0.600
Total costs 21.1 (14.4−32.6) 25.8 (16.8−43.1) 0.065 21.6 (14.4−33.5) 23.2 (17.7−32.6) 0.352
* See Appendix Table 5.10 for values converted using the PPP conversion factor.
5.3.5 Provider costs
For the healthcare provider, the total cost of usual care per patient treated ranged
from US$8.9 in Vietnam to $12.4 in Indonesia (Table 5.5). The lower costs in Vietnam
were due to the lower cost of goods alongside high clinic throughputs for all patients.
Table 5.6 provides details on the overhead components. When excluding the costs of
drugs and diagnostics (including all laboratory costs), the total visit cost was US$6.7
in Ethiopia, US$12.7 in Indonesia and US$4.0 in Vietnam.
Table 5.5: Cost of usual care for P. vivax infections (2016 US$).*
Country Staff Consumables Equipment Overheads Total Notes
Ethiopia 0.8 6.0 0.5 5.0 12.3 Includes finger prick blood draw
and microscopy.
Indonesia 1.5 9.1 0.4 4.2 15.2 Includes finger prick blood draw,
malaria RDT and primaquine
(0.25mg/kg).
Vietnam 1.0 3.1 2.4 1.9 8.3 Includes venous blood draw,
malaria RDT, microscopy and
primaquine (0.25mg/kg).
* See Appendix Table 5.11 for values converted using the PPP conversion factor.
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Table 5.6: Breakdown of reported monthly patient attendance and overhead costs (2016
US$).*
Overhead Ethiopia Indonesia Vietnam
Number of patients per month 600 250 1200
Costs
Cleaning and laundry 783.2 118.3 87.9
Electricity 13.4 59.1 109.9
Fuel for transformer − 465.4 −
Internet 158.3 72.5 9.7
Maintenance 44.8 − 175.8
Building cost or rent 1941.5 158.9 1851.3
Security − 167.8 −
Telephone 67.1 − 8.3
Water 17.9 − −
Total 5994.2 1042.1 2242.8
* See Appendix Table 5.12 for values converted using the PPP conversion factor.
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Table 5.7: Additional cost per patient and time per test required for laboratory tests (2016 US$).*
Test by
country
Time in
minutes
Cost per patient Notes
Staff Consumables Equipment Total
Malaria RDT
Ethiopia − − − − −
Indonesia 15.8 0.59 0.49 0.00 1.07 Included in visit cost.
Vietnam 12.0 0.32 0.98 0.00 1.30 Included in visit cost.
Microscopy
Ethiopia 10.2 0.26 0.49 0.08 0.83 Included in visit cost.
Indonesia − − − − −
Vietnam 10.2 0.27 0.14 0.85 1.26 Included in visit cost.
FST Time is average from Indonesia and Vietnam.
Ethiopia 70.2 1.81 5.01 6.86 13.68
Indonesia 70.2 3.12 16.52 1.12 20.76 Assumed 1.2 tests needed per patient.
Vietnam 70.2 2.07 17.24 0.34 19.64 Assumed 1.1 tests needed per patient.
G6PD RDT
Ethiopia 15.0 0.46 0.73 0.00 1.18
Indonesia 15.8 0.70 15.79 0.00 16.50 Assumed 1.2 tests needed per patient.
Vietnam 12.0 0.35 1.08 0.00 1.43 Assumed 1.1 tests needed per patient.
HaemocueTM
Ethiopia 2.3 0.06 0.15 0.00 0.21
Indonesia 0.6 0.02 1.07 0.46 1.56
Vietnam 0.6 0.02 0.76 0.00 0.78
* See Appendix Table 5.14 for values converted using the PPP conversion factor and Table 5.8 for the per test costs.
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Table 5.8: Cost per FST and G6PD RDT administered (2016 US$).*
Test by country Staff Consumables Equipment Total
FST
Ethiopia 1.81 5.01 6.86 13.68
Indonesia 2.60 13.76 1.12 17.49
Vietnam 1.88 15.67 0.34 17.89
G6PD RDT
Ethiopia 0.35 0.56 0.00 0.91
Indonesia 0.70 13.16 0.00 13.86
Vietnam 0.32 0.98 0.00 1.30
* See Appendix Table 5.13 for values converted using the PPP conversion factor.
Table 5.7 shows the cost per patient and the associated laboratory time required.
Implementing FST in these settings with relatively low throughputs resulted in a cost
per test ranging from US$13.7−17.9 for FST compared to US$0.9−13.9 for G6PD RDT
(Table 5.8). Indonesia and Vietnam reported having to repeat both FST and G6PD
RDT for 10−20% of patients, increasing the cost of screening per patient (Table 5.7).
G6PD RDT was consistently cheaper than FST per patient, even in Indonesia where the
unit cost of a G6PD RDT was US$13.2. The potential cost savings per patient treated
using a G6PD RDT instead of FST were US$6.9 in Indonesia and US$18.2 in Vietnam.
Other vivax-specific costs included primaquine (US$0.43 to increase from 0.25mg/kg to
0.5mg/kg and US$0.86 if not using primaquine) and the cost of a HaemocueTM test,
which ranged from US$0.78 in Vietnam to US$1.56 in Indonesia.
5.4 Discussion
These cost data from four countries represent the largest collection on the cost of P.
vivax malaria to both households and healthcare providers to date. Whilst the cost for
facilities to provide standard care was similar across sites (US$8.3−15.2), the mean
total household cost per episode varied considerably (US$8.4 in Afghanistan to US$68.6
in Indonesia), reflecting differences in both duration of time off normal activities and
GDP per capita. Treatment seeking at other locations prior to trial enrolment varied by
country, ranging from 5% in Ethiopia to 66% in Indonesia. Since only the enrollment
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visit is included in this analysis, it is unlikely that treatment-seeking behaviour prior to
visiting the clinic would be different. The direct costs of treatment seeking in Indonesia
are similar to those reported by the hospital exit surveys in Timika (Chapter 2);
however, the indirect costs are higher. The higher costs are likely due to the utilisation
of a second interview to capture costs incurred after seeking treatment.
The total costs to the patient were consistently more than double that of the provider.
The mean cost to the patient was US$13.5 in Ethiopia, US$25.7 in Vietnam, US$68.6
in Indonesia compared to US$6.7, US$10.4 and US$12.4 for the healthcare provider,
respectively. As malaria tends to disproportionately impact the poor (Chapter 2),
it could be that the use of GDP per capita per day for lost wages has resulted in
an overestimate of the indirect costs of vivax malaria. For example, a recent study
that used the monthly wages for agricultural workers reported a mean indirect cost
of US$3.8 per vivax episode in rural Ethiopia [26]. While Chapter 2 indicated that
patients diagnosed with malaria at public providers were likely to experience similar
costs regardless of whether they have P. vivax or P. falciparum, the aforementioned
study from Ethiopia found a significant difference in indirect and total costs by species
[26]. Furthermore, the healthcare facility costs reported here are consistently higher
than the cost of a visit to an outpatient facility with beds reported in WHO-CHOICE
(CHOosing Interventions that are Cost-Effective) [9] inflated to 2016 [21] and converted
to US$ [22] resulting in costs of US$0.9 in Ethiopia, US$2.7 for Vietnam and US$5.3
in Indonesia. The costs presented here are 593%, 7% and 44% higher, respectively. If
patient costs were compared with the WHO-CHOICE visit costs plus malaria-specific
costs instead of those found in this study, then the proportion of P. vivax costs borne
by the household would be even higher.
While the focus of most costing studies is the direct costs of seeking treatment for
malaria, such as payments for tests and transportation, previous research indicates
that the indirect costs of lost productivity can be the largest cost component [27]. The
results of this chapter are consistent with those findings: while the total costs varied by
country, the largest cost component for households was consistently the indirect costs
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due to lost productivity. For many households, the burden of disease is not only the
time that an individual cannot work or attend school due to illness or treatment seeking,
but also the time required by another household member to care for that individual
instead of performing his or her usual activities; in most places this constituted over
80% of the total cost of a malarial episode. The indirect costs were highest in Indonesia
where individuals reported the most days off work for both patients and carers (3.9
and 2.7 days respectively). As 42% of the population were children, my methods for
valuing the productivity costs may be an overestimate; however, this could be offset by
educational losses [28, 29], which I did not attempt to include.
Previous studies reporting indirect costs in P. vivax patients have been limited. One
vivax-specific study by Hansen and colleagues in Afghanistan reported patients with P.
vivax personally losing almost a day and a half in addition to one half-day for their carers
[16]. Other malaria studies that included vivax malaria patients showed approximately
five productive days were lost for each malaria episode in Vietnam [30] and 14 days
in Ethiopia [31]. While a better understanding of productivity losses is important for
quantifying the burden of vivax malaria, their inclusion in economic evaluation can be
controversial due to concerns around double counting (with productivity losses already
potentially factored in to the valuation of disability or quality of life used to construct
DALYs and QALYs, respectively). Many malaria studies use the outcome of infections
averted rather than DALYs or focus on the years of life lost rather than the years of
life with disability since the time with illness is often too small to have a significant
impact on the ICER. These losses become more important for P. vivax malaria, which
rarely results in direct mortality but often results in long-term morbidity [32, 33].
The ability to test for G6PD deficiency as advocated for ensuring safe radical cure by
the WHO [3] resulted in additional costs ranging from US$1.2 for the RDT in Ethiopia
to US$20.8 for the FST in Indonesia. At approximately US$20.0 per test the FST is an
expensive option for facilities with low numbers of P. vivax cases, more than doubling
the cost of a visit for malaria. The main reasons for this incremental cost was the
limited lifetime of the reagents. The G6PD RDT was consistently less expensive than
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the FST, but the costs savings were dependent on in-country costs, ranging from US$1.4
per person in Vietnam to US$13.9 in Indonesia. In settings such as those found in
Indonesia, where primaquine is prescribed without G6PD testing, it will be difficult to
convince policymakers to implement G6PD testing since the incremental cost per person
treated is so high. Finally, if primaquine treatment is to be routinely administered, the
additional use of a HaemocueTM test (or equivalent) might be viewed as a necessity
that needs to be factored into the cost estimates. While it is a relatively inexpensive
test (less than US$2.0), it is likely that facilities would want to use it more than once
per P. vivax episode to monitor patients for anaemia.
This study has a number of limitations. While uncertainty intervals were reported
where possible, only point estimates were available for the provider costs (Tables 5.5
to 5.8). As these were collected remotely, these are likely to have a great deal of
uncertainty, which could not be quantified in a meaningful way. While every effort was
made to ensure that these were collected systematically, it is likely that some bias was
introduced through the use of local staff to collect the costs. Accordingly, the provider
cost data are not as reliable as the patient cost data. The provider costs are for those
patients diagnosed with malaria and does not include the costs of diagnosing malaria
in those who test negative. Since the cost of diagnostic tests are included, these could
be used in cost-effectiveness analyses alongside the diagnostic accuracy to determine
the overall screening costs. Since much of the data were gathered in the setting of a
clinical trial, it is possible that direct payments for treatment may have been lower
than normal. Finally, some settings may prefer to use a fridge for the storage of FST
reagents rather than purchasing a freezer. While that would be less expensive in the
short-term, the overall cost per test would increase as the reagents last twice as long in
the freezer unless the fridge has a −20°C compartment as the facilities in Ethiopia and
Vietnam did. The cost of FST would decrease for facilities that treat a higher number
of vivax patients.
In conclusion, the burden of P. vivax malaria is substantial at the household level
with the largest component being productivity losses. Ensuring safe radical cure through
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G6PD RDTs should enable a reduction in this burden, but high test costs may impede
their uptake. The provider costs presented from three countries and patient costs from
four countries represent the largest collection of costs resulting from vivax malaria alone,
and an important resource with which to embark upon more robust cost-effectiveness
estimates in the future.
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5.5 Appendix: Tables in international dollars
The following tables present costs in 2016 I$ converted using the PPP conversion factor.
These correspond to Tables 5.3-5.8.
Table 5.9: Direct, indirect and total household costs in 2016 I$ per patient with vivax
malaria (N = 2007). Other treatment and other transport include all costs of treatment
seeking at other locations up to day 13. (From Table 5.3.)
Country
Direct costs Indirect costs Total costs
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Afghanistan total 11.1 (7.9) 10.2 (6.1−13.9) 5.3 (3.0) 5.4 (3.1−6.2) 16.4 (9.1) 14.8 (9.7−20.1)
Other treatment 0.9 (5.5) 0.0 (0.0−0.0)
Other transport 0.3 (1.3) 0.0 (0.0−0.0)
Visit cost 0.1 (0.6) 0.0 (0.0−0.0)
Transport cost 9.8 (5.5) 9.2 (6.1−13.9)
Ethiopia total 6.1 (4.0) 5.9 (4.4−7.4) 11.1 (9.3) 7.8 (4.9−14.6) 17.2 (10.8) 14.8 (10.1−21.4)
Other treatment 0.2 (2.5) 0.0 (0.0−0.0)
Other transport 0.1 (0.4) 0.0 (0.0−0.0)
Visit cost 1.1 (1.7) 0.7 (0.0−1.3)
Transport cost 4.7 (2.4) 4.7 (2.3−5.8)
Indonesia total 12.9 (23.3) 8.6 (4.9−15.6) 64.6 (64.5) 48.9 (14.7−97.8) 77.5 (73.4) 60.8 (27.6−105.1)
Other treatment 4.5 (20.8) 0.2 (0.0−4.9)
Other transport 1.7 (3.0) 0.0 (0.0−0.0)
Visit cost 1.6 (3.2) 0.0 (0.0−3.7)
Transport cost 5.1 (4.5) 4.4 (2.4−4.9)
Vietnam total 10.9 (7.6) 7.9 (7.9−11.9) 22.0 (15.7) 18.0 (12.0−30.0) 32.9 (18.7) 28.5 (19.9−41.2)
Other treatment 2.1 (6.1) 0.0 (0.0−0.0)
Other transport 0.7 (1.7) 0.0 (0.0−2.4)
Visit cost 0.0 (0.0) 0.0 (0.0−0.0)
Transport cost 8.0 (2.9) 7.9 (5.3−10.6)
Overall total 11.0 (17.0) 8.1 (5.3−13.9) 37.5 (52.7) 14.7 (6.2−48.9) 48.6 (59.0) 25.9 (14.4−61.7)
131
CHAPTER 5. ECONOMIC COSTS OF P. VIVAX EPISODES: A
MULTI-COUNTRY COMPARATIVE ANALYSIS USING PRIMARY TRIAL DATA
Table 5.10: Median costs (IQR) for each country compared by age and gender using
the Mann-Whitney test (2016 I$) from Table 5.4.
Gender Age
Male Female p value 15+ years <15 years p value
Afghanistan − N (%) 239 (68%) 112 (32%) 143 (41%) 208 (59%)
Direct costs 10.2 (6.1−13.9) 13.9 (7.4−13.9) 0.005 10.2 (6.1−13.9) 10.2 (6.1−13.9) 0.844
Indirect costs 4.6 (3.1−6.2) 6.2 (3.1−7.7) 0.007 4.6 (3.1−6.2) 6.2 (3.1−6.2) 0.019
Total costs 13.3 (9.7−20.1) 19.7 (11.2−21.6) 0.002 14.3 (9.7−20.3) 15.9 (10.2−20.1) 0.407
Ethiopia − N (%) 212 (58%) 151 (42%) 229 (63%) 134 (37%)
Direct costs 5.5 (4.4−7.4) 5.9 (4.5−7.6) 0.616 5.9 (4.5−7.3) 5.6 (4.4−7.7) 0.981
Indirect costs 7.8 (3.9−13.6) 9.7 (5.8−15.5) 0.056 7.8 (3.9−13.6) 10.2 (5.8−16.5) < 0.001
Total costs 13.7 (10.1−20.9) 15.3 (10.1−22.0) 0.199 13.6 (9.3−20.0) 15.8 (11.2−22.9) 0.006
Indonesia − N (%) 529 (55%) 435 (45%) 515 (53%) 449 (47%)
Direct costs 8.7 (4.9−15.9) 8.6 (1.5−4.8) 0.754 9.0 (4.9−16.6) 8.3 (4.9−14.7) 0.256
Indirect costs 44.0 (9.8−97.8) 58.7 (4.9−15.9) 0.064 34.2 (9.8-78.2) 58.7 (19.6−97.8) < 0.001
Total costs 55.5 (25.7−102.9) 62.6 (30.1−111.2) 0.136 47.6 (23.5−92.9) 68.9 (35.4−112.9) < 0.001
Vietnam − N (%) 283 (86%) 47 (14%) 285 (86%) 45 (14%)
Direct costs 7.9 (5.3−10.6) 10.6 (7.9−15.9) 0.073 7.9 (6.6−10.6) 7.9 (7.9−13.2) 0.226
Indirect costs 18.0 (12.0−27.0) 24.0 (12.0−35.9) 0.104 18.0 (12.0−30.0) 18.0 (12.0−30.0) 0.600
Total costs 28.5 (19.9−40.5) 31.9 (22.9−52.9) 0.066 23.2 (19.9−41.2) 31.2 (23.3−43.6) 0.202
Table 5.11: Cost of usual care for P. vivax infections (2016 I$) from Table 5.5.
Country Staff Consumables Equipment Overheads Total Notes
Ethiopia 2.0 13.2 1.2 12.8 29.3 Includes finger prick blood draw
and microscopy.
Indonesia 4.9 15.0 1.4 13.3 34.6 Includes finger prick blood draw,
malaria RDT and primaquine
(0.25mg/kg).
Vietnam 3.0 5.7 6.9 5.5 21.1 Includes venous blood draw,
malaria RDT, microscopy and
primaquine (0.25mg/kg).
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Table 5.12: Breakdown of reported monthly patient attendance and overhead costs
(2016 I$) from Table 5.6.
Overhead Ethiopia Indonesia Vietnam
Number of patients per month 600 250 1200
Costs
Cleaning and laundry 1993.5 378.7 259.2
Electricity 34.2 189.4 323.9
Fuel for transformer − 1490.4 −
Internet 402.8 232.1 28.5
Maintenance 113.9 – 518.3
Building cost or rent 4941.9 509.0 5459.0
Security − 537.5 −
Telephone 170.9 – 24.6
Water 45.6 − −
Total 7702.7 3337.1 6613.5
Table 5.13: Cost per FST and G6PD RDT administered (2016 I$) from Table 5.8.
Test by country Staff Consumables Equipment Total
FST
Ethiopia 4.62 9.27 13.99 27.88
Indonesia 8.34 39.36 3.50 51.20
Vietnam 5.55 39.44 0.99 45.97
G6PD RDT
Ethiopia 0.90 1.59 0.00 2.49
Indonesia 2.25 42.15 0.00 44.39
Vietnam 0.95 0.98 0.00 1.93
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Table 5.14: Additional cost per patient and time per test required for laboratory tests (2016 I$) from Table 5.7.
Test by
country
Time in
minutes
Cost per patient Notes
Staff Consumables Equipment Total
Malaria RDT
Ethiopia − − − − −
Indonesia 15.8 1.87 0.49 0.00 2.36 Included in visit cost.
Vietnam 12.0 0.95 0.98 0.00 1.93 Included in visit cost.
Microscopy
Ethiopia 10.2 0.67 1.23 0.21 2.11 Included in visit cost.
Indonesia − − − − −
Vietnam 10.2 0.81 0.25 2.50 3.56 Included in visit cost.
FST Time is average from Indonesia and Vietnam.
Ethiopia 70.2 4.62 9.27 13.99 27.88
Indonesia 70.2 10.01 47.24 3.50 60.74 Assumed 1.2 tests needed per patient.
Vietnam 70.2 6.10 43.38 0.99 50.47 Assumed 1.1 tests needed per patient.
G6PD RDT
Ethiopia 15.0 1.17 2.07 0.00 3.23
Indonesia 15.8 2.25 42.15 0.00 44.39 Assumed 1.2 tests needed per patient.
Vietnam 12.0 1.04 1.08 0.00 2.12 Assumed 1.1 tests needed per patient.
HaemocueTM
Ethiopia 2.3 0.15 0.44 0.00 0.59
Indonesia 0.6 0.07 3.44 1.47 4.98
Vietnam 0.6 0.05 2.25 0.00 2.30
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Chapter 6
Global economic costs due to vivax
malaria treatment and the potential
cost-benefit of radical cure
6.1 Introduction
Although P. vivax was once regarded as a benign infection, it is increasingly recognised
that its ability to relapse results in a cumulative risk of anaemia and associated direct
and indirect attributable mortality [1, 2]. Women and young children are particularly
at risk since P. vivax in pregnancy can cause premature delivery and low birth weight,
which both contribute to perinatal and infant mortality [2, 3, 4]. Access to early
diagnosis and highly effective antimalarial treatment, and intensive vector control
measures have reduced the global burden of P. falciparum malaria by 40% since 2000
[5]; however, in areas where such control interventions have driven down falciparum
malaria, there has been a relative rise in vivax malaria [6, 7].
P. vivax is more difficult to cure than P. falciparum, as the parasite is able to
form dormant liver stages (hypnozoites) that reactivate periodically, causing recurrent
infections (relapses) and further ongoing transmission [8], Relapses require a hypno-
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zonticidal drug for radical cure in addition to the schizonticidal drug for the blood
stage infection. Primaquine is the only available drug for radical cure at present, but
it causes haemolysis in those with G6PD deficiency. This haemolysis can range from
mild to life-threatening, depending on the type of G6PD deficiency. Many countries do
not use primaquine regularly due to concerns about triggering haemolysis. Recently,
point-of-care RDTs for G6PD deficiency have become available. These tests have the
potential to enable remote settings with limited laboratory equipment to test before
prescribing primaquine, excluding those with G6PD deficiency. In addition these tests
are less expensive than the fluorescent spot test (FST) (Chapter 5). Accordingly,
widespread radical cure following G6PD screening represents a new opportunity for the
control of vivax malaria.
The economic impact of malaria is huge, both to the individual and society. Previous
work by Gallup and Sachs indicated that countries with a high percentage of the
population at risk of P. falciparum infection were likely to experience reductions in
growth as great as 2% GDP per capita [9]. However Gallup and Sachs did not elucidate
other economic impacts that are more challenging to ascertain, such as the demographic
consequences of high childhood mortality rates, the ability to develop human and
physical capital, decreases in tourism and foreign investment, and co-infections with
other diseases [10]. These estimates were derived more than 15 years ago and focused
on P. falciparum in Africa. The global economic impact of P. vivax has not been
ascertained.
The economic impact of vivax malaria is more challenging to estimate for a number
of reasons. Whilst the risk of acute mortality is considerably lower following P. vivax
infections compared to P. falciparum, when patients with uncomplicated malaria are
treated with an ineffective antimalarial regimen, each episode of uncomplicated malaria
is associated with a similar household cost, with an episode of vivax malaria costing
around 9% of a households monthly income for the 60% of families making less than
US$500 per month (Chapter 2). Furthermore, an infectious bite from a mosquito
can produce hypnozoites, which in high relapsing areas can result in eight or more
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recurrences per year in the absence of effective radical cure [11, 12]. Hence relapses
have the potential to disrupt occupational and educational activities multiple times,
with both short and long term consequences. In Brazil where nearly 70% of infections
are due to P. vivax, it was demonstrated that the occurrence of one or more episodes
of malaria impaired school performance [13]. Lastly, episodes of vivax malaria often
happen in remote settings with poor healthcare services, rendering it difficult to access
care.
The aim of this chapter is to collate information on the direct and indirect costs
of illness due to P. vivax from a variety of endemic settings and match these with
incidence estimates in order to provide the best possible estimate of the current global
economic cost of illness to both healthcare providers and the households of patients.
These estimates for the global costs due to vivax malaria are then used to conduct a
thought experiment on the potential cost-benefit of implementing radical cure following
a normal G6PD test result globally.
6.2 Methods
6.2.1 Summary
Global cost estimates were calculated for a base case, which reflects current practices for
the diagnosis and treatment for P. vivax clinical cases in countries where it is endemic,
and two alternative scenarios. These explore the potential cost-benefit of a global policy
change to radical cure with 14 day primaquine in those who test G6PD normal. The
first scenario assumes that radical cure is very effective and that a high investment is
required to achieve adherence through supervised therapy. The second scenario does
not include the costs of ensuring adherence and therefore assumes that the effectiveness
is low. Key assumptions for the base case estimate are found in Table 6.1.
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Table 6.1: Key assumptions used in the base case global cost estimates.
Parameter Details Source
COUNTRY-LEVEL
P. vivax episode
estimates
Generated by MAP for 47 countries. Listed in
Table 6.2 by whether or not they sought treatment
for their illness episode.
[14]
Percent of cases
receiving a malaria test
Taken from the World Malaria Report. Listed in
Table 6.2.
[15]
Percent of cases
diagnosed by RDT
Taken from the World Malaria Report. Listed in
Table 6.2.
[15]
Treatment of blood
stage infections
Taken from the World Malaria Report. For
countries where P. vivax treatment was not listed,
the treatment for uncomplicated P. falciparum
was used. Listed in Table 6.2.
[15]
Implementation of
G6PD screening
Taken from MMV country prioritisation for
tafenoquine. Listed in Table 6.2.
MMV
Use of radical cure with
primaquine
Taken from MMV country prioritisation for
tafenoquine. Listed in Table 6.2.
MMV
Percent ineligible
for primaquine
Those younger than six months, pregnant or
lactating. Listed in Table 6.2.
[16]
Percent with G6PD
deficiency
G6PD deficiency for males and females with
<30% enzyme activity in general population that
is eligible for primaquine. These estimates do not
adjust for the protective effect of P. vivax and so
may be overestimates. Listed in Table 6.2.
[17]
REGIONAL
Mean number of
productive days lost
Productivity losses to patients and their carers.
These were extrapolated out by WHO region.
For Southeast Asia and Western Pacific, the
mean of Indonesia and Vietnam was used.
[18] for South
America and
Chapter 5 for
all others
Unit costs Regional extrapolations from available data.
See Table 6.3.
[19, 20, 21, 22, 23]
and Chapter 5
GLOBAL
Primaqune use The cost of a primaquine prescription was
included for 90% of patients in all
countries listed as prescribing primaquine.
Assumption
Percent cases that are
severe in those seeking
treatment
A systematic review of 140 studies with 53,164
P. vivax patients found a pooled prevalence of
severe anaemia of 2% (95% CI: 1.3−2.8).
[24]
MMV = Medicines for Malaria Venture
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6.2.2 Cases of vivax malaria
The number of annual episodes of P. vivax were derived from those generated by
the Malaria Atlas Project (MAP), which adjust country-level reports of clinical cases
according to treatment-seeking rates and reporting completeness [14]. These estimates
do not distinguish between new infections and relapses. Case estimates were available
for all countries that reported P. vivax cases in 2015 [15] plus six additional countries
that did not report cases (Democratic Republic of the Congo, Gabon, Madagascar,
Somalia, Sudan and Tajikistan). Cases were adjusted for treatment-seeking rates at
public facilities to adjust for those cases that would be missed by the national reporting
system (i.e. those who did not seek treatment or sought treatment through private
providers). Estimates of treatment seeking at any facility were also used to inform the
lower bound of clinical cases; these assumed that any fevers that sought treatment were
caused by malaria [25]. Here, treatment-seeking behaviour was categorized according
to whether patients sought treatment with any provider (including public or private
healthcare providers, pharmacies or shops) or did not seek treatment outside of their
own home.
6.2.3 Usual care for vivax malaria
For those seeking treatment at healthcare providers, the proportion of malaria cases
diagnosed by RDT and microscopy and drugs prescribed for the treatment of P. vivax
blood stage infections were taken from the 2016 World Malaria Report [15]. For
countries in Africa that did not report vivax-specific drug treatments, it was assumed
that these countries did not distinguish between species and that P. vivax patients were
treated with the drugs listed for uncomplicated confirmed P. falciparum. The use of
G6PD screening and prescription of radical cure at the country level was taken from
the Medicines for Malaria Venture (MMV) country prioritisation, which are listed in
Table 6.2. Malaysia was the only country that regularly tests for G6PD deficiency before
treatment, and the cost of a FST was added for each case. The cost of G6PD testing
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was not included in the base case scenario for any other country. For the 36 countries
that prescribed primaquine, the cost of a prescription was included for 90% of the
population in order to exclude those who are under the age of six months, lactating or
presumed pregnant. It is also assumed that primaquine effectiveness is only 15% when
prescribed without supervision [26]. Assumptions about diagnostic tests, treatment,
days lost to illness and case estimates by country are shown in Table 6.2.
6.2.4 Cost data
Costs were collected in local currencies when possible, inflated to 2016 using GDP
deflators [27] and then converted to US$ using the exchange rate for mid-2016 [28].
When GDP deflators were missing for one or more years, the GDP deflator from the
US was used instead. Costs to patients and healthcare providers were taken from the
IMPROV study (Chapter 5) and three other locations reviewed by White et al. [29]:
two in Brazil [20, 30] and one in Afghanistan [21]. These three studies provided data
on diagnostic tests. The study in Afghanistan presented cost data for both low and
high transmission areas: the mean of these were used for Eastern Mediterranean &
Europe regions [21]. A literature review with the aim of updating White and colleagues
[29] with more recent studies found no further relevant cost data sources (Chapter
1). Transportation costs for Brazil were taken from a clinical trial on tafenoquine [18].
When country-specific data were not available, costs were applied by WHO region;
Table 6.3 summarizes these costs.
Overhead treatment costs for P. vivax were taken from WHO-CHOICE [31] and
supplemented with drug costs for a 60 kg adult from the International Medical Products
Price Guide [23]. The cost of a primary care health centre without beds was used for
the cost of outpatient visits and the cost per bed day in a primary-level hospital was
used for inpatient visits [31]. Visit costs were not available for French Guiana, North
Korea or Somalia, and in these cases the costs from neighbouring countries were used
instead (Suriname, Cambodia and Ethiopia, respectively). It was assumed that 2%
of patients who sought treatment had severe malaria [24] and therefore required three
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Table 6.2: Case estimates, mean number of productive days lost by patients and their
carers, usual care for vivax malaria, ineligibility for primaquine, and G6PD deficiency
(<30% activity) in those who are eligible for primaquine.
Country Number of cases [14] Productive
days lost
[19] &
Ch. 5
Diagnosis & Treatment
Did not
seek
treatment
Sought
any
treatment
% received
malaria
test [15]
% diag-
nosed by
RDT [15]
Blood
stage
drug [15]
PQ
used?†
Routine
G6PD
testing?†
% not
eligible for
PQ [17]
% G6PD
deficient
[16]*
Afghanistan 125,934 213,180 3.5 30% 16% CQ Yes No 4.9% 13%
Bangladesh 787 931 5.9 100% 76% CQ Yes No 3.0% 6%
Belize 3 10 1.1 100% 0% CQ Yes No 3.7% 3%
Bhutan 9 26 5.9 100% 19% CQ Yes No 3.4% 10%
Bolivia 5,035 7,020 1.1 100% 0% CQ Yes No 4.1% 0%
Brazil 231,335 158,795 1.1 100% 2% CQ Yes No 3.5% 8%
Cambodia 3,315 23,414 5.9 100% 78% DHP No No 4.0% 25%
China 15 59 5.9 99% 0% CQ Yes No 2.3% 8%
Colombia 13,264 18,833 1.1 92% 7% CQ Yes No 2.5% 8%
Democratic Republic
of the Congo
116,405 143,942 5.9 100% 84% ASAQ No No 5.1% 8%
East Timor 8 24 1.1 100% 0% CQ Yes No 3.6% 7%
Ecuador 200 620 1.1 100% 0% CQ Yes No 2.9% 5%
El Salvador 1 3 5.7 100% 0% CQ No No 5.0% 7%
Eritrea 6,142 6,743 5.7 80% 57% ASAQ No No 5.2% 2%
Ethiopia 2,193,480 802,980 1.1 86% 0% CQ Yes No 3.2% 1%
French Guiana 140 314 5.7 100% 37% CQ No No 4.3% 22%
Gabon 1,635 3,571 1.1 11% 15% ASAQ Yes No 4.2% 4%
Guatemala 5,381 10,182 1.1 100% 19% CQ Yes No 2.7% 5%
Guyana 5,873 11,840 1.1 100% 0% CQ Yes No 3.5% 5%
Honduras 1,613 2,722 5.9 100% 1% CQ Yes No 6.5% 14%
India 980,869 3,045,940 6.6 100% 0% CQ Yes No 4.7% 12%
Indonesia 78,859 402,964 3.5 100% 0% DHP No No 3.1% 21%
Iran 190 706 5.9 100% 42% CQ No No 4.4% 29%
Laos 19,156 39,701 5.7 100% 88% CQ No No 5.4% 37%
Madagascar 36,550 38,045 5.9 99% 99% ASAQ Yes No 2.6% 13%
Malaysia 35 97 1.1 100% 0% CQ Yes FST 4.1% 2%
Mexico 175 635 5.9 100% 0% CQ Yes No 2.8% 10%
Myanmar 22,722 39,352 5.9 100% 92% CQ Yes No 3.4% 9%
Nepal 2,755 6,432 1.1 9% 39% CQ Yes No 3.1% 2%
Nicaragua 1,017 2,086 5.9 100% 0% CQ Yes No 3.3% 0%
North Korea 3,426 8,378 5.7 95% 0% CQ No No 6.1% 37%
Pakistan 635,613 2,720,491 3.5 5% 32% CQ Yes No 3.9% 27%
Panama 197 599 1.1 100% 0% CQ Yes No 2.9% 1%
Papua New Guinea 49,118 104,130 5.9 54% 78% AL Yes No 4.7% 13%
Peru 36,892 78,698 1.1 100% 0% CQ Yes No 3.4% 0%
Philippines 869 915 5.9 100% 3% CQ Yes No 5.2% 43%
Solomon Islands 7,415 16,253 3.5 47% 38% AL Yes No 5.8% 5%
Somalia 496 649 5.9 53% 100% AL Yes No 1.4% 0%
South Korea 172 634 5.9 100% 0% CQ Yes No 3.6% 4%
Sudan 56,780 84,751 3.5 53% 0% AL Yes No 3.7% 28%
Suriname 47 111 1.1 100% 8% CQ Yes No 2.6% 1%
Tajikistan 0 1 3.5 100% 0% CQ No No 4.5% 1%
Thailand 1,062 2,328 5.9 96% 0% CQ Yes No 1.5% 24%
Vanuatu 139 312 5.9 61% 96% AL Yes No 4.9% 13%
Venezuela 78,382 214,873 1.1 100% 0% CQ Yes No 2.7% 15%
Vietnam 4,281 6,102 3.7 48% 0% CQ Yes No 2.6% 15%
Yemen 1,046 1,775 3.5 72% 45% CQ No No 4.6% 8%
Total 4,728,840 8,222,167
PQ = primaquine; CQ = chloroquine; DHP = dihydroartemisinin-piperaquine; ASAQ
= artesunate-amodiaquine; AL = artemether-lumefantrine; FST = fluorescent spot test.
† Taken from MMV country prioritisation for tafenoquine
* These are calculated for the population that is not pregnant, lactating or under the
age of six months.
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Table 6.3: Unit costs and assumptions by WHO region (2016 US$).
Region Africa Americas Asia * Eastern
Mediterranean
& Europe
Assumptions
Microscopy 0.83 5.84 2.62 5.74 Americas from [20], Eastern
Mediterranean & Europe average from
[21], Chapter 5 for others
Malaria RDT 1.19 1.16 1.19 1.81 Americas from [20], Eastern
Mediterranean & Europe average from
[21], Chapter 5 (average of Vietnam
and Indonesia) for others
FST − − 20.76 − Chapter 5
G6PD RDT 1.18 3.48 1.43 2.03 Americas from [22], Chapter 5 for Asia
(Vietnam) and for Africa, Eastern
Mediterranean & Europe is average of
other regions
Chloroquine 0.30 0.30 0.30 0.30 [23] Only available buyer price
Dihydroartemisinin-piperaquine 2.80 2.80 2.80 2.80 [23] Median supplier price
Artesunate-amodiaquine 0.35 0.35 0.35 0.35 [23] Only available supplier price
Artesunate-lumefantrine 0.79 0.79 0.79 0.79 [23] Only available buyer price
Primaquine 0.85 1.42 1.13 1.13 [23] Africa and Americas taken from
regional prices then averaged
for other regions.
Treatment seeking 0.10 0.65 1.45 0.40 Chapter 5 (Americas is average from
other regions).
Transport 1.80 1.15 2.15 2.80 [18] for Americas and Chapter 5 for
others.
* Includes both South-East Asia and Western Pacific regions.
days of inpatient care [32]. Provider costs were obtained from the public sector; these
were assumed to be representative of the true costs of illness for private providers (i.e.
excluding profits). The cost of deaths due to P. vivax were excluded.
Table 6.4 describes the assumptions for individuals seeking treatment as compared
to those who did not seek treatment for their P. vivax episode. For those seeking
treatment, direct costs to the patient included the cost of transport to the healthcare
facility in addition to payments for treatment and transport for any other treatment
seeking (Chapter 5).
6.2.5 Costs of productivity losses
Indirect costs included the cost of the days when patients were unable to attend to
usual activities due to illness and also the days when their caregiver was required to
stop doing usual activities to look after the patient (Chapter 5). The time lost by
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Table 6.4: How household cost categories were applied by treatment-seeking behaviour.
Cost category Seeking treatment at any
provider
Not seeking treatment
Cost of diagnosis and
treatment
Costs for diagnosis and treatment
by country policy.
Not included.
Transport costs Cost for the patient to get to and
from the healthcare provider.
Not included.
Cost of previous treatment
seeking
Costs to the household for
treatment and transport for any
treatment taking before diagnosis.
Not included.
Indirect cost of time off
usual activities
Cost per day using GDP per capita
per day. Patient and carer days
taken from country-level data when
possible. When not possible, taken
from average of studies from WHO
region.
Cost per day using GDP per capita
per day. Patient and carer days
taken from country-level data when
possible. When not possible, taken
from average of studies from WHO
region.
patients and caregivers were valued equally, and indirect costs were included for all cases,
regardless of age or employment status. When days of illness data were not available
for a country, these were applied by WHO region (Table 6.2). For Asia, this was the
weighted average of Indonesia and Vietnam by number of patients in each country. The
days of illness were multiplied by the GDP per capita per day to calculate the indirect
costs per episode. GDP per capita estimates were taken from The World Bank for
all but seven countries [33]. For six countries (East Timor, Eritrea, Iran, Papua New
Guinea and Vietnam), the GDP per capita estimate was taken from the International
Monetary Fund [34]; and the GDP per capita was estimated to be US$1,300 for North
Korea [35].
6.2.6 Low and high cost bounds
Low and high cost bounds were calculated for the base case estimate. The lower
and upper case bounds were provided by MAP [14] utilising estimation methods from
Cibulskis and colleagues [25]. The 95% CIs for treatment seeking were also provided
by MAP [14], and the 95% CIs for hospitalisations due to severe disease were taken
from a systematic review [24]. The low cost bound combined the lower case estimate,
lower 95% CI on treatment seeking and low 95% CI for hospitalisations due to severe
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disease. Likewise, the high cost bound used the higher case estimate, higher 95% CI on
treatment seeking and high 95% CI for hospitalisations.
Figure 6.1: Flow diagram of P. vivax patient case management in the scenario analyses.
6.2.7 Global cost-benefit of implementing G6PD testing
with highly effective radical cure
A scenario analysis explored the potential impact of implementing G6PD screening in
those who sought treatment followed by supervised primaquine therapy over 14 days,
following a G6PD normal test result. A cost-benefit analysis was then carried out for this
Highly effective radical cure scenario as compared to the base case estimates, including
the health benefits in terms of increased productivity and direct costs averted due to
lower relapse episodes. Figure 6.1 shows the flow of P. vivax patients and how costs
were applied. A proportion of the population are ineligible for primaquine due to them
being under the age of six months, pregnant or lactating; these proportions are listed by
country in Table 6.2 [16]. To ensure that pregnant women did not receive primaquine,
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the cost of providing a pregnancy test (Chapter 4) for 25% of the population was
included. After excluding those who were ineligible for primaquine, the cost of a G6PD
RDT was applied to the rest of the population. Individuals who are confirmed to
be G6PD normal would receive 14 day primaquine under supervision to ensure full
adherence, and those identified as deficient would not receive radical cure due to their
risk of primaquine-induced haemolysis. These costs replaced any pre-existing costs of
screening and primaquine in the base case analysis. The percent of the population with
G6PD deficiency (<30% activity) in those eligible for primaquine (i.e. not pregnant,
lactating or under six months old) is also listed in Table 6.2 [17].
The following assumptions were made for those who were prescribed primaquine:
1. All patients were adherent to their regimens. The cost of supervised treatment in
order to achieve this was estimated to be 3.25 healthcare worker days (1/4th day
for 13 days) with time valuated using the GDP per capita per day. This represents
the additional investment necessary to achieve complete adherence. (Other lower
cost options, such as text message reminders are available, but adherence is also
likely be lower.)
2. Primaquine was assumed to be effective at preventing relapses in 85% of the
individuals who completed treatment [12, 36].
3. For the 85% of patients who received an effective dose of primaquine, a reduction
in relapses resulted in cost savings due to relapse episodes averted. Table 6.5 lists
the clinical incidence per person year observed for countries grouped into nine
zoogeographical zones from Battle et al., which was assumed to be the relapse
incidence following primary infections [37]. For each infection treated with an
effective dose of primaquine, the relapse incidence in Table 6.5 was multiplied
by the mean cost per treatment-seeking episode using the base case scenario to
calculate the cost savings per relapse prevented.
4. Since countries currently prescribing primaquine were assumed to have an effec-
tiveness of 15% through unsupervised therapy [26], it was assumed that the base
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Table 6.5: Countries and relapse incidence among cases per person year observed by
zoogeographical zone from Battle and colleagues [37].
Zoogeographical
zones
Countries
Relapse incidence per
person year observed
North America Mexico 1.7
Central America
Belize, Guatemala, Honduras, Nicaragua, Panama,
El Salvador
0.9
South America
Bolivia, Brazil, Columbia, Ecuador, French Guiana, Guyana,
Peru, Suriname, Venezuela
4.0
Sub-Saharan Africa
Democratic Republic of the Congo, Eritrea, Ethiopia, Gabon,
Madagascar, Somalia, Sudan, Yemen
0.8
Monsoon Asia India, Iran, Pakistan 0.2
South East Asia
Bangladesh, Bhutan, Indonesia, Cambodia, Laos, Myanmar,
Malaysia, Nepal, Philippines, Thailand, East Timor, Vietnam
3.1
Northern Europe & Asia Afghanistan, China, North Korea, South Korea, Tajikistan 0.5
Melanesia Papua New Guinea, Solomon Islands, Vanuatu 4.5
case estimates inherently reflected those prevented relapses. Accordingly, the
implementation of supervised primaquine would reduce cases in only 70% of those
who received the prescription instead of 85%.
6.2.8 Global cost-benefit of radical cure with low adherence
The Low adherence to radical cure scenario investigated what would happen if pri-
maquine was administered unsupervised with a lower level of adherence assumed. This
scenario differs from the Highly effective radical cure scenario in the following ways:
1. The costs of supervised primaquine therapy were excluded.
2. It was assumed that for countries that currently do not prescribe primaquine,
introduction of an unsupervised regimen would only reduce relapses in 15% of those
prescribed primaquine [26]. Again, this was equivalent to the relapse incidence
found in Table 6.5. In countries where primaquine is already used, no additional
benefits were seen in terms of cases averted.
152
CHAPTER 6. GLOBAL ECONOMIC COSTS DUE TO VIVAX MALARIA
TREATMENT AND THE POTENTIAL COST-BENEFIT OF RADICAL CURE
6.3 Results
6.3.1 Global cost burden estimates
The total global cost of vivax malaria in 47 countries was estimated to be US$330
million per year (Table 6.6). Figure 6.2 displays a global map of the costs. The lower
bound was US$205 million while the upper bound was US$459 million. Of the base case
estimates, 80% (US$263 million) was attributable to indirect patient costs, 12% (US$41
million) to healthcare provider costs and 8% (US$26 million) to direct costs to the
patient. India carried the highest cost burden with US$137 million, accounting for 42%
of the total global cost, of which 80% (US$111 million) were due to indirect costs. Other
high cost countries were Pakistan (US$64 million), Indonesia (US$37 million), Ethiopia
(US$36 million), Brazil (US$12 million) and Venezuela (US$12 million). Tajikistan had
the lowest country cost at US$18 for its one case (Table 6.6).
6.3.2 Global cost-benefit of implementing effective G6PD
testing and radical cure
In the Highly effective radical cure scenario, the additional provider costs of G6PD
screening in conjunction with administration of a supervised 14 day primaquine regimen
were calculated to be US$113 million, which would be offset by a cost savings of US$34
million due to relapses prevented (Table 6.7 and Figure 6.4B). In total, the net cost to
providers was US$121 million, a nearly three-fold increase as compared with their base
case costs (Figure 6.3). Despite these global increases in healthcare provider costs, four
countries (Bolivia, Cambodia, Columbia and Solomon Islands) had net cost savings
to the provider due to implementation of G6PD screening followed by radical cure
(Table 6.7). Most of the cost savings were seen at the patient level, where total costs
dropped by US$124 million (47%) to US$165 million. Overall, the Highly effective
radical cure scenario resulted in a reduction in costs due to vivax malaria treatment of
US$45 million (14%) to US$285 million (Figure 6.3).
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Table 6.6: Base case global cost estimates by country (2016 US$).
Country
Provider
costs
Patient costs
Total costs
Low
bound
High
boundDirect Indirect
Afghanistan 950,631 682,176 1,826,776 3,459,583 1,954,160 4,652,628
Bangladesh 3,235 3,353 37,526 44,114 20,851 68,661
Belize 157 18 190 365 257 488
Bhutan 169 92 1,568 1,830 1,340 2,337
Bolivia 77,164 12,648 112,803 202,616 126,329 285,707
Brazil 1,440,678 286,124 10,170,028 11,896,829 5,041,109 19,088,287
Cambodia 146,552 84,291 545,447 776,290 626,294 934,013
China 681 211 7,668 8,561 8,515 8,613
Colombia 392,272 33,935 561,583 987,790 641,448 1,363,177
Democratic Republic
Of the Congo
289,615 273,489 1,807,218 2,370,322 1,503,599 3,260,443
East Timor 106 86 1,149 1,341 1,054 1,631
Ecuador 9,949 1,117 14,737 25,803 17,665 35,035
El Salvador 24 6 56 86 63 110
Eritrea 20,756 12,812 165,628 199,196 94,363 310,318
Ethiopia 1,550,348 1,525,662 33,072,053 36,148,063 10,712,909 62,238,153
French Guiana 4,482 566 50,426 55,473 29,688 82,593
Gabon 46,848 6,785 583,686 637,320 450,102 831,136
Guatemala 133,165 18,347 194,492 346,003 210,707 499,494
Guyana 120,718 21,334 237,891 379,942 244,746 527,286
Honduras 30,017 4,905 30,851 65,773 46,112 86,917
India 15,855,861 10,965,385 110,611,817 137,433,063 80,381,482 195,581,742
Indonesia 4,426,936 1,450,669 31,105,873 36,983,479 25,112,593 49,563,239
Iran 8,737 2,258 34,008 45,004 44,419 45,671
Laos 181,807 142,922 2,225,591 2,550,321 1,502,555 3,645,747
Madagascar 96,550 72,286 467,503 636,339 352,326 935,028
Malaysia 3,756 349 20,195 24,301 17,782 31,099
Mexico 14,129 1,145 20,023 35,297 25,384 46,663
Myanmar 132,338 141,669 1,271,820 1,545,827 1,015,362 2,094,345
Nepal 10,841 23,155 107,703 141,698 86,063 201,295
Nicaragua 18,341 3,759 20,121 42,222 29,601 55,816
North Korea 39,785 30,161 246,595 316,541 183,469 460,003
Pakistan 8,038,548 8,705,572 47,249,127 63,993,247 55,417,789 72,911,019
Panama 14,528 1,079 32,798 48,405 35,249 62,985
Papua New Guinea 454,528 374,868 6,375,537 7,204,933 4,734,435 9,752,043
Peru 1,272,823 141,801 2,106,023 3,520,647 2,329,525 4,852,976
Philippines 6,614 3,295 84,627 94,537 41,776 149,787
Solomon Islands 96,004 58,512 762,754 917,270 602,677 1,247,188
Somalia 1,734 2,076 4,766 8,575 2,894 15,583
South Korea 27,640 2,282 280,565 310,488 307,197 314,249
Sudan 689,194 271,204 3,277,569 4,237,968 2,697,750 5,851,658
Suriname 1,735 200 3,089 5,024 3,525 6,675
Tajikistan 7 3 7 18 18 18
Thailand 27,086 8,382 321,838 357,306 236,057 483,015
Vanuatu 2,322 1,121 20,713 24,157 16,021 32,670
Venezuela 4,554,376 387,168 6,734,572 11,676,116 7,896,058 16,011,003
Vietnam 23,095 21,966 230,045 275,105 164,461 390,291
Yemen 13,478 5,682 26,794 45,953 32,709 59,948
Total 41,230,793 25,786,923 263,047,634 330,065,351 204,991,498 459,056,632
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Figure 6.2: Global map of P. vivax economic cost burden in the base case (2016 US$). Countries in grey are thought to be P. vivax
endemic not enough information is available to generate estimates.
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Figure 6.3: Provider, patient and overall cost comparison between the global base
case estimate and the Low adherence to radical cure and Highly effective radical cure
scenarios (2016 US$).
6.3.3 Global cost-benefit of radical cure with low adherence
The Low adherence to radical cure scenario had a much smaller impact with total costs
similar to the base case estimates at US$328 million (Figures 6.3 & 6.4A). Since an
additional investment to improve adherence through observed therapy was not included,
the overall costs to the healthcare provider were reduced by US$0.3 million (1%) to
US$41 million (Table 6.8). Around 81% (US$0.3 million) of these cost savings were
due to the reduction in cases; the additional savings were due to the prevention of
primaquine prescriptions in G6PD deficient patients. Thirteen countries had reductions
in healthcare provider costs due in this scenario as compared to the base case scenario.
At the patient level, the Low adherence to radical cure scenario resulted in modest cost
savings of US$1 million (6%) to US$287 million.
6.4 Discussion
The cost figures presented in the base case scenario bring together country-level epi-
demiological data with recently available disease-specific cost data to present the best
available evidence on the current global economic burden of P. vivax malaria. The
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Table 6.7: Results of the Highly effective radical cure scenario as compared to the base
case estimates (2016 US$). The net benefit to the healthcare providers is the sum of
the additional screening and treatment costs and the reduction in provider costs due to
relapses prevented.
Country Base case
total costs
Additional costs
for screening &
treatment
Provider cost
savings due to
averted cases
Overall change
in provider
costs
Household cost
savings due to
averted cases
Net benefit*
Afghanistan 3,459,583 874,463 270,384 604,079 520,659 -83,420
Bangladesh 44,114 10,304 6,295 4,009 46,104 42,095
Belize 365 397 97 301 99 -202
Bhutan 1,830 561 316 245 2,329 2,084
Bolivia 202,616 186,240 205,977 -19,736 209,101 228,837
Brazil 11,896,829 10,861,059 3,572,391 7,288,668 10,974,097 3,685,429
Cambodia 776,290 209,144 272,119 -62,975 1,043,713 1,106,688
China 8,561 3,828 210 3,618 2,429 -1,189
Colombia 987,790 873,929 982,896 -108,967 910,682 1,019,649
Democratic Republic
of the Congo
2,370,322 410,776 112,579 298,197 494,712 196,515
East Timor 1,341 438 239 198 2,123 1,925
Ecuador 25,803 29,608 24,963 4,645 30,771 26,125
El Salvador 86 120 15 106 30 -76
Eritrea 199,196 49,177 12,187 36,990 58,412 21,422
Ethiopia 36,148,063 5,372,359 955,889 4,416,470 6,404,985 1,988,515
French Guiana 55,473 98,749 11,992 86,756 94,815 8,059
Gabon 637,320 173,285 23,178 150,107 201,452 51,345
Guatemala 346,003 345,419 80,842 264,577 88,389 -176,187
Guyana 379,942 436,174 312,434 123,740 466,775 343,035
Honduras 65,773 52,819 18,280 34,538 14,784 -19,755
India 137,433,063 37,033,390 2,020,176 35,013,214 12,057,185 -22,956,029
Indonesia 36,983,479 10,721,289 7,927,212 2,794,077 49,181,818 46,387,742
Iran 45,004 24,850 1,289 23,561 5,350 -18,212
Laos 2,550,321 600,587 265,535 335,052 2,401,336 2,066,284
Madagascar 636,339 100,692 37,806 62,886 121,667 58,781
Malaysia 24,301 6,897 6,772 125 27,304 27,179
Mexico 35,297 43,839 15,502 28,337 18,482 -9,855
Myanmar 1,545,827 390,452 247,145 143,307 1,770,325 1,627,017
Nepal 141,698 36,916 20,440 16,476 185,824 169,348
Nicaragua 42,222 38,022 11,489 26,533 10,827 -15,705
North Korea 316,541 94,514 13,157 81,357 67,855 -13,502
Pakistan 63,993,247 24,236,502 887,763 23,348,739 5,191,279 -18,157,461
Panama 48,405 69,867 9,201 60,666 16,317 -44,349
Papua New Guinea 7,204,933 1,994,263 1,184,088 810,176 12,262,021 11,451,846
Peru 3,520,647 4,085,640 3,420,526 665,114 4,234,350 3,569,236
Philippines 94,537 22,360 13,104 9,256 92,517 83,261
Solomon Islands 917,270 149,633 161,288 -11,654 978,284 989,938
Somalia 8,575 2,256 843 1,412 2,324 912
South Korea 310,488 152,863 9,300 143,562 95,171 -48,391
Sudan 4,237,968 1,242,687 259,434 983,253 840,899 -142,354
Suriname 5,024 6,187 4,667 1,520 6,370 4,850
Tajikistan 18 10 3 7 4 -3
Thailand 357,306 91,625 43,437 48,188 367,930 319,743
Vanuatu 24,157 6,515 5,979 536 39,757 39,222
Venezuela 11,676,116 12,100,628 10,569,922 1,530,707 12,350,755 10,820,049
Vietnam 275,105 97,946 40,833 57,113 277,858 220,745
Yemen 45,953 15,631 7,855 7,776 13,138 5,362
Total 330,081,139 113,354,909 34,048,047 79,306,862 124,183,409 44,876,547
* Positive numbers indicate cost savings as compared to the base case estimate.
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Figure 6.4: Global map of changes in the P. vivax cost burden in the scenario analyses
as compared to the base case: A) Low adherence to radical cure and B) Highly effective
radical cure scenario. Green signifies net benefits (i.e. cost savings) and purple indicates
cost increases. Costs are in 2016 US$. Countries in grey are thought to be P. vivax
endemic, but not enough information is available to generate estimates.
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Table 6.8: Results of the Low adherence to radical cure scenario as compared to the
base case estimates (2016 US$). The net benefit to the healthcare providers is the sum
of the additional screening and treatment costs and the reduction in provider costs due
to relapses prevented.
Country Base case
total costs
Additional costs
for screening &
treatment
Provider cost
savings due to
averted cases
Overall change
in provider
costs
Household cost
savings due to
averted cases
Net benefit*
Afghanistan 3,459,583 -11,419 - -11,419 - 11,419
Bangladesh 44,114 36 - 36 - -36
Belize 365 4 - 4 - -4
Bhutan 1,830 1 - 1 - -1
Bolivia 202,616 735 - 735 - -735
Brazil 11,896,829 1,256 - 1,256 - -1,256
Cambodia 776,290 19,607 48,021 -28,414 184,185 212,598
China 8,561 3 - 3 - -3
Colombia 987,790 401 - 401 - -401
Democratic Republic
of the Congo
2,370,322 75,658 19,867 55,791 87,302 31,511
East Timor 1,341 26 42 -17 375 391
Ecuador 25,803 18 - 18 - -18
El Salvador 86 4 - 4 - -4
Eritrea 199,196 5,268 2,151 3,118 10,308 7,190
Ethiopia 36,148,063 657,672 168,686 488,985 1,130,292 641,306
French Guiana 55,473 37 - 37 - -37
Gabon 637,320 2,366 4,090 -1,724 35,550 37,275
Guatemala 346,003 509 - 509 - -509
Guyana 379,942 749 - 749 - -749
Honduras 65,773 150 - 150 - -150
India 137,433,063 -254,628 - -254,628 - 254,628
Indonesia 36,983,479 -18,119 - -18,119 - 18,119
Iran 45,004 634 227 406 944 538
Laos 2,550,321 31,798 - 31,798 - -31,798
Madagascar 636,339 20,137 6,672 13,466 21,471 8,005
Malaysia 24,301 -23 - -23 - 23
Mexico 35,297 59 - 59 - -59
Myanmar 1,545,827 -162 - -162 - 162
Nepal 141,698 36 - 36 - -36
Nicaragua 42,222 193 - 193 - -193
North Korea 316,541 838 - 838 - -838
Pakistan 63,993,247 -558,136 - -558,136 - 558,136
Panama 48,405 67 - 67 - -67
Papua New Guinea 7,204,933 -5,311 - -5,311 - 5,311
Peru 3,520,647 8,926 - 8,926 - -8,926
Philippines 94,537 53 - 53 - -53
Solomon Islands 917,270 -6,283 - -6,283 - 6,283
Somalia 8,575 14 - 14 - -14
South Korea 310,488 77 - 77 - -77
Sudan 4,237,968 -17,912 - -17,912 - 17,912
Suriname 5,024 16 - 16 - -16
Tajikistan 18 3 0.1 3 1 -2
Thailand 357,306 -335 - -335 - 335
Vanuatu 24,157 -18 - -18 - 18
Venezuela 11,676,116 -15,637 - -15,637 - 15,637
Vietnam 275,105 -346 - -346 - 346
Yemen 45,953 1,823 1,386 437 2,318 1,881
Total 330,081,139 -59,156 251,143 -310,299 1,472,745 1,783,044
* Positive numbers indicate cost savings as compared to the base case estimate.
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alternative scenarios provide insights into how costs might be impacted in a world that
embraces G6PD screening and radical cure prescription.
While it was possible to gather data about country-level policies, such as the percent
receiving a malaria test (Table 6.1), it was more challenging to find country-specific cost
data (Table 6.3). As a result, the WHO-CHOICE costs were used for the visit costs
alongside regional extrapolations of vivax-specific costs. The P. vivax case estimates
(Table 6.2) also have uncertainty linked to the quality of reporting in each country. The
cases reported here, prior to adjusting for treatment seeking and reporting, are from
the World Malaria Report [15]. For the majority of countries, these are the nationally
reported estimates, and so are the best available evidence. The case estimates from
the three countries with the highest numbers (Ethiopia, India and Pakistan) have been
inflated from the nationally reported data to reflect reporting completeness. These
inflations may have been too extreme in either direction, which would then impact the
global costs.
The estimates in this chapter highlight the need to gather further data on the
epidemiology and costs of P. vivax and can be updated as this data becomes available.
While the various data issues design a great deal of uncertainty about the economic
costs related to vivax malaria treatment, this is the first global estimate of the costs of
vivax malaria illness that attempts to incorporate country-level estimates. The only
previous estimate of $1.4-4.0 billion was by Price et al., which combined global case
estimates for clinical cases with regional costs from WHO-CHOICE and assumed a
daily wage of $1.5 for all patients [38]. These higher costs were the result of using case
estimates that were ten-fold higher than those used here (106-313 million as compared
to 13 million). Future work should include a PSA to investigate the uncertainty further,
though choosing ranges and distributions necessary will be a challenging task. It is
possible that if the global cost burden is reported without a nuanced discussion of
the data limitations, then this information might be used to advocate for more or less
investment in P. vivax treatment and control. Such actions would be misguided as the
base case estimate provides information on the cost burden but does not indicate how
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resources should be allocated (i.e. cost-effectiveness).
These base case estimates were also a valuable opportunity to look at the potential
cost-benefit of implementing G6PD screening before radical cure. Both alternative
scenarios resulted in cost savings overall when both patient and healthcare provider
costs were included. A surprising finding was that the majority of the cost savings in
both scenarios were at the patient level due to the prevention of clinical relapses. This
is due to the assumptions around productivity losses including the losses to individuals
who do not seek treatment. Since the investment in G6PD screening and radical cure
will likely be made by the healthcare providers, this finding could present a challenge
in terms of financing. The Low adherence to radical cure scenario provides insight
into what would happen without supervised treatment for radical cure: fewer cases
were averted but modest decreases were seen in the healthcare provider costs due to
primaquine prescriptions being limited to only those who could take it safely.
The Highly effective radical cure scenario told a different story with provider costs
increasing three-fold in order to screen for pregnancy and G6PD deficiency and prescribe
14 day supervised primaquine therapy. This increase of US$80 million in healthcare
provider expenses in the Highly effective radical cure scenario would represent only 3%
of the US$2.7 billion spent on malaria control and elimination in 2016 [39]. It should be
noted that while India and Pakistan have high cost and case estimates, they have a very
low relapse incidence at 0.2 per year, which had a large impact on the overall cost-benefit
results. If these two countries were excluded, the cost savings in this scenario would
be more considerable due to the exclusion of the high costs of supervision and the low
benefits of radical cure in these settings. This illustrates how it will be more challenging
for G6PD deficiency followed by radical cure to be cost-effective in long latency settings.
For countries with long latency relapse patterns, a transmission model with a longer
time horizon would be more appropriate to capture the long-term benefits of relapses
prevented; however, this would introduce uncertainty since little data are available
on relapses that occur beyond the first year. Furthermore, the alternative scenarios
relied on relapse incidence data that divided countries into zoographical zones. Within
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countries like India a variety of relapse patterns can occur, so the cost-effectiveness
of radical cure might also vary within the country. The results presented here do not
reflect the aforementioned nuances.
Given that little operational research has been done on how to provide supervised
primaquine therapy or what costs would be associated with this, the reality of moving
toward global radical cure is likely to lie somewhere between these two scenarios until a
safer drug or one with a much shorter regimen is available. Furthermore, it is likely
that interventions to increase adherence will need to be tailored to individual settings.
Supervision could be via mobile phone, education programs, or less frequent visits
than the daily supervision that was costed in the Highly effective radical cure scenario.
While the introduction of single dose tafenoquine will alleviate the issue with adherence
relative to a 14 day primaquine regimen, many individuals will not be prescribed this
drug, including those with G6PD enzyme activity less than 70%, which will exclude
more people than the current 30% cut off currently recommended for primaquine. These
individuals will need to take 14 day primaquine or the regimen of eight weekly doses in
order to achieve radical cure. In more remote settings where healthcare staff are unable
to interpret a quantitative test for G6PD deficiency, primaquine is likely to continue to
be the standard of care. Until a drug that is safe for individuals with G6PD deficiency
is available, the design and implementation of interventions to improve adherence to
primaquine regimens will continue to be critical to malaria elimination efforts.
An issue that arose in generating the global cost burden was the valuation of
productivity losses, or costs associated with inability to work or participate in leisure
activities due to illness or death. While no attempt was made to capture the cost of
death, an attempt was made to valuate the time lost to illness, which was possible.
While it is accepted that time is a limited resource with opportunity costs, economic
evaluation methods do not agree on whether it should be included or how to do so.
Chapter 5 reported days that patients and any carers were unable to participate in
usual activities, but it also reported that the majority of individuals were not in paid
employment. Vivax malaria disproportionately affects the poor, with the majority of
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individuals in Chapter 5 reporting that they missed school or another unpaid activity,
such as housework or subsistence farming. In an attempt to capture those losses, the
use of one GDP per capita per day was used for each day missed. This is equivent
to 1/365th of a DALY if a willingness to pay threshold of one GDP per capita was
used. The P. vivax case estimates did not indicate cases by age (i.e. children vs.
adults), so productivity losses were equivalent for both children and adults. If childrens’
time had been valuated at a lower value than adults, then the overall costs would
have decreased; however, this helps to ameliorate their educational losses that would
otherwise be unaccounted for. In order for educational losses to be included properly
in these estimates, further studies need to be designed to measure these losses. These
would need to be followed by a consensus on best practice for valuating the loss.
As demonstrated in Chapters 2 & 5, vivax malaria often disproportionately affects
the poor, which has implications in terms of productivity losses and equity. If the
reported wages from those who had vivax had been available and used here, the global
costs would have been lower. If these figures were used to generate ICERs which were
then compared with other diseases, it could exacerbate inequity between those who
are rich and poor. This further supports the use of GDP per capita per day as a
shadow price for productivity losses. When considering the scenario analyses, the use of
G6PD screening before radical cure could further exacerbate inequity if a safe option is
not available for remote settings with higher concentrations of poor households where
community health workers have limited training and are not able to deploy G6PD tests.
This would likely result in a drop in P. vivax episodes in richer areas while the disease
burden in poorer areas remained stagnate.
The scenario analyses use a cost model that calculates the benefits of radical cure
without accounting for its potential to prevent onward transmission of P. vivax infections;
consequently the results underestimate the benefits of radical cure and are less robust
than what would be possible with a dynamic transmission model. In terms of the
impact on cost estimates, it is important to note that the increased investment in
radical cure was calculated using the number of episodes in the base case estimate;
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however, the benefit of radical cure would result in fewer cases requiring this increased
investment, meaning that the necessary investment has likely been overestimated. While
the costs were calculated over one year, the benefits would stretch out further into the
future (i.e. a patient treated on day 365 of that year would have benefits in terms of
decreased relapses over the following year). Furthermore, the time to first relapse from
a primary infection can take longer than one year, but our relapse estimates use only
the mean number of relapses in one year [37]. Data on longer-term outcomes are sparse.
Decreasing the transmission potential is one of the only means currently available to
protect those who cannot safely receive primaquine treatment.
The costs of the scenario analyses may have been underestimated due to the exclusion
of the cost of primaquine-induced haemolysis and the cost of any HaemocueTM tests
required. Primaquine-induced haemolysis was not included in any of the estimates
due to uncertainty around its frequency and severity [40]. In countries that are
prescribing primaquine without first testing for G6PD deficiency, it is possible that
haemolysis already occurs. In settings where primaquine is not being prescribed,
the alternative scenarios might increase the incidence of haemolysis further where
imperfect diagnostic accuracy and human error could lead to some individuals with
G6PD deficiency incorrectly being prescribed primaquine therapy; though it is hoped
that some of this would be prevented with supervised therapy. Other limitations are
related to the availability of data. While the vivax-specific cost data were extrapolated
by region, it is likely that these costs will vary considerably from country to country.
Public provider costs were applied to all individuals seeking treatment. While this
reflects the true cost of treatment, patient costs would likely be higher when seeking
treatment at private providers due to treatment fees.
In addition to the aforementioned valuation of productivity losses, the costs of the
scenario analyses may have been overestimated due to a number of factors. Vivax
malaria cases were not stratified by age and so all treatment costs are for adults. It
was assumed that a change in policy would change both the private and the public
sectors, potentially overestimating both the costs and the benefits. While public policy
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does not mandate its adoption by private providers, Chapter 3 showed that private
providers may also shift their behaviour, particularly if patients know where to get
efficacious treatment. It is also possible that screening would not be cost-effective
in areas where G6PD deficiency has a low prevalence or mild severity in the general
population, meaning that only the costs of primaquine therapy should be included in
the Highly effective radical cure scenario.
In conclusion, the economic costs due to vivax malaria treatment and productivity
losses are substantial. The scenario analyses indicate that utilising G6PD screening to
safely prescribe radical cure in those who are G6PD normal would be cost-beneficial
globally, but may not be economically justifiable in low-relapse settings.
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Chapter 7
Discussion
7.1 Summary
While P. vivax was once considered a neglected disease [1], recent gains in understanding
its long-term impact on health coupled with the rise of P. vivax in countries targeting P.
falciparum elimination have brought it to the fore [2]. This thesis further demonstrates
that the burden of vivax malaria is high through a range of studies in a variety of
settings, beginning with evidence that the cost to households was similar for both
vivax and falciparum malaria (Chapter 2). This burden can be ameliorated via
improvements in the care provided in formal sector, as shown by the large beneficial
impact on health and treatment-seeking behaviour in Chapter 3. The biggest obstacle
to radical cure is the risk of haemolysis in those who have G6PD deficiency. The results
of the decision model in Chapter 4 demonstrated that treatment strategies using
G6PD RDTs and radical cure were cost-effective. Accordingly, this strategy should
also be rolled out, and Chapter 6 showed how this could be cost-beneficial from a
global perspective drawing on cost data specific to P. vivax from Chapter 5. Novel
treatment options for radical cure will become available in the near future alongside
the newly developed point-of-care G6PD tests necessary to enable their use. This is a
promising time for vivax malaria research, and a comprehensive understanding of the
economic consequences of alternative options for the management of vivax malaria is
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critical for optimising malaria control strategies in Asia, South and Mesoamerica and
the Horn of Africa. An ongoing theme was the paucity of data available relating to
the costs and cost-effectiveness of P. vivax. Accordingly, the aim of this thesis was to
describe the economic burden of P. vivax malaria and the costs and cost-effectiveness
of screening and treatment strategies for its optimal management. While each of the
previous chapters has its own focus, they come together to provide a comprehensive
view of the economics of P. vivax treatment.
7.2 Empirical findings
The first objective was to describe the costs due to vivax malaria episodes from the
societal and healthcare provider perspectives. The first important finding on costs came
from the healthcare facility exit surveys in Chapter 2, which found that costs incurred
during P. vivax or P. falciparum malaria episodes were similar when patients were
managed in public facilities. Additional information on household costs due to P. vivax
episodes are presented in Chapter 5, including the costs of illness incurred up to 13
days following diagnosis. The cost estimates for vivax malaria are also expanded in
Chapter 5 to include the provider costs per episode and the additional costs required
to provide G6PD screening before prescribing high-dose primaquine. Importantly, the
cost data in Chapter 5 only included vivax malaria patients (i.e. no P. falciparum
patients); this is the first study to report these for healthcare provider costs [3]. Another
key finding was that screening for G6PD deficiency via RDTs consistently cost less
than the fluorescent spot test (FST). These data expand what is known about the cost
of P. vivax treatment considerably. As demonstrated in Chapters 1 & 6, cost data is
still unavailable for many countries.
The second objective was to describe the treatment-seeking behaviour and provider
compliance following a change in antimalarial policy requiring blood test confirmation
of malaria and treatment with DHP for malaria due to any species in Timika, Indonesia,
where a large proportion of cases are due to vivax malaria. Chapters 2 & 3 highlighted
how changes in policy have the potential to lead to meaningful improvements in both
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provider and patient behaviour. Firstly, household surveys showed a ten-fold decrease
in the proportion of individuals reporting fever in the preceding month (from 42% to
4%); and those individuals with fever were more likely to seek treatment at a public
provider as compared to seeking treatment at private providers only. Both public and
private providers were more likely to adhere to local antimalarial guidelines with an
increase in the percentage of patients receiving blood tests for malaria and prescriptions
of the correct antimalarial drug regimen. The improvement in providers adhering to
the guidelines was most apparent in the private sector. Furthermore, a significant
increase in treatment with 14 day primaquine was observed in those who reported being
diagnosed with P. vivax (from 9% to 63%).
Importantly, the proportion of household members with symptomatic malaria
dropped significantly, from 32% to 6%, indicating that the changes in patient behaviour
were likely a result of patients receiving more effective treatment and patients being
aware of the benefits of the new treatments. The universal policy of ACT for all species
of malaria also led to a significant decrease in repeat visits to healthcare providers
and thus a significant fall in the indirect costs per fever episode. While these findings
include both P. vivax and P. falciparum and the species may not have been reported
correctly due to recall bias, a large percentage of cases in this area are due to P. vivax.
Accordingly, these chapters demonstrate that it is important to ensure effective P.
vivax treatment and that policy decisions have an impact on the behaviour of P. vivax
patients and healthcare providers.
The next objective was to evaluate the cost-effectiveness of screening for G6PD
deficiency before treatment with supervised primaquine therapy. Chapter 4 demon-
strates that on the Thailand-Myanmar border, screening for G6PD deficiency prior
to administration of a supervised 14 day primaquine regimen resulted in substantial
health benefits for the patients. The costs were similar when compared to a strategy of
no radical cure, and cost savings were seen in the comparison with a strategy where
primaquine is given without screening. While our findings should be relevant for settings
that are similar to the Thailand-Myanmar border, the epidemiology of P. vivax, G6PD
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deficiency and costs vary greatly across endemic areas. In order to address these other
settings, an online tool was created where the model parameters can be adjusted to
reflect other settings, and the cost-effectiveness of radical cure following G6PD screening
is reported for those parameter values.
The final objective was to describe what is currently known about the global economic
cost burden due to P. vivax malaria, the potential costs associated with a worldwide
policy of screening before giving radical cure, and the potential cost-benefit associated
with a reduction in vivax episodes. In Chapter 6, the provider and household costs
presented in Chapter 5 were extrapolated and combined with data available from
other cost studies to estimate the global economic cost burden due to P. vivax malaria.
The annual global burden of disease was estimated to be US$330 million, with a range
between US$205 and 459 million. This is the first detailed estimate of global costs due to
vivax malaria and highlights the lack of cost data available to construct these estimates.
Since regional extrapolations were required for the costs in many vivax-endemic areas,
these estimates need to be interpreted with caution as the costs in countries where
data are not available could be substantially different from the countries where data
are available.
Chapter 6 also presents the results of two cost-benefit analyses of alternative global
scenarios for case management. In the Highly effective radical cure scenario, G6PD
screening was implemented and individuals who were G6PD normal were prescribed
a supervised course of primaquine radical cure. Whilst implementing such a policy
would increase the healthcare provider costs by nearly three-fold (from US$41 million
to US$121 million) due to the assumed costs of supervised treatment, the potential
benefits would result in a reduction in the overall costs by US$45 million. Adherence to
primaquine regimens remains a major concern as highlighted in Chapters 1 & 4, so
the Low adherence to radical cure scenario excluded the cost of supervising radical cure
and decreased its effectiveness to 15%. In this scenario fewer benefits were accrued due
to averted cases, but overall modest cost savings were demonstrated at the healthcare
provider level due to a lower investment in strategies to improve adherence. These
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scenarios are likely to be conservative, since effective radical cure will not only reduce
relapses in individuals but also prevent the onward parasite transmission associated
with those infections, and thus the subsequent case-load. This potential reduction in
transmission was not included in the current analysis. Although widespread use of a
supervised 14 day regimen of primaquine may not be feasible in many locations, the
potential long-term benefits of radical cure may be far greater than the short-term
costs. While an US$80 million increase in healthcare provider expenditure in the Highly
effective radical cure scenario is a large sum of money, it represents just 3% of the
US$2.7 billion spent on malaria control and elimination in 2016 [4].
7.3 Methodological approaches
Whilst the majority of the findings presented were empirical, some methodological
contributions were also provided throughout. Chapters 2 & 3 use a Discriminant
Analysis of Principal Components to split households into meaningful SES categories
through the maximisation of between group variability while minimising the within group
variability. This enabled the analysis to capture the heterogeneity in ownership that
would not have been seen using the standard principal component analysis. Re-settled
Papuans had been provided with house and land by the local government resulting in
many of the poorer households having high levels of house and land ownership but little
other disposable income. Unlike the principal components analysis, the results from
the Discriminant Analysis of Principal Components were able to explain almost all of
the differences between groups using only two discriminant functions.
Due to the heterogeneity in the epidemiology of vivax malaria and G6PD deficiency,
Chapter 5 included the development of a customisable online model, which can
be found at https://malaria.shinyapps.io/g6pd_screening/. For some model
parameters with limited evidence, world experts in vivax malaria have a wide range
of opinions that are difficult to reconcile into the single value needed for a decision
model. While the sensitivity analysis addresses this to a certain extent, the online model
provided a practical way to illustrate how their differing views would drive changes in
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the cost-effectiveness outcomes. It is hoped that this transparent analytical decision
support tool will contribute to more rational and well-informed debates about how to
treat vivax malaria.
Chapter 5 presented the results from standardised costing tools applied to collect
household cost data across seven study sites in four countries and provider cost data
in three countries. This is the first time this has been done for malaria, regardless of
species. These costs are later expanded in Chapter 6 to present a first attempt to
look at the global costs of vivax malaria treatment as well as the potential cost benefit
of radical cure on the global cost burden. While this is rudimentary work, which should
be seen as a thought experiment rather than a definitive costing study, Chapter 6
provides a framework for future research in this area by identifying knowledge gaps.
7.4 Policy implications
The generation of policy-relevant research has been a priority for this thesis. Meetings
with the Asia Pacific Malaria Elimination Network (APMEN), PATH, MMV and
GlaxoSmithKline have provided forums for ongoing interaction with policymakers and
other stakeholders. During these meetings, results were presented, ideas for future work
were generated and refined, and advice was exchanged on operational barriers to the
roll out of G6PD tests and tafenoquine and future research needs. As a result, much of
the information presented in this thesis relates to the costs and cost-effectiveness of
radical cure, a pressing need in the field of vivax malaria. This thesis has demonstrated
the potential cost-effectiveness of giving primaquine to patients after screening for
G6PD deficiency to ensure safe radical cure. Chapter 4 included the cost of 14 days
of primaquine therapy supervised by a healthcare worker in an attempt to match the
effectiveness data from the clinical trial. While this is almost certainly an overestimate
of the investment needed to ensure adherence, it was still cost-effective to screen for
G6PD deficiency before radical cure. It is hoped that this will encourage both country
policymakers and healthcare providers to pursue programs that give radical cure after
G6PD screening.
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In order to prevent the adverse consequences of subsequent relapsing infections, novel
public health strategies will be needed to educate both providers and populations about
the benefits of taking a full course of primaquine. Considering the results in Chapter 4
& 6, it is likely that these new strategies will be cost-effective, but it is difficult to do a
cost-effectiveness analysis for an intervention that has not been designed. Interventions
currently under consideration range from a few minutes of education for the patients
receiving the medication to text message reminders to observed therapy by family
members. These interventions will need to be adapted to the needs of the population
where they are implemented. Regardless of method chosen, ensuring adherence to radical
cure is important. This is highlighted by other studies in Timika, Indonesia: whilst
Chapters 2 & 3 indicated that more patients were prescribed 14 days of primaquine
after the policy change, the effectiveness of P. vivax radical cure remained suboptimal
as evidenced by the observed degree of multiple recurrences following treatment with
an unsupervised regimen [5]. A policy priority should be developing the tools needed
to achieve effective radical cure: this will be an important milestone in the journey
towards malaria elimination.
7.5 Limitations
The work presented in Chapters 2-6 presented a range of challenges in terms of
data and methodology. The immediate challenge was to acquire cost data to use in
cost-effectiveness models. As indicated in Chapter 1 and the review by White et al.,
limited previous studies have investigated the costs associated with P. vivax treatment.
While the cost data presented in Chapter 2 is dated and the malaria epidemiology
in that setting may limit its generalisability, it is valuable in that few other cost data
sources exist, and it enabled the comparison of household costs for patients with P.
vivax to those with P. falciparum. Chapter 5 presented new cost data from a range of
countries. Together, these chapters greatly expand what is known about the costs of
vivax malaria.
The methodology used to obtain costs, however, has not been consistent throughout
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the thesis in terms of inflation factors and conversion sources. In Chapters 2-3 , the
average exchange rate over one year was taken from www.OANDA.com [6], but in 2016
the website ceased providing this service for free. No other sources of annual conversion
rates could be identified. As a result, Chapter 5 uses point estimates from mid-year (1
July) from www.XE.com [7]. While this methodology was applied consistently across all
countries included in the analysis, these estimates from a single time point could bias
the results if the date chosen saw a short-term spike or dip in the rate, which could be
avoided if an average annual rate had been available.
Another alternative would have been to use purchasing power parity (PPP) rates to
exchange local currencies into international dollars (I$), which enables the comparison
of currencies in terms of their ability to buy the same amount of goods and services.
These are calculated using a large basket of goods and services, enabling a more reliable
method of international economic comparisons than exchange rates. PPPs, however,
have their own limitations. Generating PPPs for such a large basket of goods and
services requires a huge amount of data, which means that calculations happen at
infrequent intervals. The most recent survey was conducted in 2011, and PPPs since
then have been based on estimates, potentially introducing measurement inaccuracies.
Furthermore, the surveys do not cover all countries, which means that PPPs for missing
countries must be imputed. Finally, while I$ would enable a comparison of purchasing
power across countries, the use of market exchange rates enables the aggregation of
actual expenditures on vivax malaria across countries. Accordingly, Chapters 2-4
report US$ since each uses costs from a single country, but I$ are reported in addition
to US$ in Chapter 5 to aid comparisons across countries. Since the aim of Chapter 6
was to estimate worldwide expenditures on vivax malaria treatment, costs are reported
in US$.
In Chapters 2 & 3, the local currency was inflated to 2014 US$ using the consumer
price index (CPI) for Indonesia [8]. Chapter 4 also used CPIs to inflate costs. In
Chapters 5 & 6 the costs are inflated using GDP deflators [9]. While CPIs reflect
changes in price level in a basket of goods and services for the average consumer, GDP
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deflators reflect price changes in the economy as a whole (i.e. a measurement of changes
in the price level of GDP relative to real output). Since the GDP encompasses all
aspects of the economy instead of those in a static basket of goods, it was deemed to
be more appropriate for eliminating inflation over time. Considering the rapid rates of
inflation over that time period, it is possible that the choice of CPIs in Chapters 2
& 3 may have impacted the results. For example, a significant change in total costs
over the entire fever period had been anticipated due to the availability of effective
treatment. While it is not ideal to have presented such a range of methodologies and
cost years in one document, these changes reflect a growth in understanding.
Another inconsistency related to the costs was the valuation of productivity losses.
The survey described in Chapters 2 & 3 asked individuals to indicate their daily
wage. The mean daily wage for all who reported one was calculated and multiplied
by the number of days missed by the individual taking treatment in addition to any
companions, caretakers and substitute labourers. For adults who work at home, this
could mean an overestimate of the costs; however, it enabled the valuation of their time
loss, which could be devastating to the households that depend on them. Children were
not asked the number of days missed, which meant that their productivity costs were
not included. This methodology was not possible in Chapter 5 since the trial surveys
did not ask about wages. In order to account for productivity losses, GDP per capita
per day was used to valuate each day lost to illness for both children and adults. Since
vivax malaria disproportionately affects the poor and children, it is possible that this
is an overestimate of the productivity losses. Given that the largest cost component
in Chapter 5 was due to productivity losses, this assumption potentially had a large
impact on the results in Chapters 5 & 6.
Chapters 2 & 3 also presented challenges in terms of data management and
interpretation. The data files were separated by survey sections and required merging
and reshaping to prepare the data for analysis. In addition to not having a data
dictionary, the variable and data labels were not always complete, so some data cleaning
was required alongside careful study of the surveys. The time interval since collecting
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the survey data in 2005 meant that some of the individuals who had been involved were
no longer contactable. Those individuals who were still available were relied upon to
reconstruct some of the details of the study that were needed to understand the data
and write those chapters.
The cost-effectiveness analysis in Chapter 4 also presented challenges in terms of
data selection and presentation. Routine care could either be the chloroquine strategy
or the primaquine strategy, which are two extremes of the spectrum as compared to
the screening strategy. Separating these comparisons made the results more relevant to
policy, but this made it difficult to choose what values would be the most conservative
for the screening strategy. Since pregnant and lactating women are ineligible for
primaquine and G6PD deficiency varies by gender, the results had to be further separated
into males and females. This necessitated the presentation of four comparisons per
setting. In order to explore the results in other settings without further increasing
the number of comparisons presented in Chapter 4, an online tool was developed
(https://malaria.shinyapps.io/g6pd_screening/). This model is freely available
online to help policymakers and providers explore the potential cost-effectiveness of
screening for G6PD deficiency before giving primaquine. The interactive model is also
useful for investigating the impact of model parameters that have limited data available
and radical differences in expert opinion (i.e. mortality due to primaquine-induced
haemolyis if blood transfusion not given).
Due to logistical issues, the healthcare facility data presented in Chapter 5 were
collected remotely. To address this challenge, tools were developed to enable local staff
to collect cost data and applied consistently across sites. Cost data collected remotely
could be more vulnerable to error and therefore less comparable across sites; however,
every effort was made to standardise the data collection.
Lastly, many of the other limitations in Chapters 2-5 were related to the under-
standing of vivax malaria, which are mostly related to data availability as highlighted
in Chapter 1. Particular issues include (1) the inability to distinguish a relapse from
a new infection, (2) variations in G6PD severity and distribution, (3) variations in P.
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vivax relapse patterns and (4) the poorly understood relationship between primaquine
adherence and effectiveness. What is known about these issues are brought together
with the cost data and case estimates in Chapter 6. This chapter represents the first
time that case estimates from the Malaria Atlas Project have been used to generate
global cost burden estimates. The global cost burden estimates presented in Chapter
6 use the most comprehensive costs due to P. vivax to data, highlighting the areas
where more research is needed.
7.6 Future research directions
In response to the research findings, policy implications and limitations, the following
research priorities are proposed to address the knowledge gaps.
7.6.1 Utilising the cost-effectiveness model
Further data collection using economic questionnaires are currently being gathered as
part of a large multi-centred primaquine clinical trial (IMPROV) that will be completed
in March 2018 [10]. The cost-effectiveness model developed and presented in Chapter
4 will be parameterised to these additional data and will provide important information
on patient characteristics and efficacy that will complement the unit cost data presented
in Chapter 5. The efficacy data from this trial includes a one year follow up period
for patients receiving seven day and 14 day primaquine treatment as well as patients
who did not receive radical cure. This will enable exploration of the cost-effectiveness
of further options for vivax malaria case management and how these vary by setting
from a healthcare provider and societal perspective.
The cost-effectiveness model will also be adapted to incorporate data from recent
clinical trials investigating the efficacy of tafenoquine, a new treatment that can achieve
radical cure with administration of a single dose [11, 12, 13]. Tafenoquine is a long-acting
drug, and may increase the risk of haemolysis. For this reason the manufacturer will
recommend that it should only be prescribed once the patient has been confirmed to have
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>70% of population mean G6PD activity. Novel and more stringent quantitative G6PD
tests will be required to exclude individuals with intermediate deficiency, particularly
in risk-averse environments where primaquine has not been widely used. Although
this approach would exclude some patients who could probably receive primaquine
safely, the increased confidence in the low risk of haemolysis is likely to improve
provider compliance. Furthermore, tafenoquine’s single dose regimen will circumvent
the challenge of poor patient adherence to primaquine. Further analyses will be carried
out to verify and quantify those potential benefits.
7.6.2 Targeting vulnerable risk groups
Vulnerable risk groups are highlighted throughout the thesis: from Chapter 2 where
poor individuals were more likely to report fever in the past month to Chapters 4 & 6,
which had to exclude pregnant and breastfeeding women from receiving primaquine in
the analyses due to contraindications. Although pregnant women are typically given at
least one test for malaria during antenatal care in endemic areas, research on alternative
treatments for malaria in pregnancy have been largely neglected, despite increasing
evidence of the negative impact of malaria episodes during pregnancy and on the
subsequent development of the child [14, 15, 16]. Post-partum women are more likely to
get P. vivax malaria and less likely to have P. falciparum episodes when compared to
non-pregnant, non-post-partum women [17]. Hence, prevention and control of P. vivax
could have significant health benefits in the most vulnerable populations and should
be prioritised in the future. In the setting of the Thailand-Myanmar border described
in Chapter 4, approximately 15% of patients have sub-microscopic infections [18].
Recent evidence indicates that primaquine is not excreted in the breast milk and so can
be given to women who are breastfeeding [19], creating an opportunity for providing
radical cure to women soon after delivery and before the next pregnancy. Further
research is needed to investigate the cost-effectiveness of options for vulnerable risk
groups. Some examples include using weekly prophylaxis or the postpartum delivery of
primaquine in women diagnosed with vivax malaria during pregnancy.
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7.6.3 Unified drug treatment
Chloroquine-resistant P. vivax is on the rise [20], and in some areas where high-grade
resistance is observed policymakers are switching to a universal policy of ACT for
both P. falciparum and P. vivax malaria [21]. A unified drug treatment would be a
pragmatic alternative to species-specific treatment, making diagnosis and treatment
easier for the healthcare provider. The experience of such a strategy in Indonesia is
described in Chapter 3; however, the risk of recurrent infection following ACT in
some locations may be high. A study form Thailand found that 51% of individuals
with P. falciparum treated with a short-lasting ACT and 20% of individuals treated
with a long-lasting ACT came back with P. vivax within 63 days [22], which cannot be
explained entirely by reinfection. It is hypothesised that these recurrent parasitaemias
are due to the acute febrile illness of P. falciparum reactivating the dormant and hidden
P. vivax hypnozoites. Indeed, the risk of returning with P. vivax infection following
P. falciparum infection in a high relapse setting is higher than the risk of returning
with P. vivax infection following blood stage treatment for P. vivax in settings with
low frequency relapse [23].
In the context of malaria elimination, where the percentage of malaria cases due to
P. vivax is increasing as efforts focus on P. falciparum, a unified treatment for malaria
using ACT plus radical cure for all malaria cases could be a cost-effective alternative
to treatment by species. Such a policy would ensure high efficacy against the asexual
stages of the parasite even in areas where chloroquine resistance is emerging, as well
as the potential benefits of preventing P. vivax relapses in patients with either acute
falciparum or vivax malaria.
Microscopy and RDTs for both P. vivax and P. falciparum are known to misdiagnose
the species of malaria, and this can result in the administration of inappropriate
treatment. For example, a study in Ethiopia found that approximately 9% of P.
falciparum microscopy confirmed cases tested RDT positive for P. vivax, whereas 1% of
P. vivax microscopy cases tested RDT positive for P. falciparum only. Furthermore,
72% of P. falciparum mono-infected individuals and 11% of P. vivax mono-infected
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individuals according to microscopy tested as mixed infection with the RDT, suggesting
that the most appropriate treatment would have been an ACT plus primaquine to
treat both infections [24]. When microscopy is used, it can be difficult to differentiate
between species of malaria at low parasitaemias. Under a unified drug policy, all cases
will get drugs that are efficacious for both diseases, regardless of whether the RDT
correctly identified the type of malaria the individual has, resulting in a decrease in the
number of days individuals are infectious.
In Chapter 4, the increased costs due to drugs and G6PD testing was offset by
the cost savings due to prevention of future episodes resulting from hypnozoites and an
increase in the number of individuals receiving radical cure. Some settings may not
have a high enough proportion of patients with falciparum malaria who have vivax
hypnozoites to justify the increased cost of a unified treatment for malaria including
G6PD screening and radical cure in those who test normal. In these settings, individuals
with severe variants of G6PD-deficiency who test G6PD normal would be of particular
concern as an incorrect prescription for radical cure for falciparum malaria could result
in haemolysis. This risk may not be justifiable in patients who are at low risk of having
a P. vivax relapse.
A model-based analysis would allow the circumstances under which a unified treat-
ment might be cost-effective to be identified. The correct treatment and prevention of
relapses will result in fewer episodes of clinical malaria and the associated decrease in
DALYs. Extending this work to include onward transmission would enable the model
to capture the additional benefit of primaquine in terms of reduced transmission due to
relapses. The use of primaquine in patients with P. falciparum will increase the risk
of haemolysis in G6PD deficient individuals who are prescribed primaquine, causing
further costs and DALYs in those with significant haemolysis. This could be extended to
standardising high-dose primaquine after G6PD screening in areas of co-endemicity. As
demonstrated in Chapters 4 & 6, provider and patient adherence influence primaquine
effectiveness; however, once tafenoquine is available, the issues with patient adherence
would be alleviated for those who are G6PD normal. Such integrated management
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could be key to ensuring that malaria elimination is achievable (Chapter 1).
7.7 Conclusion
This thesis contributes to an understanding of the costs and global economic burden of P.
vivax and provides novel information on how to optimise P. vivax patient management,
particularly the implementation of primaquine radical cure. Despite the limitations,
this represents the most extensive estimation of the costs of vivax malaria to date, and
the cost-effectiveness of its treatment. This information provides the foundation from
which policymakers and healthcare providers can explore new drugs and strategies,
including single dose tafenoquine and novel G6PD diagnostics, as they become available.
Understanding the costs and cost-effectiveness of alternative options for vivax malaria
treatment and control will be critical in the journey towards malaria elimination.
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